Incorporated in the Cayman Islands with limited liability

于开曼群岛注册成立之有限公司

(Stock Code

股份代号 ：

8143)

A

N

N

U

A

L

R

E

P

O

R

T

年

报

/

---

金威医疗集团有限公司

2024/2025

年报

CHARACTERISTICS OF GEM OF THE STOCK

EXCHANGE OF HONG KONG LIMITED (THE

“STOCK EXCHANGE”)

GEM has ben positioned as a market designed to acomodate

smal and mid-sized companies to which a higher investment

risk may be atached than other companies listed on the Stock

Exchange. Prospective investors should be aware of the potential

risks of investing in such companies and should make the decision

to invest only after due and careful consideration.

Given that the companies listed on GEM are generaly smal and

mid-sized companies, there is a risk that securities traded on GEM

may be more susceptible to high market volatility than securities

traded on the Main Board of the Stock Exchange and no asurance

is given that there wil be a liquid market in the securities traded

on GEM.

Hong Kong Exchanges and Clearing Limited and The Stock

Exchange of Hong Kong Limited (the “Stock Exchange”)

take no responsibility for the contents of this report, make no

representation as to its acuracy or completenes and expresly

disclaim any liability whatsoever for any los howsoever arising

from or in reliance upon the whole or any part of the contents of

this report.

This report, for which the directors (the “Directors”) of God

Felow Healthcare Holdings Limited (the “Company”) colectively

and individualy acept ful responsibility, includes particulars given

in compliance with the Rules Governing the Listing of Securities

on GEM of the Stock Exchange (the “GEM Listing Rules”) for the

purpose of giving information with regard to the Company. The

Directors, having made al reasonable enquiries, confirm that, to

the best of their knowledge and belief the information contained

in this report is acurate and complete in al material respects and

not misleading or deceptive, and there are no other maters the

omision of which would make any statement herein or this report

misleading.

香港联合交易所有限公司（「联交

所」）

GEM

之特色

GEM

乃为投资风险较其他于联交所上市之公

司为高之中小型公司提供上市之市场。有意

投资之人士应了解投资于该等公司之潜在风

险，并应经过审慎周详之考虑后方作出投资

决定。

由于在

GEM

上市之公司一般为中小型公司，

在

GEM

买卖之证券可能会较在联交所主板买

卖之证券承受较大之市场波动风险，同时无

法保证在

GEM

买卖之证券会有高流通量之市

场。

香港交易及结算所有限公司以及香港联合交

易所有限公司（「联交所」）对本报告之内容概

不负责，对其准确性或完整性亦不发表任何

声明，并明确表示概不就因本报告全部或任

何部分内容而产生或因倚赖该等内容而引致

之任何损失承担任何责任。

本报告乃根据联交所

GEM

证券上市规则

（「

GEM

上市规则」）提供有关金威医疗集团

有限公司（「本公司」）之资料，本公司之各董事

（「董事」）愿就本报告之内容共同及个别承担

全部责任。各董事在作出一切合理查询后确

认，据彼等所深知及确信，本报告所载之资料

于各重大方面均属准确完整，且无误导或欺

骗成分，而本报告亦无遗漏其他事项，以致本

报告所载任何陈述或本报告有所误导。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/20252

Contents

目

录

Corporate Information 3

公司资料

Chairman’s Statement 6

主席报告

Management Discusion and Analysis 8

管理层讨论及分析

Directors’ and Senior Management’s Profiles 22

董事及高级管理人员简历

Corporate Governance Report25

企业管治报告

Report of the Directors 44

董事会报告

Independent Auditors’ Report 65

独立核数师报告

Consolidated Statement of Profit or Los and Other Comprehensive Income 73

综合损益及其他全面收益表

Consolidated Statement of Financial Position 75

综合财务状况表

Consolidated Statement of Changes in Equity 77

综合权益变动表

Consolidated Statement of Cash Flows 79

综合现金流量表

Notes to the Consolidated Financial Statements 81

综合财务报表附注

Financial Sumary 184

财务摘要

#

The English translation of Chinese names or words in this report,

where indicated, is included for information purpose only, and

should not be regarded as the oficial English translation of such

Chinese names and words.

For the purposes of ilustration only, amounts denominated in

RMB in this report have ben translated into HK$ at the rate of

RMB1.00 = HK$1.072. Such translation should not be constructed

as a representation that the amounts in question have ben, could

have ben or could be converted at any particular rate at al.

#

本报告内载入之中文名称或词语之英文译名

（如有指示）仅供参考之用，而不应视为有关

中文名称及词语之官方英文译名。

为仅供说明之用，本报告内以人民币计值的

金额乃按人民币

1.00

元兑

1.072

港元之汇率换

算为港元，惟该换算不应视为表示有关金额

已经、可能已经或可以任何特定汇率进行换

算。

---

金威医疗集团有限公司

2024/2025

年报

Corporate Information

公司资料

EXECUTIVE DIRECTORS

Ng Chi Lung (Chairman)

Wu Qiyou

INDEPENDENT NON-EXECUTIVE DIRECTORS

Wong Ka Wai, Jeane

Lau Tak Kei Arthur

Lin Yaomin (apointed with efect from 17 April 2024)

COMPLIANCE OFICER

Ng Chi Lung

AUTHORISED REPRESENTATIVES

Ng Chi Lung

Lam Wiliamson

COMPANY SECRETARY

Lam Wiliamson

执行董事

吴志龙（主席）

吴其佑

独立非执行董事

黄嘉慧

刘德基

林�（自二零二四年四月十七日起获委任）

监察主任

吴志龙

授权代表

吴志龙

林全智

公司秘书

林全智

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/20254

Corporate Information

公司资料

AUDIT COMITE

Wong Ka Wai, Jeane (Chairlady)

Lau Tak Kei Arthur

Lin Yaomin (apointed with efect from 17 April 2024)

REMUNERATION COMITE

Wong Ka Wai, Jeane (Chairlady)

Wu Qiyou

Lau Tak Kei Arthur

Lin Yaomin (apointed with efect from 17 April 2024)

NOMINATION AND CORPORATE

GOVERNANCE COMITE

Ng Chi Lung (Chairman)

Wong Ka Wai, Jeane

Lau Tak Kei Arthur

Lin Yaomin (apointed with efect from 17 April 2024)

REGISTERED OFICE

Vistra (Cayman) Limited

P.O. Box 31119 Grand Pavilion

Hibiscus Way, 802 West Bay Road,

Grand Cayman KY1-1205

Cayman Islands

HEAD OFICE AND PRINCIPAL PLACE OF

BUSINES IN HONG KONG

Rom 2101, 21/F,

China Merchants Tower, Shun Tak Centre

168-200 Conaught Road Central

Hong Kong

审核委员会

黄嘉慧（主席）

刘德基

林�（自二零二四年四月十七日起获委任）

薪酬委员会

黄嘉慧（主席）

吴其佑

刘德基

林�（自二零二四年四月十七日起获委任）

提名及企业管治委员会

吴志龙（主席）

黄嘉慧

刘德基

林�（自二零二四年四月十七日起获委任）

注册办事处

Vistra (Cayman) Limited

P.O. Box 31119 Grand Pavilion

Hibiscus Way, 802 West Bay Road,

Grand Cayman KY1-1205

Cayman Islands

总办事处及香港主要营业地点

香港

干诺道中

168-200

号

信德中心招商局大厦

楼

室

---

金威医疗集团有限公司

2024/2025

年报

Corporate Information

公司资料

PRINCIPAL SHARE REGISTRAR AND

TRANSFER OFICE

Vistra (Cayman) Limited

P.O. Box 31119 Grand Pavilion

Hibiscus Way, 802 West Bay Road,

Grand Cayman KY1-1205

Cayman Islands

HONG KONG BRANCH SHARE REGISTRAR

AND TRANSFER OFICE

Tricor Investor Services Limited

17/F, Far East Finance Centre

16 Harcourt Road

Hong Kong

PRINCIPAL BANKER

Bank of Comunications Co., Ltd.

20 Peder Stret

Central, Hong Kong

AUDITORS

HLB Hodgson Impey Cheng Limited

Certified Public Acountants

31/F, Gloucester Tower

The Landmark

11 Peder Stret

Central, Hong Kong

STOCK CODE

WEBSITE

w.gf-healthcare.com

主要股份过户登记处

Vistra (Cayman) Limited

P.O. Box 31119 Grand Pavilion

Hibiscus Way, 802 West Bay Road,

Grand Cayman KY1-1205

Cayman Islands

香港股份过户登记分处

卓佳证券登记有限公司

香港

夏悫道

号

远东金融中心

楼

主要往来银行

交通银行股份有限公司

香港中环

毕打街

号

核数师

国卫会计师事务所有限公司

执业会计师

香港中环

毕打街

号

置地广场

告罗士打大厦

楼

股份代号

网址

w.gf-healthcare.com

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/20256

Chairman’s Statement

主席报告

On behalf of the board (the “Board”) of directors (the

“Directors”) of God Felow Healthcare Holdings Limited (the

“Company”), I am pleased to present the audited consolidated

financial results of the Company and its subsidiaries (colectively

refered to as the “Group”) for the year ended 31 March 2025

(the “Year”).

FINANCIAL REVIEW

The year ended 31 March 2025 was a critical year and ful of

chalenges for the Group. During the Year, the Group continued to

focus on the provision of general hospital services in the People’s

Republic of China (the “PRC”). The Group’s revenue for the

Year was aproximately HK$16.120 milion (2024: aproximately

HK$38.962 milion), representing a decrease of aproximately

58.63% as compared with 2024. The operating los from

operation for the Year was aproximately HK$7.178 milion (2024:

aproximately HK$16.036 milion). Net los atributable to owners

of the Company for the Year was aproximately HK$10.127

milion (2024: net los of aproximately HK$17.110 milion).

OPERATION REVIEW

General hospital services

The Group operates one general hospital in Beijing (2024: one

general hospital in Beijing), in the PRC the operation of which

has ben suspended since 12 December 2024 and remained

suspended as at 31 March 2025. The segmental revenue for the

Year was aproximately HK$10.945 milion (2024: aproximately

HK$38.962 milion), representing a decrease of aproximately

71.90% as compared with the year ended 31 March 2024.

本人谨代表金威医疗集团有限公司（「本公

司」）董事（「董事」）会（「董事会」），欣然提呈本

公司及其附属公司（统称「本集团」）截至二零

二五年三月三十一日止年度（「本年度」）之经

审核综合财务业绩。

财务回顾

截至二零二五年三月三十一日止年度对本

集团而言乃关键及充满挑战之一年。于本年

度，本集团继续专注于中华人民共和国（「中

国」）提供综合性医院服务。本集团于本年度

之收益约为

16,120,000

港元（二零二四年：

约

38,962,000

港元），较二零二四年减少约

58.63%

。于本年度，经营业务之经营亏损约

为

7,178,000

港元（二零二四年：约

16,036,000

港元）。于本年度，本公司拥有人应占亏损净

额约为

10,127,000

港元（二零二四年：亏损净

额约

17,110,000

港元）。

营运回顾

综合性医院服务

本集团经营一间位于中国北京市之综合性医

院（二零二四年：一间位于北京市之综合性医

院），该医院自二零二四年十二月十二日起暂

停营运，并于二零二五年三月三十一日仍暂

停营运。本年度该分部收益约为

10,945,000

港元（二零二四年：约

38,962,000

港元），较

截至二零二四年三月三十一日止年度减少约

71.90%

。

---

金威医疗集团有限公司

2024/2025

年报

Chairman’s Statement

主席报告

APRECIATION

On behalf of the Board, I would like to thank our customers,

supliers, busines partners for their suport. Also, I would like to

ofer my highest gratitude to our shareholders for their devotion

and to our employes for their loyalty and contributions made

during the Year.

Ng Chi Lung

Chairman

Hong Kong, 26 June 2025

致谢

本人谨此代表董事会感谢本集团之客户、供

应商、业务伙伴之鼎力支持。本人亦谨此就本

年度内本集团股东之奉献及本集团员工之忠

诚服务及所作之贡献致以最诚挚谢意。

主席

吴志龙

香港，二零二五年六月二十六日

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/20258

Management Discusion and Analysis

管理层讨论及分析

FINANCIAL HIGHLIGHTS

Sumary of the results of the Group for the financial year ended

31 March 2025 is as folows:

• $16.120 milion (2024:

aproximately HK$38.962 milion), representing a decrease

of aproximately 58.63% as compared with last year.

• $8.369 milion (2024:

aproximately HK$18.674 milion), representing a decrease

of aproximately 55.18% as compared with last year.

• The operating los from the operation was aproximately

HK$7.178 milion (2024: aproximately HK$16.036 milion).

Net los atributable to owners of the Company was

aproximately HK$10.127 milion (2024: aproximately

HK$17.110 milion).

• The Directors do not recomend the payment of a final

dividend for the year ended 31 March 2025 (2024: Nil).

财务概要

本集团截至二零二五年三月三十一日止财政

年度之业绩概要如下：

•

收益约为

16,120,000

港元（二零二四

年：约

38,962,000

港元），较去年减少约

58.63%

。

•

毛利约为

8,369,000

港元（二零二四年：

约

18,674,000

港元），较去年减少约

55.18%

。

•

经营业务之经营亏损约为

7,178,000

港元（二零二四年：约

16,036,000

港

元）。本公司拥有人应占亏损净额约

为

10,127,000

港元（二零二四年：约

17,110,000

港元）。

•

董事并不建议就截至二零二五年三月

三十一日止年度派付末期股息（二零

二四年：无）。

---

金威医疗集团有限公司

2024/2025

年报

Management Discusion and Analysis

管理层讨论及分析

BUSINES REVIEW

The Group is principaly engaged in the provision of general

hospital services in the PRC.

Revenue

The Group recorded revenue of aproximately HK$16.120 milion

(2024: aproximately HK$38.962 milion) for the year ended

31 March 2025, representing a decrease of aproximately 58.63%

as compared with last year.

General hospital services

During the year ended 31 March 2025, the Group operated one

general hospital (the “Huicheng Hospital”) in Beijing in the PRC,

the operation of which has ben suspended since 12 December

2024 and remained suspended as at 31 March 2025 (2024:

one general hospitals in Beijing). The Hospital was principaly

engaged in the provision of general hospital services, including

but not limited to medical wards, surgical wards, medical

checkup and examination. The management envisaged that more

diversified hospital services wil be made available to the public

to satisfy various neds in the next few years, from comon

ilnes treatments to treatments of special and dificult diseases.

Therefore, the Group wil continue to alocate resources to

develop such services either from its existing hospitals or through

colaboration with strategic partners.

Other revenue

Other revenue, primarily including bank interest income and

sundry income amounted to aproximately HK$0.987 milion

(2024: aproximately HK$0.149 milion) for the year ended 31

March 2025.

Other los

Other los, primarily los on disposal of property, plant and

equipment amounted to aproximately HK$7.819 milion (2024:

aproximately HK$2.075 milion) for the year ended 31 March

2025.

业务回顾

本集团主要在中国从事提供综合性医院服务。

收益

截至二零二五年三月三十一日止年度，本

集团录得收益约为

16,120,000

港元（二零

二四年：约

38,962,000

港元），较去年减少约

58.63%

。

综合性医院服务

截至二零二五年三月三十一日止年度，本集

团于中国北京市营运一间综合性医院（「惠城

医院」），该医院自二零二四年十二月十二日起

暂停营运，并于二零二五年三月三十一日仍

暂停营运（二零二四年：一间位于北京市之综

合性医院）。该医院主要从事提供综合性医院

服务，包括（但不限于）医院病房、手术室、身

体检查及检验。管理层预见于未来数年，将可

向公众提供自普通疾病治疗至治疗特别及严

重病症等更多元化之医院服务，以满足各类

患者的需求。因此，本集团将继续以其现有之

医院或透过与战略伙伴合作分配资源发展有

关服务。

其他收益

截至二零二五年三月三十一日止年度，其他

收益（主要包括银行利息收入及杂项收入）约

为

987,000

港元（二零二四年：约

149,000

港

元）。

其他亏损

截至二零二五年三月三十一日止年度，其他

亏损（主要为出售物业、厂房及设备之亏损）约

为

7,819,000

港元（二零二四年：约

2,075,000

港元）。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/202510

Management Discusion and Analysis

管理层讨论及分析

Gain on disposal of subsidiaries

For the year ended 31 March 2025, the Group recorded a gain on

disposal of subsidiaries of aproximately HK$10.5 milion (2024:

nil). For details, please refer to the section headed “Discloseable

Transaction in relation to the Disposal of the Entire Isued Share

Capital of Sino Busines Investment Development Limited” below.

Seling and distribution expenses

Seling and distribution expenses primarily consisted of (1) salaries

and wages of sales and marketing personel; (2) depreciation

expense; and (3) transportation expenses. For the year ended

31 March 2025, seling and distribution expenses amounted to

aproximately HK$3.105 milion (2024: aproximately HK$8.918

milion), representing a decrease of aproximately 65.18% as

compared with last year. Such decrease was due to the suspension

of operation (the “Suspension”) of

北京紫荆医院有限公司

(for

transliteration purpose only, Beijing Zijing Hospital Co., Limited

#

)

(“Beijing Zijing”) (curently known as

北京惠城医院有限公司

)

(for transliteration purpose only, Beijing Huicheng Hospital Co.,

Ltd

#

), since 12 December 2024 and the operations of Beijing Zijing

remained suspended as at 31 March 2025. For further details

of the Suspension, please refer to the anouncements of the

Company dated 13 December 2024 and 10 February 2025.

Administrative expenses

Administrative expenses for the year ended 31 March 2025

amounted to aproximately HK$15.060 milion (2024:

aproximately HK$20.271 milion), representing a decrease of

aproximately 25.7% as compared with last year. Such decrease

was due to the Suspension. For further details of the Suspension,

please refer to the anouncements of the Company dated 13

December 2024 and 10 February 2025.

出售附属公司之收益

截至二零二五年三月三十一日止年度，本集

团录得出售附属公司收益约

10,500,000

港元

（二零二四年：无）。详情请参阅下文「有关

出售

Sino Busines Investment Development

Limited

全部已发行股本之须予披露交易」章

节。

销售及分销费用

销售及分销费用主要包括

(1)

销售和营销人员

之薪金及工资；

(2)

折旧开支；及

(3)

运输费用。

截至二零二五年三月三十一日止年度，销售

及分销费用约为

3,105,000

港元（二零二四年：

约

8,918,000

港元），较去年减少约

65.18%

。

有关减少乃由于北京紫荆医院有限公司（「北

京紫荆」）（现称北京惠城医院有限公司）自二

零二四年十二月十二日起暂停营运（「暂停营

运」）及于二零二五年三月三十一日北京紫荆

仍暂停营运所致。有关暂停营运的进一步详

情，请参阅本公司日期为二零二四年十二月

十三日及二零二五年二月十日之公告。

行政开支

截至二零二五年三月三十一日止年度之行政

开支约为

15,060,000

港元（二零二四年：约

20,271,000

港元），较去年减少约

25.7%

。有关

减少乃由于暂停营运所致。有关暂停营运的

进一步详情，请参阅本公司日期为二零二四

年十二月十三日及二零二五年二月十日之公

告。

---

金威医疗集团有限公司

2024/2025

年报

Management Discusion and Analysis

管理层讨论及分析

Finance costs

For the year ended 31 March 2025, the finance costs of the

Group were aproximately HK$0.190 milion (2024: aproximately

HK$0.308 milion), representing a decrease of aproximately

38.31% as compared with last year. Such decrease in finance costs

was due to the decrease in interest expenses on lease liabilities.

Los before taxation

The Group recorded a net los before taxation of aproximately

HK$7.368 milion for the year ended 31 March 2025 (2024:

aproximately HK$16.344 milion), representing an decrease of

aproximately 9.05% as compared with last year.

Dividends

The Directors do not recomend the payment of a final dividend

for the year ended 31 March 2025 (2024: Nil).

OUTLOK AND FUTURE PROSPECTS

Over the past year, the Group has pragmaticaly translated the

strategic blueprint outlined in the interim report of the Company

for the six months ended 30 September 2024 into concrete

actions. Facing the continuously evolving healthcare industry, the

Group remains comited to empowering traditional healthcare

services through technology, enhancing eficiency via optimised

resource alocation, and exploring inovative growth oportunities

within a compliant framework. The Group is confident that its

strategic transformation wil generate sustainable returns for its

shareholders.

财务费用

截至二零二五年三月三十一日止年度，本集

团之财务费用约为

190,000

港元（二零二四年：

约

308,000

港元），较去年减少约

38.31%

。有

关财务费用减少乃由于租赁负债之利息开支

减少所致。

除税前亏损

截至二零二五年三月三十一日止年度，本集

团录得除税前亏损净额约为

7,368,000

港元

（二零二四年：约

16,344,000

港元），较去年

减少约

9.05%

。

股息

董事并不建议就截至二零二五年三月三十一

日止年度派付末期股息（二零二四年：无）。

前景及未来展望

过去一年，本集团以务实的态度，将本公司截

至二零二四年九月三十日止六个月的中期报

告中的战略蓝图转化为具体行动。面对持续

演进的医疗健康产业，本集团继续致力于以

技术赋能传统医疗服务、优化资源配置提升

效能，在合规框架下探索创新增长点。本集团

有信心通过战略重塑为其股东创造可持续回

报。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/202512

Management Discusion and Analysis

管理层讨论及分析

The Group regards the resumption of operation of its general

hospital busines as a core mision. For site selection, the

management has identified a suitable site in Beijing, and is

evaluating, among others, the transportation acesibility,

scalability of medical facilities, and long-term operational

eficiency. To facilitate the resumption of operation, the

management has concurently initiated medical department

planing, key personel recruitment, and pre-review of

compliance documentation, advancing multiple workstreams to

solidify the foundation for its resumption of operation. The Group

proceds with prudent optimism at every step and maintain

transparency through regular disclosures. The upgraded hospital

aims to become a significant provider of comprehensive medical

services in the North PRC. In adition, the Group also serves as a

strategic operational partner to the Internet Hospital operated by

Yuerwan Qingdao. This coperation model delivers triple values:

stable cash flows, cost synergies through shared resources, and

future data-driven marketing potential.

Proceds from the Rights Isue (as defined below) wil be aplied

for the purposes as disclosed in the prospectus of the Company

dated 22 May 2025, prioritising a stronger financial foundation

and sustainable growth. Key alocations include repayment of

shareholder’s loans, which is expected to significantly reduce

interest burdens and enhance capital eficiency of the Group.

This wil synergisticaly suport the resumption of operation of

the general hospital busines of the Group, including Beijing

Huicheng’s new site renovation and/or equipment procurement.

The Group wil continue to implement its action plan centered

on technology-driven eficiency, optimised resource deployment,

and compliant inovation, rigorously advancing the resumption of

operation of the general hospital busines. The Group is dedicated

to converting its strategic vision into sustainable shareholder

returns, positioning the Group to capture enduring value

oportunities within the healthcare industry transformation.

本集团将综合性医院业务的恢复营运视为核

心任务。在选址方面，管理层已于北京物色一

个合适的地点，且正进行评估，考量交通衔接

便利性、医疗配套延展潜力及长期运营效益。

为方便恢复营运，管理层已同步启动医疗科

室规划、骨干人才招聘及合规材料预审工作，

多线并行夯实复业基础。本集团秉持审慎乐

观的态度推进每一步，并通过定期公告保持

透明度。该医院升级后旨在成为华北地区综

合医疗服务的重要供应商。此外，本集团亦为

悦尔湾青岛所运营互联网医院的战略运营伙

伴。通过此合作模式，本集团获得稳定现金

流、透过资源共享带来成本协同效益及未来

数据衍生营销潜力三重价值。

本次供股（定义见下文）资金将按本公司于二

零二五年五月二十二日刊发之供股章程所披

露之用途运用，核心目标是构建更稳健的财

务基础与可持续增长路径。其中重点投向股

东贷款偿还，此举预计显著减轻本集团利息

负担并提高资本效益，这将协同支持本集团

综合性医院业务的恢复营运，包括北京惠城

新址翻新及╱或设备导入。

本集团将继续以技术赋能医疗效率、资源优

化配置、合规创新增长为行动纲领，扎实推进

综合性医院业务恢复营运落地。本集团致力

于将战略蓝图转化为可持续的股东回报，令

本集团在医疗健康产业变革中把握长期价值

机遇。

---

金威医疗集团有限公司

2024/2025

年报

Management Discusion and Analysis

管理层讨论及分析

LIQUIDITY AND FINANCIAL RESOURCES

The Group had total cash and bank balances of aproximately

HK$3.829 milion as at 31 March 2025 (2024: aproximately

HK$3.644 milion).

The Group recorded total curent asets of aproximately

HK$8.559 milion as at 31 March 2025 (2024: aproximately

HK$8.705 milion) and total curent liabilities of aproximately

HK$16.587 milion as at 31 March 2025 (2024: aproximately

HK$25.615 milion). The curent ratio of the Group, calculated

by dividing the curent asets by the curent liabilities, was

aproximately 0.52 as at 31 March 2025 (2024: aproximately

0.34).

Gearing ratio, defined as total debts (comprising borowings and

lease liabilities) les cash and bank balances, divided by total

equity (including al capital and reserves of the Group), maintained

at 99.19% as at 31 March 2025 (31 March 2024: N/A).

流动资金及财政资源

本集团于二零二五年三月三十一日之总现金

及银行结余约为

3,829,000

港元（二零二四年：

约

3,644,000

港元）。

本集团于二零二五年三月三十一日录得流动

资产总值约为

8,559,000

港元（二零二四年：约

8,705,000

港元），而于二零二五年三月三十一

日之流动负债总额则约为

16,587,000

港元（二

零二四年：约

25,615,000

港元）。以流动资产

除以流动负债计算，本集团于二零二五年三

月三十一日之流动比率约为

0.52

（二零二四

年：约

0.34

）。

于二零二五年三月三十一日，资产负债比率

（界定为债务总额（包括借款及租赁负债）减

现金及银行结余除以总权益（包括本集团全部

资本及储备）维持于

99.19%

（二零二四年三月

三十一日：不适用）。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/202514

Management Discusion and Analysis

管理层讨论及分析

CAPITAL COMITMENTS

As at 31 March 2025 and 2024, the Group had no material capital

comitment.

CONTINGENT LIABILITIES

As at 31 March 2025, no member of the Group was engaged

in any litigation or arbitration of material importance and no

litigation or claim of material importance was known to the

directors to be pending or threatened against any member of the

Group.

FINANCING AND TREASURY POLICIES

The Group continues to adopt prudent financing and treasury

policies. Al the Group’s financing and treasury activities are

centraly managed and controled. Implementation of the

Group’s related policies is made under colective but extensive

considerations on liquidity risk, financing cost and exchange rate

risk.

FOREIGN EXCHANGE RISK

Since almost al transactions of the Group are denominated in

Renminbi and Hong Kong dolars and most of the bank deposits

are being kept in Renminbi and Hong Kong dolars to minimise

exposure to foreign exchange risk, the Directors consider the

Group’s risk exposure to curency fluctuations to be minimal.

Therefore, the Group had not implemented any formal hedging

or other alternative policies to deal with such exposure during the

year ended 31 March 2025. The Directors wil continue to monitor

foreign exchange exposure and wil consider to implement

hedging policies should the ned arises.

资本承担

于二零二五年及二零二四年三月三十一日，

本集团概无任何重大资本承担。

或然负债

于二零二五年三月三十一日，本集团成员公

司概无涉及任何重大诉讼或仲裁，而董事概

不知悉本集团任何成员公司有任何未决或面

临之重大诉讼或申索。

融资及库务政策

本集团继续采纳审慎之融资及库务政策。本

集团所有融资及库务活动均进行集中管理及

监控。本集团于仔细考虑整体流动资金风险、

融资成本及汇率风险后推行相关政策。

外汇风险

由于本集团绝大部分交易均以人民币及港元

计价，而大部分银行存款均以人民币及港元

存置，借此尽量减低外汇风险，故此董事认为

本集团之货币波动风险极微。因此，本集团于

截至二零二五年三月三十一日止年度并无实

施任何正式对冲或其他替代政策以应付有关

风险。董事将继续监控外汇风险，并于必要时

考虑实施对冲政策。

---

金威医疗集团有限公司

2024/2025

年报

Management Discusion and Analysis

管理层讨论及分析

CHARGES ON GROUP’S ASETS

As at 31 March 2025 and 2024, the Group had no bank

borowings and had no charges on any asets of the Group.

SEGMENT INFORMATION

During the year ended 31 March 2025, the revenue of the Group

was principaly generated from provision of general hospital

services. Financial information in respect of these operations is

presented in Note 4 to the consolidated financial statements.

CAPITAL STRUCTURE

As at 31 March 2025, the total isued share capital of the

Company was aproximately HK$29.168 milion (2024:

aproximately HK$29.168 milion) comprising (i) 563,649,988

ordinary shares of HK$0.05 each; and (i) 19,700,000 preference

shares of HK$0.05 each (2024: 563,649,988 ordinary shares of

HK$0.05 each and 19,700,000 preference shares of HK$0.05

each).

集团资产抵押

于二零二五年及二零二四年三月三十一日，

本集团并无银行借款且本集团资产并无涉及

任何抵押。

分类资料

于截至二零二五年三月三十一日止年度，本

集团之收益主要来自提供综合性医院服务。

有关该等业务之财务资料载于综合财务报表

附注

。

股本架构

于二零二五年三月三十一日，本公司全部已

发行股本约为

29,168,000

港元（二零二四年：

约

29,168,000

港元），包括

(i)563,649,988

股每

股面值

0.05

港元的普通股；及

(i)19,700,000

股每股面值

0.05

港元之优先股（二零二四年：

563,649,988

股每股面值

0.05

港元之普通股及

19,700,000

股每股面值

0.05

港元之优先股）。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/202516

Management Discusion and Analysis

管理层讨论及分析

EMPLOYES AND REMUNERATION POLICY

As at 31 March 2025, the Group had 21 (2024: 137) ful time

employes (including Directors and senior management) as shown

in the folowing table:

Number of Staf

Location

地区员工人数

Hong Kong

香港

PRC

中国

For the year ended 31 March 2025, staf costs (including Directors

emoluments) amounted to aproximately HK$13.072 milion

(2024: aproximately HK$22.669 milion). The Group remunerates

its employes based on individual performance and qualification.

Apart from the basic remuneration, staf benefits include the

contribution to the Mandatory Provident Fund Scheme, bonus

and medical coverage in Hong Kong; and basic insurance for

the elderly, basic medical insurance, work injury insurance and

unemployment insurance to the employes in the PRC. The Group

also adopted employe share option schemes to provide eligible

employes a performance incentive for continuous and improved

services with the Group and to enhance their contributions to

increase profits by encouraging capital acomodation and

share ownership. As at 31 March 2025 and 2024, there were no

outstanding share options under the share option schemes.

SIGNIFICANT INVESTMENTS

During the Year, there was no significant investment held by the

Group.

FUTURE PLANS FOR MATERIAL INVESTMENTS

OR CAPITAL ASETS

The Group did not have other plans for material investments and

capital asets.

雇员及薪酬政策

于二零二五年三月三十一日，本集团聘有

名

（二零二四年：

名）全职雇员（包括董事及

高级管理层），详情载于下表：

截至二零二五年三月三十一日止年度，员工

成本（包括董事酬金）约为

13,072,000

港元（二

零二四年：约

22,669,000

港元）。本集团根据

雇员之个别表现及资历厘定雇员报酬。除基

本酬金外，于香港之员工福利亦包括强制性

公积金计划供款、花红及医疗保险，而中国员

工则享有基本养老保险、基本医疗保险、工伤

保险及失业保险。本集团亦采纳雇员购股权

计划，向合资格员工提供绩效奖励，推动员

工继续为本集团提供更优质之服务，并藉著

鼓励资本承担及股份拥有权，让彼等为增加

盈利作出更大之贡献。于二零二五年及二零

二四年三月三十一日，购股权计划项下并无

尚未行使购股权。

重大投资

于本年度，本集团并无持有重大投资。

重大投资或资本资产的未来计划

本集团就重大投资及资本资产并无其他计划。

---

金威医疗集团有限公司

2024/2025

年报

Management Discusion and Analysis

管理层讨论及分析

MATERIAL ACQUISITIONS AND DISPOSALS OF

SUBSIDIARIES AND AFILIATED COMPANIES

Save as disclosed in the section headed “Discloseable Transaction

in relation to the Disposal of the Entire Isued Share Capital of

Sino Busines Investment Development Limited”, the Group did

not have any material acquisitions and disposals of subsidiaries,

asociates or joint ventures during the year ended 31 March 2025.

APOINTMENT OF INDEPENDENT

NON-EXECUTIVE DIRECTOR

Mr. Lin Yaomin was apointed as an independent non-executive

Director and a member of each of the audit comite, the

remuneration comite and the nomination and corporate

governance comite of the Company with efect from 17 April

2024.

For more details, please refer to the anouncement of the

Company dated 17 April 2024.

DISCLOSEABLE TRANSACTION IN RELATION

TO THE DISPOSAL OF THE ENTIRE ISUED

SHARE CAPITAL OF SINO BUSINES

INVESTMENT DEVELOPMENT LIMITED

On 20 September 2024, the Company, as the vendor and Ms. Lin

Xuejiao, as the purchaser (the “Purchaser”) entered into a sale

and purchase agrement, pursuant to which, the Company has

agred to sel and the Purchaser has agred to purchase the entire

isued share capital of the Sino Busines Investment Development

Limited (the “Disposal Company”), a then direct wholy-owned

subsidiary of the Company, at the consideration of HK$60,000.

As such, upon completion of the disposal on 23 September 2024,

the Disposal Company ceased to be a subsidiary of the Company

and the financial information of the Disposal Company and its

subsidiaries ceased to be consolidated into the consolidated

financial statements of the Group.

For more details, please refer to the anouncements of the

Company dated 20 September 2024 and 23 September 2024.

重大收购及出售附属公司及联属

公司

除「有关出售

Sino Busines Investment

Development Limited

全部已发行股本之须予

披露交易」章节所披露者外，本集团于截至二

零二五年三月三十一日止年度并无任何重大

收购及出售附属公司、联营公司或合营企业。

委任独立非执行董事

林瑶珉先生已获委任为本公司独立非执行董

事及审核委员会、薪酬委员会以及提名及企

业管治委员会各自之成员，自二零二四年四

月十七日起生效。

有关更多详情，请参阅本公司日期为二零

二四年四月十七日之公告。

有关出售

SINO BUSINES

INVESTMENT DEVELOPMENT

LIMITED

全部已发行股本之须予披

露交易

于二零二四年九月二十日，本公司（作为卖方）

及林雪娇女士（作为买方）（「买方」）订立买卖

协议，据此，本公司已同意出售而买方已同意

购买

Sino Busines Investment Development

Limited

（「出售公司」，本公司当时之直接全资

附属公司）之全部已发行股本，代价为

60,000

港元。因此，于二零二四年九月二十三日完成

出售后，出售公司不再为本公司之附属公司

及出售公司及其附属公司的财务资料不再综

合入账至本集团的综合财务报表。

有关更多详情，请参阅本公司日期为二零

二四年九月二十日及二零二四年九月二十三

日之公告。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/202518

Management Discusion and Analysis

管理层讨论及分析

COPERATION AND OPERATIONAL

MANAGEMENT AGREMENT

On 25 October 2024, God Felow Development Limited (“God

Felow”), an indirect wholy-owned subsidiary of the Company,

entered into a coperation and operational management

agrement (the “Agrement”) with Xiamen Yuerwan Medical

Management Co., Ltd.*

（厦门悦尔湾医疗管理有限公司）

(“Xiamen Yuerwan”) and Yuerwan (Qingdao) Internet Hospital

Co., Ltd.*

（悦尔湾（青岛）互联网医院有限公司）

(“Yuerwan

Qingdao”), a direct wholy-owned subsidiary of Xiamen

Yuerwan. Pursuant to the Agrement, God Felow has agred

to provide hospital management services to Yuerwan Qingdao

and Qingdao Yuerwan Internet Hospital*

（青岛悦尔湾互联网医

院）

(the “Internet Hospital”), the Internet hospital operated by

Yuerwan Qingdao, and Yuerwan Qingdao has agred to pay to

God Felow (i) the fixed monthly management fes of HK$1.75

milion; or (i) management fes equivalent to the sum of (a) 1%

of the operating revenue of the Internet Hospital as shown in its

audited financial report of the relevant financial year; and (b) 10%

of the profits before taxation of the Internet Hospital as shown

in the Audited Report, whichever is higher. The Agrement shal

be valid for a term of five years comencing from 25 October

2024 (the “Term”), and none of the parties thereto is entitled

to unilateraly terminate the Agrement during the first year of

the Term without cause, and any party thereto may terminate

the Agrement by giving the other parties not les than thre

months’ prior writen notice during the second to the fifth year

of the Term. The Agrement is extendable by the parties and a

suplemental agrement shal be entered into if extended.

合作营运管理协议

于二零二四年十月二十五日，本公司间接全

资附属公司金威创展有限公司（「金威创展」）

与厦门悦尔湾医疗管理有限公司（「厦门悦

尔湾」）及悦尔湾（青岛）互联网医院有限公司

（「悦尔湾青岛」，厦门悦尔湾之直接全资附

属公司）订立合作营运管理协议（「该协议」）。

根据该协议，金威创展已同意向悦尔湾青岛

以及青岛悦尔湾互联网医院（「互联网医院」）

（互联网医院由悦尔湾青岛经营）提供医院

管理服务，而悦尔湾青岛已同意向金威创展

支付

(i)

每月固定管理费

1,750,000

港元；或

(i)

相当于

(a)

互联网医院于有关财政年度之经审

核财务报告所显示的经营收益的

1%

；及

(b)

经

审核报告所显示的互联网医院除税前溢利的

10%

总和的管理费（以较高者为准）。该协议

自二零二四年十月二十五日起有效期计五年

（「期限」），且该协议任何一方无权于期限第

一年内无故单方面终止该协议，及该协议任

何一方可于期限第二年至第五年内透过向其

他各方发出不少于三个月的事先书面通知终

止该协议。该协议可由各方延期，以及于延期

时应订立补充协议。

---

金威医疗集团有限公司

2024/2025

年报

Management Discusion and Analysis

管理层讨论及分析

Pursuant to the Agrement, Xiamen Yuerwan has agred to

grant an option (the “Option”) to God Felow (or its nomines)

to purchase al or part of the shares of Yuerwan Qingdao and

the Internet Hospital from Xiamen Yuerwan during the Term.

The terms of and the consideration for the acquisition of such

shares shal be subject to further negotiation. In the event that

God Felow exercises the Option and enters into any specific

agrement(s) in relation to the potential acquisition of the

shares, further anouncement(s) wil be made by the Company in

acordance with the Rules Governing the Listing of Securities on

GEM of the Stock Exchange as and when apropriate.

For more details, please refer to the anouncement of the

Company dated 25 October 2024.

CHANGE OF ADRES OF THE HEAD OFICE

AND PRINCIPAL PLACE OF BUSINES IN

HONG KONG

With efect from 7 December 2024, the adres of the head ofice

and principal place of busines in Hong Kong of the Company has

ben changed to Rom 2101, 21/F, China Merchants Tower, Shun

Tak Centre, 168-200 Conaught Road Central, Hong Kong.

The telephone number, facsimile number and website of the

Company remain unchanged.

根据该协议，厦门悦尔湾已同意授予金威创展

（或其代名人）于期限内向厦门悦尔湾购买悦

尔湾青岛及互联网医院全部或部分股份的购

股权（「购股权」）。收购有关股份的条款及代价

有待进一步磋商。倘金威创展就潜在收购股

份行使购股权并订立任何特定协议，本公司

将于适当时候根据联交所

GEM

证券上市规则

作出进一步公告。

有关更多详情，请参阅本公司日期为二零

二四年十月二十五日之公告。

变更总办事处及香港主要营业地

点之地址

本公司总办事处及香港主要营业地点之地址

已变更为香港干诺道中

168-200

号信德中心招

商局大厦

楼

室，自二零二四年十二月

七日起生效。

本公司之电话号码、传真号码及网址均维持

不变。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/202520

Management Discusion and Analysis

管理层讨论及分析

CHANGE OF PRINCIPAL SHARE REGISTRAR

AND TRANSFER OFICE AND REGISTERED

OFICE IN THE CAYMAN ISLANDS

With efect from 31 December 2024, the principal share registrar

and transfer ofice and the registered ofice of the Company in the

Cayman Islands have ben changed to:

Vistra (Cayman) Limited

P.O. Box 31119 Grand Pavilion

Hibiscus Way, 802 West Bay Road,

Grand Cayman KY1-1205

Cayman Islands

The Company’s branch share registrar and transfer ofice in Hong

Kong remains unchanged.

RIGHTS ISUE ON THE BASIS OF ONE (1)

RIGHTS SHARE FOR EVERY ONE (1) EXISTING

SHARE HELD ON THE RECORD DATE

On 14 March 2025, the Company proposed to raise gros

proceds of up to aproximately HK$28.2 milion (asuming ful

subscription under the Rights Isue by isuing up to 563,649,988

shares (the “Rights Share(s)”) of the Company at the

subscription price of HK$0.05 per Rights Share on the basis of one

(1) Rights Share for every one (1) existing share of the Company.

For more details, please refer to the anouncements of the

Company dated 14 March 2025, 12 June 2025 and 26 June 2025

and the prospectus of the Company dated 22 May 2025.

变更开曼群岛主要股份过户

登记处及注册办事处

自二零二四年十二月三十一日起，本公司于

开曼群岛的主要股份过户登记处及注册办事

处已变更为：

Vistra (Cayman) Limited

P.O. Box 31119 Grand Pavilion

Hibiscus Way, 802 West Bay Road,

Grand Cayman KY1-1205

Cayman Islands

本公司的香港股份过户登记分处则维持不变。

按于记录日期每持有一

(1)

股现有

股份获发一

(1)

股供股份之基准

进行供股

于二零二五年三月十四日，本公司建议按每

持有一

(1)

股本公司现有股份获发一

(1)

股供股

股份的基准，以认购价每股供股份

0.05

港元

发行最多

563,649,988

股本公司股份（「供股

份」）而筹集最多约

28,200,000

港元（假设供股

获全数认购）的所得款项总额。

有关更多详情，请参阅本公司日期为二零

二五年三月十四日、二零二五年六月十二日

及二零二五年六月二十六日之公告及本公司

日期为二零二五年五月二十二日之供股章程。

---

金威医疗集团有限公司

2024/2025

年报

Management Discusion and Analysis

管理层讨论及分析

SIGNIFICANT EVENTS AFTER THE REPORTING

PERIOD

Save as disclosed in this report, no other significant event tok

place subsequent to the end of the reporting period.

PRINCIPAL RISKS AND UNCERTAINTIES

The Group’s financial condition, results of operations, busineses

and prospects may be afected by a number of risks and

uncertainties. The folowings are the key risks and uncertainties

identified by the Group. There may be other risks and

uncertainties in adition to those shown below which are not

known to the Group or which may not be material for the time

being but may be material in the future.

Market Risks

As the PRC government has recently restructured its central

ministries and agencies responsible for the healthcare afairs, the

functions of diferent departments are being reasigned, thus

potentialy slowing down the procedures and work in relation

to the hospital operations and management engaged by the

Company. The changes wil also have some potential impact on the

establishment of policies and regulations at various levels of the

local governments which may impose risks on the execution of the

Group’s marketing plans and implementation of the coperation.

Operational Risks

It is noted that the regional governance of the hospitals in the

PRC varies from city to city due to the diferent focuses on

local medical services and social welfare. This wil certainly have

some impact on the Group’s operations because the Group

manages hospitals located in diferent cities in the PRC. This has

ben and wil be a huge chalenge to the management for the

standardisation and consistency of hospital operations. The Group

wil comply with the regional policy as wel as the core guidelines

isued by the central government to ensure the smoth and

efective operation.

报告期后重大事项

除本报告所披露者外，于报告期末后，并无发

生任何其他重大事项。

主要风险及不明朗因素

本集团的财务状况、营运业绩、业务及前景可

能受多个风险及不明朗因素的影响。以下为

本集团知悉的主要风险及不明朗因素。除下

文所列者外，或会存在本集团并未知悉或目

前可能不重要但日后可能变得重要的其他风

险及不明朗因素。

市场风险

由于中国政府近期重组了主管卫生事宜的中

央部门及机构，不同部门的职能进行重新划

分，从而有可能会导致本公司从事的有关医

院营运及管理的程序及工作效率减缓。有关

变动亦将会对各级地方政府政策及法规的制

定带来一定的潜在影响，而此可能会对执行

本集团的市场推广计划及落实合作带来风险。

营运风险

注意到，各地区对国内医院的规管会因城市

的不同而有所差异，乃由于各地方医疗服务

及社会福利的关注点不同。此情况确实会对

本集团的营运带来一定影响，因为本集团在

中国不同的城市管理医院。此已并将会对医

院营运的标准化及一致性管理带来巨大挑

战。本集团将遵守地区政策以及中央政府发

出的核心指引以确保平稳有效营运。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/202522

Directors’ and Senior Management’s Profiles

董事及高级管理人员简历

EXECUTIVE DIRECTORS

Mr. Ng Chi Lung (“Mr. Ng”), aged 36, has twelve years

of experience in founding new busines and comercial

management. Mr. Ng studied at Macquarie University (major

in acounting) in Australia after obtained his diploma from

the Sydney Institute of Busines and Technology in 2008.

Since February 2012, Mr. Ng founded and managed busines

including the scope of manufacturing and services sector. He

was an executive director of Yueshou Environmental Holdings

Limited (curently known as China Gem Holdings Limited) (stock

code:1191), being a company listed on the Main Board of the

Stock Exchange, from September 2014 to April 2016. He was also

a vice chairman and an executive director of Theme International

Holdings Limited (stock code: 990), being a company listed on the

Main Board of the Stock Exchange, from April 2016 to July 2018.

Mr. Ng was apointed as an executive Director and chairman of

the Board on 23 July 2018. Mr. Ng is also a director of various

subsidiaries of the Group.

Mr. Wu Qiyou (“Mr. Wu”), aged 31, poseses profound

expertise in busines management, strategic planing and risk

management. Mr. Wu obtained a Bachelor of Busines (Banking

and Finance) from the Monash University in 2016 and a Master of

Busines Administration from the same university in 2022.

From 2016 to 2020, Mr. Wu served as an investment manager at

Cornerstone Capital Investment Group Pty Ltd, leading multiple

comercial real estate projects involving retirement and medical

asets, monitoring compliance and conducting risk control for

those projects. From 2021 to 2022, Mr. Wu was a member of

the management team at Lunghealth Medtech Company Limited,

spearheading the strategic rolout of the magnetic navigation

bronchoscope system in the Chinese market, ensuring the safety

of the product and overseing the compliance with the relevant

laws and regulations. In December 2022, Mr. Wu founded

Dynamiq Advisory Pte Ltd (“Dynamiq Advisory”) and has ben the

chief executive oficer Dynamiq Advisory thereafter, providing its

clients with comprehensive corporate services, including but not

limited to compliance and risk management services.

Mr. Wu was apointed as an executive Director with efect from

22 August 2023.

执行董事

吴志龙先生（「吴先生」），

岁，拥有十二年创

办发展新业务及商业管理的经验。吴先生在

二零八年取得雪梨商业及科技学院之证书

后曾就读于澳大利亚麦觉理大学（主修会计）。

自二零一二年二月起，吴先生创办及管理包

括制造及服务行业范畴在内之业务。彼于二

零一四年九月至二零一六年四月担任粤首环

保控股有限公司（现称为中国中石控股有限公

司（股份代号：

），一间于联交所主板上

市之公司）之执行董事。彼于二零一六年四月

至二零一八年七月亦为荣晖国际集团有限公

司（股份代号：

，一间于联交所主板上市

之公司）之副主席及执行董事。吴先生于二零

一八年七月二十三日获委任为执行董事及董

事会主席。吴先生亦为本集团多间附属公司

之董事。

吴其佑先生（「吴先生」），

岁，于业务管理、

战略规划及风险管理方面拥有丰富的专业

知识。吴先生于二零一六年获得蒙纳殊大学

(Monash University)

商学（银行与金融）学士学

位及于二零二年获得该大学的工商管理硕

士学位。

于二零一六年至二零二零年，吴先生于

Cornerstone Capital Investment Group Pty Ltd

担任投资经理，牵头多个涉及退休及医疗资

产的商业房产项目，监察该等项目的合规性

并开展风险控制。于二零二一年至二零二

年，吴先生担任

Lunghealth Medtech Company

Limited

管理团队成员，带领磁导航支气管镜

系统于中国市场的战略部署，确保产品安全

性及监督相关法律法规的合规情况。于二零

二年十二月，吴先生成立

Dynamiq Advisory

Pte Ltd

（「

Dynamiq Advisory

」），其后一直担任

Dynamiq Advisory

行政总裁，为其客户提供全

面的企业服务，包括但不限于合规及风险管

理服务。

吴先生已自二零二三年八月二十二日起获委

任为执行董事。

---

金威医疗集团有限公司

2024/2025

年报

Directors’ and Senior Management’s Profiles

董事及高级管理人员简历

独立非执行董事

黄嘉慧女士（「黄女士」），

岁，于金融、会

计、税务及企业事务拥有逾

年经验。彼为澳

洲及新西兰特许会计师公会之会员、香港会

计师公会之执业会计师、信托及遗产学会

员及香港之注册税务顾问。黄女士持有澳洲

悉尼大学经济学士学位。黄女士现时为一间

提供顾问及管理服务之私人公司之董事总经

理，亦为一间本地律师行之财务总监及一间

本地注册会计师事务所之顾问。黄女士现时

为品创控股有限公司（股份代号：

，一间

于

GEM

上市之公司）之独立非执行董事。黄女

士于二零七年十一月一日获委任为独立非

执行董事。

刘德基先生（「刘先生」），

岁，於伦敦政治经

济学院

(The London Schol of Economics and

Political Science)

取得法学士学位，并于香港

大学取得经济学硕士学位。彼乃可从事香港

法例第

章证券及期货条例项下第

类（就证

券提供意见）及第

类（资产管理）受规管活动

之持牌人。

刘先生于亚洲对冲基金、私募股权及投资

银行方面拥有逾

年经验。彼为

Ark Pacific

Capital Management

（专注于大中华区之多策

略另类资产管理人）之联合创始人及现时为

Ark Pacific Capital Management

之合伙人。彼

曾担任

Eliot Advisors (HK) Ltd

（「

Eliot

」，全球

多策略对冲基金

Eliot Asociates

之亚洲分支

机构）之投资主管。于

Eliot

任职期间，彼负责

投资事务，涵盖包括中国、香港及东南亚之公

开上市证券、私募股权、结构性信贷、房地产

及基金投资等资产类别。于此之前，彼曾于花

旗集团

(Citigroup)

科技、媒体及电信团队中担

任投资银行家，负责各类并购及企业融资交

易。彼职业生涯始于香港

JPMorgan

的投资银

行部。刘先生亦为中国人民政治协商会议北

京市委员会委员。刘先生于二零一九年十月

四日获委任为独立非执行董事。

INDEPENDENT NON-EXECUTIVE DIRECTORS

Ms. Wong Ka Wai, Jeane (“Ms. Wong”), aged 61, has over 31

years of experience in finance, acounting, taxation and corporate

afairs. She is a member of the Chartered Acountants in Australia

and New Zealand, a Certified Public Acountant of the Hong Kong

Institute of Certified Public Acountants, a member of the Society

of Trust and Estate Practitioner and the Certified Tax Advisor in

Hong Kong. Ms. Wong holds a bachelor degre in economics

from the University of Sydney, Australia. Ms. Wong is curently

the managing director of a private company providing consulting

and management services, as wel as the chief financial oficer

of a local law firm and consultant of a local CPA firm. Ms. Wong

is curently an independent non-executive director of Phoenitron

Holdings Limited (stock code: 8066), being a company listed on

GEM. Ms. Wong was apointed as an independent non-executive

Director on 1 November 2007.

Mr. Lau Tak Kei Arthur (“Mr. Lau”), aged 43, holds a bachelor

degre of laws from The London Schol of Economics and Political

Science and a master of economics from The University of Hong

Kong. He is licenced to cary out Type 4 (advising on securities)

and Type 9 (aset management) regulated activities under the

Securities and Futures Ordinance (Chapter 571 of the Laws of

Hong Kong).

Mr. Lau has over 19 years of experience spaning hedge

fund, private equity and investment banking in Asia. He is

the co-founder and curently a partner of Ark Pacific Capital

Management, a multi-strategy alternative aset manager focusing

in Greater China. He was investment director of Eliot Advisors

(HK) Ltd (“Eliot”), the Asian arm of Eliot Asociates, a global

multi-strategy hedge fund. During his tenure at Eliot, he was

responsible for investments acros aset clases including publicly-

listed securities, private equity, structured credit, real estate and

fund-of-funds investments in China, Hong Kong and South East

Asia. Prior to this, he worked as an investment banker at Citigroup

in the Technology, Media & Telecom team runing a wide range

of mergers and acquisitions and corporate finance transactions.

He began his carer at JPMorgan’s investment banking division

in Hong Kong. Mr. Lau is also a member of the Beijing Municipal

Comite of the Chinese People’s Political Consultative

Conference. Mr. Lau was apointed as an independent non-

executive Director on 4 October 2019.

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/202524

Directors’ and Senior Management’s Profiles

董事及高级管理人员简历

林�先生（「林先生」），

岁，于一九八二

年获得南京大学理学士学位及中国科学院

（「中国科学院」）理学硕士学位。林先生为一

名高级经济师，并于一九年起获指定为

寿险管理学会之寿险管理师。

林先生于管理及金融、医疗保险行业拥有逾

年经验。自一九八六年十二月至一九三

年四月，林先生担任中国保险管理干部学

院教研室主任、团委书记。林先生其后自

一九五年三月至二零年一月约五年间

担任中国平安人寿保险股份有限公司（「平安

人寿」）厦门分公司总经理。自二零年一月

至二零二年七月，林先生调任平安人寿湖

北分公司担任总经理。自二零六年六月至

二零一五年三月，林先生加入昆仑健康保险

股份有限公司担任常务副总裁，其最后职位

为董事长兼总裁。于二零一七年三月，林先生

于天星数科担任高级顾问，并于二零二一年

十二月退任。此后，彼创立今日保，并担任其

研究所长。

林先生已自二零二四年四月十七日起获委任

为独立非执行董事。

高级管理人员

林全智先生（「林先生」），

岁，于二零七

年十二月加入本集团。林先生为本集团之财

务总监兼本公司之公司秘书。彼于财务及公

司秘书职务方面拥有逾

年经验。林先生乃

澳洲会计师公会员及香港会计师公会资深

会员。

Mr. Lin Yaomin (“Mr. Lin”), aged 64, obtained a bachelor’s

degre in Science from the Nanjing University in 1982 and a

master’s degre in Science from The Chinese Academy of Sciences

（中国科学院）

(the “CAS”). Mr. Lin is a senior economist and has

also ben designated as a Felow, Life Management Institute from

Life Ofice Management. Asociation since 1999.

Mr. Lin has over 30-year experience in management and in the

industry of financial, medical and healthcare insurance. From

December 1986 to April 1993, Mr. Lin served as the head of

the teaching and research department and the secretary of the

youth league comite at the China Insurance Management

Cadre Colege. Mr. Lin then served as the general manager at the

Xiamen branch of Ping An Life Insurance Company of China, Ltd

(“Ping An Life”) for about 5 years from March 1995 to January

2000. From January 2000 to July 2002, Mr. Lin was relocated

to the Hubei branch of the Ping An Life to serve as a general

manager. From June 2006 to March 2015, Mr. Lin joined Kunlun

Health Insurance Co. Ltd. as an executive vice president, with his

last position as the chairman and chief executive oficer. In March

2017, Mr. Lin worked as a senior consultant at Airstar Digital

Technology and retired in December 2021. Thereafter, he founded

Insurance Today and has ben the director of its research institute.

Mr. Lin was apointed as an independent non-executive Director

with efect from 17 April 2024.

SENIOR MANAGEMENT

Mr. Lam Wiliamson (“Mr. Lam”), aged 50, joined the Group in

December 2007. Mr. Lam is the Group’s chief financial oficer and

company secretary of the Company. He has more than 20 years’

experience in finance and company secretarial functions. Mr. Lam

is a member of the Certified Practising Acountant in Australia

and also a felow member of the Hong Kong Institute of Certified

Public Acountants.

---

金威医疗集团有限公司

2024/2025

年报

Corporate Governance Report

企业管治报告

CORPORATE GOVERNANCE PRACTICES

The Company acknowledges the ned and importance of

corporate governance as one of the key elements in creating

shareholders’ value. The Company is also comited to achieving

high standard of corporate governance that can properly protect

and promote the interests of al shareholders and to enhance

corporate value and acountability of the Company. The Company

has adopted the Corporate Governance Code (the “CG Code”) as

stated in Apendix C1 to the GEM Listing Rules.

The Company has complied with the aplicable code provisions in

the CG Code contained in Apendix C1 to the GEM Listing Rules

for the year ended 31 March 2025.

COMPLIANCE WITH THE MODEL CODE FOR

SECURITIES TRANSACTIONS BY DIRECTORS

The Company has adopted a set of code for the required standard

of dealings in securities by Directors on terms no les exacting

than the required standard of dealings set out in Rules 5.48 to

5.67 of the GEM Listing Rules. Having made specific enquiries,

the Directors confirmed that they have fuly complied with the

required standard with respect to the securities dealings of the

Company and there was no event of non-compliance for the year

ended 31 March 2025.

企业管治常规

本公司确信企业管治是为股东增值之必要及

重要关键元素之一，而本公司亦努力达致高

水平之企业管治，以适当保障及提升全体股

东利益，同时提高企业价值及本公司之问责

性。本公司已采用

GEM

上市规则附录

C1

所述

之企业管治守则（「企业管治守则」）。

于截至二零二五年三月三十一日止年度，本

公司已遵守

GEM

上市规则附录

C1

所载之企业

管治守则之适用守则条文。

遵守有关董事进行证券交易之标

准守则

本公司已采纳一套有关董事进行证券交易之

规定标准守则，其条款严谨度并不低于

GEM

上市规则第

5.48

至

5.67

条所载列之规定买卖

标准。经作出具体查询后，董事确认彼等已全

面遵守有关本公司证券交易之规定标准，且

于截至二零二五年三月三十一日止年度并无

发生违反有关标准之事件。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/202526

Corporate Governance Report

企业管治报告

THE BOARD

The Board asumes overal responsibilities for leadership and

control of the Company and is colectively responsible for

promoting the suces of the Company and its busines by

directing and supervising the Company’s afairs. The Board

focuses on overal corporate strategies and policies with atention

particularly paid to the financial performance of the Company.

Al Directors have ful and timely aces to al relevant information

as wel as the advice and services of the company secretary, with a

view to ensuring that the Board procedures and al aplicable laws

and regulations are folowed. Each Director is normaly able to

sek independent profesional advice in apropriate circumstances

at the Company’s expense, upon making a request to the Board.

There is a clear division of the responsibilities of the Board and

the management. The Board delegated its responsibilities to

the Directors and senior management to deal with day-to-day

operations and review those arangements on a periodic basis.

Management has to report to the Board and obtain prior aproval

before making decisions for key maters or entering into any

comitments on behalf of the Company. The Board has a balance

of skil and experience apropriate for the requirements of the

busines of the Company.

The Board has established thre comites, namely, the audit

comite, the nomination and corporate governance comite

and the remuneration comite, for overseing particular aspects

of the Company’s afairs. Al Board comites of the Company

are established with defined writen terms of reference which are

disclosed on the Company’s website and the Stock Exchange’s

website.

Apropriate directors’ liability insurance cover has ben aranged

to indemnify the Directors for liabilities arising out of corporate

activities. The coverage and the sum insured under the insurance

policy are to be reviewed regularly.

董事会

董事会全面负责本公司之领导及监控，透过

指导及监察本公司之事务对本公司及其业务

之成功承担集体责任。董事会专责整体之企

业策略及政策，尤其著重本公司之财务表现。

所有董事均可全面及适时地取得一切相关资

料以及公司秘书之意见与服务，以确保董事

会程序、所有适用法例及规例均已遵行。各董

事一般可于适当情况下，经向董事会提出要

求后寻求独立专业意见，有关开支由本公司

承担。

董事会与管理层有明显之分工。董事会将日

常营运交由董事与高级管理人员负责，并且

定期检讨有关安排。

管理人员对重大事宜作出决定或代表本公司

作出任何承担之前，须向董事会汇报及征求

事先批准。董事会兼备各种技能及经验，配合

本公司业务所需。

董事会已成立三个委员会，即审核委员会、提

名及企业管治委员会及薪酬委员会，以监察

本公司特定范畴之事务。所有本公司董事委

员会之成立，皆以书面制订其职权范围，并已

于本公司网站及联交所网站披露。

本公司已安排购买合适的董事责任保险，以

保障董事从事公司活动所产生的责任。保单

项下的保障范围和投保金额将会定期检讨。

---

金威医疗集团有限公司

2024/2025

年报

Corporate Governance Report

企业管治报告

Board Composition and Atendance Records of Directors

The Board curently comprises two executive Directors and

thre independent non-executive Directors. During the year

ended 31 March 2025, ten ful Board metings were held and

atendance (either in person or through other electronic means

of comunication) record of each Director at the metings of

the Board together with the metings of the audit comite,

the remuneration comite and the nomination and corporate

governance comite and general meting held during the year

ended 31 March 2025 are set out below.

Atendance/Number of Metings

出席次数╱会议数目

Board

Audit

Comite

Remuneration

Comite

Nomination

and

Corporate

Governance

Comite

General

metings

held during

the year

2024/2025

Name of Directors

董事姓名董事会审核委员会薪酬委员会

提名及

企业管治

委员会

于二零二四年

/

二零二五年

举行之

股东大会

Executive Directors

执行董事

Mr. Ng Chi Lung

吴志龙先生

10/10N/A

不适用

N/A

不适用

2/21/1

Mr. Wu Qiyou

吴其佑先生

10/10N/A

不适用

2/2N/A

不适用

1/1

Independent non-

executive Directors

独立非执行董事

Ms. Wong Ka Wai, Jeane

黄嘉慧女士

10/102/22/22/21/1

Mr. Lau Tak Kei Arthur

刘德基先生

10/102/22/22/21/1

Mr. Lin Yaomin (Note 1)

林瑶珉先生（附注

）

9/92/21/11/11/1

Note:

(1) Mr. Lin Yaomin was apointed as an independent non-executive

Director with efect from 17 April 2024.

董事会之组成及董事之出席记录

董事会现时包括两位执行董事及三位独立非

执行董事。截至二零二五年三月三十一日止

年度，举行了十次全体董事会议，各董事出

席（亲身出席或透过其他电子沟通方式）董事

会议，连同审核委员会、薪酬委员会以及提

名及企业管治委员会议及于截至二零二五

年三月三十一日止年度举行之股东大会之记

录载列如下。

附注：

(1)

林瑶珉先生获委任为独立非执行董事，自二

零二四年四月十七日起生效。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/202528

Corporate Governance Report

企业管治报告

“The list of the Directors and their Role and Function” has ben

maintained on the websites of the Company and the Stock

Exchange. The Directors’ biographies and the relationship among

the Board members, if any, are disclosed under the section headed

“Directors’ and Senior Management’s Profiles” on pages 22 to 24

of this report.

Given the composition of the Board and the skils, knowledge

and expertise of each Director, the Board believes that it is

apropriately structured to provide suficient checks and balances

to protect the interests of the Group and the shareholders. The

Board wil review its composition regularly to ensure that it has the

apropriate balance of expertise, skils and experience to continue

to efectively overse the busines of the Company.

Responsibilities of Directors

The independent non-executive Directors, with diversified

expertise, skils and experience, play an important role in

formulating strategy and ensuring that the Board maintains high

standards of corporate governance. The Board had received

from each independent non-executive Director a writen anual

confirmation in respect of his/her independence pursuant to

Rule 5.09 of the GEM Listing Rules and is satisfied with the

independence of the independent non-executive Directors.

On a regular basis, senior management provides the Directors with

operational and financial reports reflecting Group’s performance,

position and prospect. Al Directors are kept informed of and duly

briefed of major changes and information that may afect the

Group’s busines in a timely maner.

Every Board member is entitled to have aces to Board papers

and related materials and has unrestricted aces to the advice

from and services of the company secretary (the “Company

Secretary”) of the Company, and has the liberty to sek external

profesional advice if so required. The Company Secretary

continuously updates al Directors on the latest development

of the GEM Listing Rules and other aplicable regulatory

requirements to ensure compliance and upkep of god corporate

governance practice.

「董事会成员名单与其角色及职能」已记录于

本公司及联交所网站。董事之个人履历及董

事会成员之间之关系（如有）于本报告第

至

第

页「董事及高级管理人员简历」一节披露。

鉴于董事会之组成及每位董事之技能、学识

与专业知识，董事会相信其架构已能适当地

提供足够制衡，以保障本集团及股东之利益。

董事会将定期检讨其组成，以确保其在专业

知识、技能及经验方面维持合适之平衡，借以

继续有效地监察本公司之业务。

董事职责

拥有广泛专门知识、技能及经验之独立非执

行董事在制定策略及确保董事会维持高水平

企业管治方面担当重要角色。根据

GEM

上市

规则第

5.09

条，董事会已接获各独立非执行董

事确认彼等独立性之年度书面确认书，并信

纳独立非执行董事之独立性。

高级管理人员定期向董事提供反映本集团业

绩、状况及前景之营运及财务报告。本集团会

适时地向所有董事汇报并简报任何有可能影

响本集团业务之重大变动及资料。

各董事会成员均有权查阅董事会文件及相关

资料，并可随时要求本公司之公司秘书（「公司

秘书」）提供意见及服务，亦可在需要时征求外

部专业意见。公司秘书一直向所有董事更新

有关

GEM

上市规则及其他适用监管规定之最

新发展以确保合规，并一直维持良好之企业

管治常规。

---

金威医疗集团有限公司

2024/2025

年报

Corporate Governance Report

企业管治报告

Training and Continuous Development for Directors

Each newly apointed Director is provided with comprehensive

induction to ensure that he/she has a proper understanding

of the operations and busineses of the Group as wel as his/

her responsibilities and obligations under the GEM Listing

Rules and relevant regulatory requirements. To kep abreast of

responsibilities and conduct as a Director and of the busines

activities and development of the Company, the Company had

provided trainings to the Directors in the form of seminars and

reading materials. The Company has devised a training record to

asist the Directors to record the training they have undertaken.

Also, the completed records are received from each of the

Directors as confirmation. In adition, the Group wil, if necesary,

provide timely and regular trainings to the Directors to ensure that

they kep abreast of the latest regulatory requirements under the

GEM Listing Rules.

The individual record of each Director who received training for

the year ended 31 March 2025 is sumarised as folow:

Seminars

Reading

materials

研讨会阅读材料

Executive Directors

执行董事

Mr. Ng Chi Lung

吴志龙先生✓

Mr. Wu Qiyou

吴其佑先生✓

Independent non-executive Directors

独立非执行董事

Ms. Wong Ka Wai Jeane

黄嘉慧女士✓

Mr. Lau Tak Kei Arthur

刘德基先生✓

Mr. Lin Yaomin

林瑶珉先生✓

The Company wil, from time to time, review the efectivenes of

the Group’s corporate governance structure and consider whether

any changes.

董事培训及持续发展

本公司向每名获委任之新董事提供全面入职

简介，以确保其对本集团之营运及业务以及

其职责与

GEM

上市规则及相关监管规定项下

责任有适当理解。为了清楚明白作为本公司

董事之责任以及行为准刖、本公司之业务活

动及发展，本公司以研讨会及阅览材料之形

式为董事提供培训。本公司已设定培训记录，

以协助董事记录彼等已接受之培训。本公司

亦从每名董事接获完整记录确认彼等已接受

之培训。此外，本集团将（如有必要）向董事提

供及时及定期培训以确保彼等同步了解

GEM

上市规则项下的最新监管规定。

截至二零二五年三月三十一日止年度，每位

接受培训的董事个人记录概述如下：

本公司将不时检讨本集团之企业管治架构之

成效，并考虑是否作出任何修改。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/202530

Corporate Governance Report

企业管治报告

DIRECTORS

Apointment and Re-election of Directors

Code provision B.2.2 of the CG Code provides that every director,

including those apointed for a specific term, should be subject to

retirement by rotation at least once every thre years.

Pursuant to article 87(1) of the articles of asociation (the

“Articles of Asociation”) of the Company, one-third of the

Directors for the time being (or, if their numbers is not a multiple

of thre, the number nearest to but not les than one-third)

shal retire from ofice by rotation provided that every Director

(including those apointed for a specific term) shal be subject to

retirement at least once every thre years. A retiring Director shal

be eligible for re-election.

Pursuant to Article 86(3) of the Articles of Asociation, any

Director apointed either to fil a casual vacancy on the Board or

as an aditional Director shal hold ofice only until the first anual

general meting of the Company after his apointment, and shal

then be eligible for re-election.

Each of the independent non-executive Directors has entered into

a leter of apointment with the Company for a term of one year,

subject to retirement by rotation and re-election at anual general

metings pursuant to the Articles of Asociation.

Folowing the resignation of Dr. Lam Huen Sum as an independent

non-executive Director with efect from 18 January 2024, there

were only two independent non-executive Directors. As a result,

the Company failed to met the requirement under Rule 5.05(1)

of the GEM Listing Rules which stipulates that every board of

directors of a listed isuer must include at least thre independent

non-executive directors.

Mr. Lin Yaomin was apointed as an independent non-

executive Director with efect from 17 April 2024, folowing his

apointment, the Board has re-complied with the said requirement

under Rule 5.05(1) of the GEM Listing Rules.

董事

委任及重选董事

企业管治守则的守则条文

B.2.2

规定，每位董事

（包括有特定任期的董事）均应至少每三年轮

值退任一次。

根据本公司之组织章程细则（「组织章程细

则」）第

87(1)

条，时任三分之一的董事（或如果

彼等的人数并非三的倍数，则为最接近但不

少于三分之一的人数）应轮值退任，惟每位董

事（包括有特定任期的董事）均应至少每三年

轮值退任一次。退任董事应符合资格重选连

任。

根据组织章程细则第

86(3)

条，任何获委任以

填补董事会的临时空缺或出任新增的董事职

位的董事，任期仅至其获委任后本公司首届

股东周年大会为止及届时可合资格膺选连任。

每位独立非执行董事均与本公司订立委任

函，任期一年，可根据组织章程细则于股东周

年大会上轮值退任及重选连任。

于林绚琛博士自二零二四年一月十八日辞

任独立非执行董事后，仅有两名独立非执行

董事。因此，本公司不符合

GEM

上市规则第

5.05(1)

条之要求，其规定其上市发行人之董

事会必须包括至少三名独立非执行董事。

林瑶珉先生获委任为独立非执行董事，自二

零二四年四月十七日起生效，于其获委任后，

董事会已重新遵守

GEM

上市规则第

5.05(1)

条

之有关规定。

---

金威医疗集团有限公司

2024/2025

年报

Corporate Governance Report

企业管治报告

Chairman and Chief Executive

Code provision C.2.1 of the CG Code provides that the roles

of chairman and chief executive should be separate and should

not be performed by the same individual. Mr. Ng Chi Lung is

the chairman of the Board. As the chairman, Mr. Ng Chi Lung

manages the Board’s busines and activities and provides guidance

and direction to other Board members to ensure that the Board

works efectively and acts in the best interests of the Company

and the shareholders as a whole.

The Company has no chief executive oficer and therefore the

daily operation and management of the Group is monitored by

the executive Directors, as wel as the senior management of the

Group. The Board believes that there is suficient balance of power

and authority as there are experienced executive Directors each

overseing various aspects of the busines. In adition, save for

the period from 18 January 2024 to 17 April 2024 where there

were only two independent non-executive Directors, there are

thre independent non-executive Directors who are suficiently

experienced and capable of monitoring the operations of the

Group. The Board wil met from time to time to discus isues

arising from operations of the Group.

Board Metings

The Board regularly mets to discus and formulate overal

strategic direction and objectives and also aprove anual, interim

and quarterly results as wel as other significant maters of the

Company. Execution of daily operational maters is delegated to

management.

主席及行政总裁

企业管治守则守则条文第

C.2.1

条订明，主席

与行政总裁之角色应有区分而不应由同一人

士担任。吴志龙先生为董事会主席。作为主

席，吴志龙先生管理董事会事务及活动并向

其他董事会成员提供指引及方向，以确保董

事会有效运作及以本公司及股东的整体最佳

利益为依归。

本公司不再有行政总裁，因此本集团的日常

经营及管理由执行董事及本集团高级管理人

员监察。董事会认为，由于各经验丰富的执行

董事负责监督业务的各个方面，因此权力与

职权之间存在充分平衡。此外，除于二零二四

年一月十八日至二零二四年四月十七日期间

仅有两名独立非执行董事之外，三名独立非

执行董事经验丰富，能够监察本集团的营运。

董事会将不时开会讨论本集团营运所产生的

问题。

董事会议

董事会定期召开会议，讨论及制定本公司整

体策略方针及目标，并审批年度、中期及季度

业绩以及其他重大事宜，日常营运事务则交

由管理人员执行。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/202532

Corporate Governance Report

企业管治报告

The Company Secretary asists the executive Directors in preparing

notices and agenda for the Board and comites metings,

and ensures that the Company complied with the corporate

governance practices and other compliance maters. Anual

meting schedules and draft agenda of each meting are normaly

made available to Directors in advance. At least 14 days’ notice

of al regular Board metings were given to al Directors, who

were al given an oportunity to include maters in the agenda

for regular discusion. Board papers together with al apropriate,

complete and reliable information are sent to al Directors at least

3 days before each regular board meting or comite meting

(or such other period as agred) to kep Directors aprised of the

latest developments and financial position of the Company and to

enable them to make informed decisions.

Al Directors have aces to the advice and services of the

Company Secretary with a view to ensuring that the Board

procedures and al aplicable rules and regulations are folowed.

Minutes of the Board or comites metings are recorded in

significant detail for any decision and recomendation made

during the metings. Draft and final versions of the minutes

are circulated to the Directors or comite members within a

reasonable time after the metings are held and taken as the true

records of the procedings of such metings. Al minutes are kept

by the Company Secretary and are open for inspection at any

reasonable time on reasonable notice by any Director.

Al Directors are entitled to have aces to Board papers and

related materials unles prohibited by the relevant legal or

regulatory restrictions.

If a substantial shareholder of the Company or a Director has a

conflict of interest in a mater which is considered by the Board to

be material, the interested shareholder and the Director shal not

vote nor shal he/she be counted towards the quorum present at

the relevant meting. Independent non-executive Directors who,

and whose asociates, have no material interest in the mater,

should be present at such meting.

公司秘书协助执行董事编制董事会及委员会

会议通告及议程，并确保本公司遵守企业管

治常规及其他合规事宜。周年大会时间表及

各大会之会议程初稿一般会预先提供予董

事。所有定期举行之董事会议之通告均会

提早不少于

天交予所有董事，而所有董事

均有机会加入定期讨论之议题。董事会文件

连同所有合适、完整及可靠之资料会于各定期

（或所协定有关其他期间）举行之董事会议

或委员会议举行前最少三日寄发予所有董

事，以通知董事有关本公司之最近发展及财

务状况，让彼等作出知情决定。

所有董事均可取得公司秘书之意见与服务，

以确保董事会程序以及所有适用规则及规定

均已遵行。

董事会或委员会议记录重点详细记录会议

过程中作出之任何决定和建议。会议记录之

草稿和定稿均须在会后合理时间交予董事或

委员会成员传阅，并且作为有关会议之程序

之真实记录。所有会议记录由公司秘书保管，

任何董事提出合理通知均可在任何合理时间

查阅。

除非因相关法律或监管限制者所禁止，否则

所有董事均可查阅董事会之文件及相关资料。

如本公司一名主要股东或一名董事在董事会

认为属重大之事宜中有利益冲突，该有利益

关系股东及董事不得投票，亦不得计入有关

会议之法定人数。其本人（及其联系人士）在有

关事宜中并无重大利益之独立非执行董事须

出席有关会议。

---

金威医疗集团有限公司

2024/2025

年报

Corporate Governance Report

企业管治报告

THE BOARD COMITES

Audit Comite

The Company established the audit comite of the Company

(the “Audit Comite”) on 2 November 2001, with writen

terms of reference in compliance with Rules 5.28 and 5.29 of the

GEM Listing Rules and is published on the websites of the Stock

Exchange and the Company. The Audit Comite comprises of

thre independent non-executive Directors, namely, Ms. Wong

Ka Wai, Jeane, Mr. Lau Tak Kei Arthur and Mr. Lin Yaomin. Ms.

Wong Ka Wai, Jeane is the chairlady of the Audit Comite.

The primary duties of the Audit Comite are to ensure the

adequacy and efectivenes of the acounting and financial

controls of the Group; to overse the performance of risk

management and internal control systems and financial reporting

proces; and to monitor the integrity of the financial statements

and compliance with statutory and listing requirements and to

overse independence and qualifications of the external auditors.

During the year ended 31 March 2025, two metings of the Audit

Comite were held.

董事委员会

审核委员会

本公司于二零一年十一月二日成立本公司

审核委员会（「审核委员会」），并遵照

GEM

上市

规则第

5.28

条及第

5.29

条以书面制订其职权

范围并于联交所及本公司网站内刊发。审核

委员会由三位独立非执行董事，即黄嘉慧女

士、刘德基先生及林�先生组成。黄嘉慧女

士为审核委员会主席。

审核委员会之主要职责为确保本集团会计及

财务控制之充足及有效；监督风险管理及内

部监控制度及财务申报程序之履行；及监察

财务报表之完整性及是否遵守法定及上市规

定以及监督外聘核数师之独立性及资格。

于截至二零二五年三月三十一日止年度，审

核委员会共举行了两次会议。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/202534

Corporate Governance Report

企业管治报告

The main duties of the Audit Comite during the year ended

31 March 2025 include:

(a) reviewing the Group’s audited anual and unaudited interim

and quarterly results and reports and considering any

significant or unusual items before submision to the Board;

(b) reviewing the relationship with the external auditors by

reference to the work performed by the auditors, their fes

and terms of engagement, and making recomendation to

the Board on the apointment, re-apointment and removal

of external auditors;

(c) reviewing the adequacy and efectivenes of the Company’s

financial reporting system, internal control system and risk

management system and asociated procedures; and

(d) advising on material events or drawing the atention of the

management on related risks.

截至二零二五年三月三十一日止年度审核委

员会之主要职责包括：

(a)

审阅本集团之经审核年度、未经审核中

期及季度业绩及报告，并在呈交予董事

会前考虑任何重大或不寻常事项；

(b)

参考核数师执行之工作、其费用及聘用

条款，检讨与外聘核数师之关系，并就

外聘核数师之委任、重新委任及罢免向

董事会提供建议；

(c)

检讨本公司之财务汇报制度、内部监控

制度及风险管理制度，以及相关程序之

充足性及有效性；及

(d)

就重大事项提供意见，或敦请管理层垂

注有关风险。

---

金威医疗集团有限公司

2024/2025

年报

Corporate Governance Report

企业管治报告

The external auditors were invited to atend the said metings to

discus with the Audit Comite on isues arising from the audit

and financial reporting maters. Besides, there is no disagrement

betwen the Board and the Audit Comite regarding the

reapointment of the external auditors.

The Group’s audited consolidated financial results for the year

ended 31 March 2025 were reviewed by the Audit Comite,

which was of the opinion that the preparation of such results

complied with the aplicable acounting standards and

requirements and that adequate disclosures have ben made.

Nomination and Corporate Governance Comite

On 11 February 2014, the Board resolved to establish a

nomination and corporate governance comite of the Company

(the “Nomination and Corporate Governance Comite”)

in place and stead of the previous nomination comite of

the Company, which was established on 27 March 2012 in

compliance with the code provision. Writen terms of reference

were published on the websites of the Stock Exchange and the

Company. The Nomination and Corporate Governance Comite

has four members comprising an executive Director, Mr. Ng Chi

Lung and thre independent non-executive Directors, namely,

Ms. Wong Ka Wai, Jeane, Mr. Lau Tak Kei Arthur and Mr. Lin

Yaomin. Mr. Ng Chi Lung is the chairman of the Nomination and

Corporate Governance Comite.

The main responsibilities of the Nomination and Corporate

Governance Comite are to review the structure, size and

composition, including the skils, knowledge and experience, of

the Board on a regular basis and make recomendations on any

proposed changes to the Board to complement the Company’s

corporate strategy; identify individuals suitable and qualified to

become Directors and select, or make recomendations to the

Board for directorships; make recomendations to the Board on

relevant maters relating to the apointment or re-apointment of

Directors; and kep the efectivenes of the corporate governance

and system of internal controls of the Group.

During the year ended 31 March 2025, two metings of the

Nomination and Corporate Governance Comite were held.

外聘核数师获邀出席上述会议，就审核及财

务申报事宜所产生之议题与审核委员会进行

讨论。此外，董事会与审核委员会并无就外聘

核数师之重新委任出现任何意见分歧。

本集团截至二零二五年三月三十一日止年度

之经审核综合财务业绩已由审核委员会审

阅，其认为有关业绩之编制已遵守适用会计

准则及规定并作出充足披露。

提名及企业管治委员会

于二零一四年二月十一日，董事会议决成立

本公司提名及企业管治委员会（「提名及企业

管治委员会」）以取代先前已于二零一二年三

月二十七日根据守则条文成立之本公司提名

委员会。书面职权范围已于联交所及本公司

网站刊发。提名及企业管治委员会有四名成

员，包括执行董事吴志龙先生及三名独立非

执行董事，即黄嘉慧女士、刘德基先生及林�

�先生。吴志龙先生为提名及企业管治委员

会主席。

提名及企业管治委员会之主要责任为定期检

讨董事会之架构、规模及组成，包括技能、知

识及经验，并向董事会推荐任何建议之改动，

以配合本公司之企业策略；物色合适的合资

格人士出任董事，并且甄选或向董事会作出

有关董事人选之推荐建议；就委任或重新委

任董事之相关事宜向董事会作出推荐建议；

及保持本集团企业管治及内部监控制度之成

效。

于截至二零二五年三月三十一日止年度，提

名及企业管治委员会共举行了两次会议。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/202536

Corporate Governance Report

企业管治报告

The main duties of the Nomination and Corporate Governance

Comite during the year ended 31 March 2025 include:

(a) reviewing the structure, size and composition, including the

skils, knowledge and experience of the Board;

(b) making recomendations on any proposed changes to the

Board to complement the Company’s corporate strategy;

(c) making recomendation on the re-election of the retiring

Directors standing for re-election at the Company’s 2025

anual general meting; and

(d) asesing the independence of al the independent non-

executive Directors.

The Board had adopted a board diversity policy on 8 November

2018, which sets out the aproach to achieve diversity on the

Board. For details, please refer to page 62 of this report.

The gender ratio in the workforce of the Group (including

senior management) for the year ended 31 March 2025 was

aproximately 76% male and aproximately 24% female. The

Group encourages gender diversity acros its workplace. To

achieve diversity at workforce level, the Group has put in place

apropriate recruitment and selection practices such that a diverse

range of candidates are considered.

Remuneration Comite

The Company established the remuneration comite of the

Company (the “Remuneration Comite”) on 3 June 2005

with writen terms of reference published on the websites of the

Stock Exchange and the Company. The Remuneration Comite

has four members comprising an executive Director, Mr. Wu Qiyou

and thre independent non-executive Directors, namely, Ms.

Wong Ka Wai, Jeane, Mr. Lau Tak Kei Arthur and Mr. Lin Yaomin.

Ms. Wong Ka Wai, Jeane is the chairlady of the Remuneration

Comite.

截至二零二五年三月三十一日止年度，提名

及企业管治委员会的主要职责包括：

(a)

检讨董事会的架构、人数及构成（包括技

能、知识及经验）；

(b)

就任何为配合本公司之公司策略而建议

对董事会作出之变动提出建议；

(c)

就重选将于本公司二零二五年股东周年

大会上接受重选的退任董事作出建议；

及

(d)

评核所有独立非执行董事之独立性。

董事会已于二零一八年十一月八日采纳董事

会成员多元化政策，其载列实现董事会成员

多元化之方法。有关详情，请参阅本报告第

页。

截至二零二五年三月三十一日止年度，本集

团员工（包括高级管理层）的性别比例约为男

性

76%

及女性约为

24%

。本集团鼓励整个工

作场所实现性别多元化。为了实现劳动力层

面的多元化，本集团已经制定适当的招聘及

选拔做法，以便考虑不同的候选人。

薪酬委员会

本公司于二零五年六月三日成立本公司薪

酬委员会（「薪酬委员会」），其书面职权范围已

于联交所及本公司网站刊发。薪酬委员会有

四名成员，包括一名执行董事吴其佑先生及

三名独立非执行董事，即黄嘉慧女士、刘德基

先生及林�先生。黄嘉慧女士为薪酬委员

会主席。

---

金威医疗集团有限公司

2024/2025

年报

Corporate Governance Report

企业管治报告

The role and function of the Remuneration Comite include

the determination of specific remuneration package of al

executive Directors, including benefits in kind, pension rights and

compensation payments, including any compensation payable

for los or termination of their ofice or apointment, making

recomendations to the Board in relation to the remuneration

of independent non-executive Directors, and reviewing and/or

aproving maters relating to share schemes under Chapter 23 of

the GEM Listing Rules.

During the year ended 31 March 2025, two metings of the

Remuneration Comite were held.

The main duties of the Remuneration Comite during the year

ended 31 March 2025 include:

(a) determining and making recomendations to the Board

regarding the specific remuneration package of each

of the executive Directors, including benefits in kind,

pension rights and compensation payments, including any

compensation payable for los or termination of their ofice

or apointment; and

(b) reviewing and making recomendations to the Board

regarding the remuneration of each of the independent non-

executive Directors and members of senior management.

The Remuneration Comite considers factors such as

salaries paid by comparable companies, time comitment and

responsibilities of the Directors, employment and responsibilities in

the Group and desirability of performance-based remuneration.

薪酬委员会之职责及功能包括厘订所有执行

董事之具体薪酬组合，包括实物福利、退休金

权益及报酬款项，包括任何就离职或终止委

任应付之补偿，就独立非执行董事之酬金向

董事会提出建议及审阅及╱或批准

GEM

上市

规则第

章项下有关股份计划的事宜。

于截至二零二五年三月三十一日止年度，薪

酬委员会共举行了两次会议。

截至二零二五年三月三十一日止年度，薪酬

委员会的主要职责包括：

(a)

厘定各执行董事的具体薪酬待遇，包括

实物福利、退休金权益及报酬款项（包括

任何就离职或终止委任应付之补偿），并

就此向董事会提出建议；及

(b)

审阅各独立非执行董事及高级管理层成

员的薪酬并就此向董事会提出建议。

薪酬委员会考虑之因素有：可资比较公司支

付之薪金、各董事付出之时间及职责、本集团

之雇佣条件及责任以及是否适宜推出与表现

挂钩的酬金。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/202538

Corporate Governance Report

企业管治报告

DIRECTORS’ AND AUDITORS’ RESPONSIBILITIES

FOR THE FINANCIAL STATEMENTS

The Directors acknowledge their responsibility for preparing the

financial statements of the Company for the year ended 31 March

2025.

The Board is responsible for presenting a balanced, clear and

understandable asesment of anual, interim and quarterly

reports, price-sensitive anouncements and other disclosures

required under the GEM Listing Rules and other statutory and

regulatory requirements. The Directors are responsible for the

preparation of the consolidated financial statements of the Group

for the relevant acounting periods under aplicable statutory

and regulatory requirements which give a true and fair view of

the state of afairs, the results of operations and cash flows of

the Group. In preparing the anual, interim and quarterly results

of the Group for the relevant acounting periods in 2024, the

Directors have adopted suitable acounting policies consistently.

The responsibility of the auditors with respect to these

consolidated financial statements is set out in the Independent

Auditor’s Report on pages 65 to 72 of this report.

COMPANY SECRETARY

During the year ended 31 March 2025, the Company Secretary

has undertaken no les than 15 hours of profesional training to

update his skils and knowledge.

RISK MANAGEMENT AND INTERNAL

CONTROL

The Board acknowledges its responsibility for the Company’s risk

management and internal control systems, and for reviewing its

efectivenes.

董事及核数师对财务报表之责任

董事确认彼等于编制本公司截至二零二五年

三月三十一日止年度之财务报表之责任。

董事会须负责就年度、中期及季度报告、股价

敏感资料之公布及其他根据

GEM

上市规则及

其他法定及监管规定须作出之披露呈报不偏

不倚、清晰及可理解之评估。董事负责根据适

用法定及规管要求编制真实及公平地反映本

集团之事务状况、经营业绩及现金流量之综

合财务报表。于编制二零二四年相关会计期

间之本集团之年度、中期及季度业绩时，董事

已采纳适合之会计政策。

核数师对该等综合财务报表应负之责任列载

于本报告第

至

页之独立核数师报告内。

公司秘书

于截至二零二五年三月三十一日止年度，公

司秘书已进行不少于

个小时之专业培训以

更新彼之技能及知识。

风险管理及内部监控

董事会确认负责本公司之风险管理及内部监

控系统，及检讨其成效。

---

金威医疗集团有限公司

2024/2025

年报

Corporate Governance Report

企业管治报告

The Group’s internal control and risk management systems are

designed to provide reasonable, but not absolute, asurance

against material mistatement or los and manage rather than

eliminating risks of failure in operational systems. During the year

ended 31 March 2025, the Board, through the audit comite,

has reviewed and is satisfied with the efectivenes and adequacy

of the internal control and risk management systems of the

Group.

The Board has the overal responsibility for evaluating and

determining the nature and extent of the risks it is wiling to take

in achieving the Company’s strategic objectives, and establishing

and maintaining apropriate and efective risk management and

internal control systems of the Group. The Board, as suported by

the audit comite, had conducted review of the efectivenes

of the Group’s risk management and internal control system for

the year ended 31 March 2025, which covers al material controls,

including financial, operational and compliance control.

To fulfil such responsibility, the management of the Group has

conducted internal audit which includes analysis and apraisal of

the adequacy and efectivenes of the Group’s risk management

and internal control systems. The management reviews al major

operations of the Group on a cyclical basis, and sumarises al

material isues and findings to the Board and the audit comite

anualy.

In particular, the Group has established guidelines and procedures

for the aproval and control of expenditures, to ensure the

reliability of the financial reporting, efectivenes and eficiency of

operation and compliance with aplicable laws and regulations.

The Board wil review the adequacy of resources, staf

qualifications and experience training programes and budget

of the Company’s acounting and financial reporting function

anualy.

本集团之内部监控及风险管理系统旨在合理地

（但并非绝对地）保证并无重大失实陈述或损

失，并管理（但并非完全消除）本集团营运系统

失误的风险。于截至二零二五年三月三十一

日止年度，透过审核委员会，董事会已审阅并

信纳本集团之内部监控及风险管理系统属有

效且充分。

董事会总体负责评估及厘定在达致本公司策

略目标过程中其愿意承担的风险的性质及程

度，并建立及具备适当且有效的本集团风险

管理及内部监控系统。董事会，于审核委员会

支持下，已于截至二零二五年三月三十一日

止年度就本集团之风险管理及内部监控系统

之效能进行检讨，涵盖所有重要监控，包括财

务、营运及合规监控。

为履行有关职责，本集团管理层已进行内部

审核，其中包括分析及评估本集团风险管理

及内部监控系统的充足性及有效性。管理层

持续审阅本集团之所有主要业务并每年向董

事会及审核委员会概述所有重大事宜及结果。

具体而言，本集团已设立开支批准及控制指

引及程序，以确保财务申报的可靠性、运作有

效性及效率以及遵守适用法律及法规。

董事会将每年检讨资源是否充足、本公司会

计及财务申报部门员工之资历及经验以及其

培训计划及预算。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/202540

Corporate Governance Report

企业管治报告

The audit reviews cover al material controls including financial,

operational and compliance controls. Results of the audit reviews

are submited to the members of the audit comite for

discusion at the audit comite metings. The internal audit

review reports are then folowed up by the management to ensure

that findings previously identified have ben properly resolved.

The Board considers that the Group has put in place adequate

measures to perform the internal audit function at diferent

aspects of the Group. The audit comite and the Board

are satisfied with the efectivenes and eficiency of the risk

management and internal control systems of the Group.

The Group has established policy for ensuring that inside

information is diseminated to the public in an equal and timely

maner in acordance with aplicable laws and regulations.

Procedures such as limiting aces to inside information to those

who ned to know and requiring external parties to execute

confidentiality agrements have ben implemented by the

Company to guard against mishandling of inside information.

The Group also reminds those relevant personel and other

profesional parties to preserve confidentiality of the inside

information until it is publicly disclosed.

AUDITORS’ REMUNERATION

During the year ended 31 March 2025, the fes paid or payable to

the auditors in respect of audit and non-audit services provided by

the auditors of the Group were as folows:

Amount (HK$’000)

Nature of services

服务性质金额（千港元）

Audit services

审核服务

Non-audit services

非审核服务

–

审核检讨涵盖包括财务、营运及合规限制等

所有重大监控。审核检讨之结果提呈予审核

委员会成员，以便于审核委员会议上讨论。

随后内部审核检讨报告由管理层跟进，以确

保先前确定的发现结果已妥善解决。

董事会认为本集团已采取充足措施于本集团

各方面履行内部审核职能。审核委员会及董

事会信纳本集团风险管理及内部控制系统之

有效性及效率。

本集团已制定政策以确保内幕消息根据适用

法律及规例公平及适时地向公众发布。本公

司执行多项程序，例如限制接触内幕消息的

人士及要求外界人士签订保密协议，以避免

不当处理内幕消息。本集团亦提醒相关人员

及其他专业人士将内幕消息保密，直至公开

披露为止。

核数师酬金

于截至二零二五年三月三十一日止年度，就

本集团核数师提供之审核及非审核服务已付

或应付予核数师之费用如下：

---

金威医疗集团有限公司

2024/2025

年报

Corporate Governance Report

企业管治报告

INVESTORS RELATIONS

The Board believes that a transparent and timely disclosure of the

Group’s information wil enable the shareholders and potential

investors of the Company to make the most informed investment

decision and to have beter understanding of the Group’s busines

performance and strategies. It is also vital for developing and

maintaining continuing investor relations with the Company’s

potential and existing investors.

The Company maintains a website at w.gf-healthcare.com as

a comunication platform with the shareholders and potential

investors of the Company, where information of and updates

on the Group’s financial information and other information are

available for public aces.

SHAREHOLDERS’ RIGHTS

Procedures for which enquiries may be put to the

Board

Shareholders are provided with contact details of the Company,

such as telephone number, fax number, email adres and postal

adres, in order to enable them to make any query that they

may have with respect to the Company. They can also send

their enquiries to the Board through these means. In adition,

shareholders can contact the share registrar of the Company, if

they have any enquires about their shareholdings.

Al resolutions put forward at general metings wil be voted on

by way of pol pursuant to the GEM Listing Rules and pol results

wil be posted on the websites of the Stock Exchange and the

Company after each general meting.

投资者关系

董事会相信，透明而及时披露本集团之资料，

有助本公司股东及潜在投资者作出最知情的

投资决定，并加深了解本集团业务表现及策

略。与本公司之准投资者及现有投资者发展

及维持续之投资者关系亦至为重要。

本公司设有网站

w.gf-healthcare.com

，作

为与本公司股东及潜在投资者沟通之平台，

本集团会在网站公布及更新财务资料与其他

资料以供公众查阅。

股东之权利

可向董事会作出查询之程序

本公司向股东提供联络资料，如电话号码、传

真号码、电邮地址及邮寄地址，以便股东提出

任何有关本公司之查询。彼等亦可以透过此

等方法向董事会提出查询。此外，股东如有任

何有关其股权之查询，可以联络本公司之股

份过户登记处。

股东大会上提呈之所有决议案将根据

GEM

上

市规则投票表决，投票结果将于各股东大会

结束后于联交所及本公司网站公布。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/202542

Corporate Governance Report

企业管治报告

Procedures for convening general metings by

shareholders

Pursuant to article 58 of the Articles of Asociation, the Board

may whenever it thinks fit cal extraordinary general metings,

and any one or more shareholders holding at the date of deposit

of the requisition in agregate of at least one-tenth of the voting

rights at general metings (on a one vote per share basis) in the

share capital of the Company shal at al times have the right,

by writen requisition to the Board or the Company Secretary,

to require an extraordinary general meting to be caled by

the Board for the transaction of any busines specified in such

requisition and/or ad resolutions to the agenda of a meting,

and such meting shal be held within two (2) months after the

deposit of such requisition. If within twenty-one (21) days of such

deposit, the Board fails to proced to convene such meting,

the requisitionist(s) himself (themselves) may convene a physical

meting at only one location, and al reasonable expenses incured

by the requisitionist(s) as a result of the failure of the Board shal

be reimbursed to the requisitionist(s) by the Company.

Procedures for puting forward proposals at general

metings

Shareholders are requested to folow article 58 of the Articles of

Asociation for including a resolution at an extraordinary general

meting. The requirements and procedures are set out above

in the paragraph headed “Procedures for convening general

metings by shareholders” above.

股东召开股东大会的程序

根据组织章程细则第

条，董事会可于其认

为合适时召开股东特别大会，及任何一名或

以上于递呈要求日期于股本中持有于本公司

股东大会表决权利十分之一（按一股一票之基

准）之股东，于任何时候均有权透过向董事会

或公司秘书发出书面要求，要求董事会召开

股东特别大会，以处理有关要求中列明之任

何事项及／或在会议程中增加决议案，而有

关大会须于递呈要求后两

(2)

个月内举行。倘

于递呈有关要求后二十一

(21)

日内，董事会未

能召开有关大会，则请求人可只在一个地点

召开实体会议，而请求人因董事会未能召开

会议所引致之所有合理开支应由本公司付还

予请求人。

于股东大会提呈议案的程序

股东于股东特别大会上提呈决议案时须遵守

组织章程细则第

条，相关规定及程序载于

上文「股东召开股东大会的程序」一段。

---

金威医疗集团有限公司

2024/2025

年报

Corporate Governance Report

企业管治报告

Pursuant to article 88 of the Articles of Asociation, no person,

other than a Director retiring at the meting, shal, unles

recomended by the Directors for election, be eligible for election

as a Director at any general meting, unles notice in writing of

the intention to propose that person for election as a Director and

notice in writing by that person of his wilingnes to be elected

shal have ben lodged at the head ofice or at the registration

ofice. The period for lodgment of the notices required wil

comence no earlier than the day after the despatch of the notice

of the general meting apointed for such election and end no

later than seven (7) days prior to the date of such general meting

and the minimum length of the period during which such notices

to the Company may be given wil be at least seven (7) days.

CONSTITUTIONAL DOCUMENTS

The Articles of Asociation have ben amended and restated with

efect from 5 August 2022. Pursuant to Rule 17.102 of the GEM

Listing Rules, the Company has published its latest Articles of

Asociation on the respective websites of the Stock Exchange and

the Company.

根据组织章程细则第

条，除非一项有意提

名选举该位人士为董事的书面通知以及一项

该位被推选人士签发表明其愿意选举之书面

通知已呈交至总办事处或注册办事处，否则

概无人士（于大会退任的董事除外）有权在任

何股东大会上选举出任董事职位（除非由董事

推选）。提交该等通知之期间须由不早于指定

进行该推选之股东大会通告寄发翌日起计，

及不迟于该股东大会举行日期前七

(7)

日结

束，而向本公司发出该等通知之最短期间须

为最少七

(7)

日。

宪章文件

组织章程细则已获修订及重述，自二零二

年八月五日起生效。根据

GEM

上市规则第

17.102

条，本公司已于联交所及本公司的有

关网站上刊发其最新组织章程细则。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/202544

Report of the Directors

董事会报告

The Directors have the pleasure to present the anual report and

the audited consolidated financial statements of the Group for the

year ended 31 March 2025.

DATE OF INCORPORATION

The Company was incorporated and registered as an exempted

company with limited liability in the Cayman Islands on 28 May

2001 under the Companies Act, Cap. 22 (Act 3 of 1961, as

consolidated and revised) of the Cayman Islands.

The shares of the Company were listed on GEM of the Stock

Exchange on 10 May 2002.

PRINCIPAL ACTIVITIES

The Company acts as an investment holding company while its

subsidiaries are principaly engaged in the provision of general

hospital services in the PRC. Details of the principal activities of

its subsidiaries are set out in Note 35 to the consolidated financial

statements.

RESULTS AND DIVIDENDS

The results of the Group for the year ended 31 March 2025 and

the state of the Group’s afairs as at 31 March 2025 are set out in

the consolidated financial statements on pages 73 to 76.

The Board does not recomend a final dividend for the year

ended 31 March 2025.

SHARE CAPITAL

Details of the movements in the share capital of the Company

during the Year are set out in Note 27 to the consolidated

financial statements.

RESERVES

Details of the movements in the reserves of the Company and the

Group during the Year are set out in Note 28 to the consolidated

financial statements and in the consolidated statement of changes

in equity respectively.

董事欣然提呈本集团截至二零二五年三月

三十一日止年度之年报及经审核综合财务

报表。

注册成立日期

本公司于二零一年五月二十八日根据开曼

群岛法例第

章（一九六一年法例三，经综合

及修订）公司法在开曼群岛注册成立及登记为

获豁免有限公司。

本公司股份于二零二年五月十日在联交所

GEM

上市。

主要业务

本公司为一间投资控股公司，而其附属公司

主要在中国从事提供综合性医院服务业务。

本公司附属公司主要业务之详情载于综合财

务报表附注

。

业绩及股息

本集团截至二零二五年三月三十一日止年度

之业绩及本集团于二零二五年三月三十一日

之事务状况载于第

至

页之综合财务报

表。

董事会并不建议派发截至二零二五年三月

三十一日止年度之末期股息。

股本

本公司于本年度之股本变动详情载于综合财

务报表附注

。

储备

本公司及本集团于本年度之储备变动详情分

别载于综合财务报表附注

及综合权益变动

表内。

---

金威医疗集团有限公司

2024/2025

年报

Report of the Directors

董事会报告

DISTRIBUTABLE RESERVES

The Company did not have any distributable reserves as at 31

March 2025 (2024: nil). Under the Companies Act, Cap. 22 (Act

3 of 1961, as consolidated and revised) of the Cayman Islands,

the share premium of the Company is available for paying

distributions or dividends to shareholders subject to the provisions

of its Memorandum and Articles of Asociation and provided that

imediately folowing the distribution or dividend the Company

is able to pay its debts as they fal due in the ordinary course of

busines. In acordance with the Articles of Asociation, dividends

shal be distributed out of the retained profits or other reserves,

including the share premium acount, of the Company.

INVESTMENT PROPERTY

The Group did not further invest in investment property during the

Year.

PROPERTY, PLANT AND EQUIPMENT

Details of the movements in property, plant and equipment of the

Group during the Year are set out in Note 15 to the consolidated

financial statements.

MAJOR CUSTOMERS

During the year ended 31 March 2025, no individual customer has

contributed over 5% of the Group’s total revenue. During the

Year, the five largest customers in agregate contributed to les

than 5% of the Group’s total revenue.

To the best knowledge of the Directors, none of the Directors or

any of their close asociates (as defined in the GEM Listing Rules)

or shareholders that owned more than 5% of the isued shares

had any direct or indirect interest in the five largest customers of

the Group during the Year.

可分派储备

于二零二五年三月三十一日，本公司并无任

何可供分派储备（二零二四年：无）。根据开曼

群岛法例第

章（一九六一年法例三，经综合

及修订）公司法，于本公司之组织章程大纲及

组织章程细则条文规限下，如紧随分派或派

息后本公司有能力偿还其于日常业务过程中

到期之债务，则本公司之股份溢价可以分派

或以股息方式派付予股东。根据组织章程细

则，股息须自本公司保留溢利或其他储备（包

括股份溢价账）拨付。

投资物业

本集团于本年度并无进一步投资于投资物业。

物业、厂房及设备

本集团物业、厂房及设备于本年度之变动详

情载于综合财务报表附注

。

主要客户

截至二零二五年三月三十一日止年度，概无

个别客户的贡献超过本集团总收益

5%

。于本

年度，五大客户的总贡献低于本集团总收益

5%

。

据董事所深知，于本年度，概无董事或彼等之

任何紧密联系人（定义见

GEM

上市规则）或拥

有

5%

以上已发行股份的股东直接或间接拥有

本集团五大客户的任何权益。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/202546

Report of the Directors

董事会报告

MAJOR SUPLIERS

During the Year, the largest suplier has contributed to les than

10% of the Group’s total purchases. During the Year, the five

largest supliers in agregate contributed to les than 30% of the

Group’s total purchases.

To the best knowledge of the Directors, none of the Directors or

any of their close asociates (as defined in the GEM Listing Rules)

or shareholders that owned more than 5% of the isued shares

had any direct or indirect interest in the five largest supliers of

the Group during the Year.

RELATIONSHIPS WITH KEY STAKEHOLDERS

The Group’s suces also depends on the suport from key

stakeholders which comprise employes, customers, supliers,

regulators and Shareholders. Employes are regarded as the most

important and valuable asets of the Group. The Group maintains

a god relationship with its employes and did not experience any

major dificulties in recruitment, nor did it experience any material

los in manpower or sufer from any material labour dispute

during the Year. The Group also understands the importance of

maintaining a god relationship with its supliers and customers

to met its short-term and long-term goals. It enjoys god

relationships with supliers and customers and strives to take an

active part in the comunities where they operate.

ENVIRONMENTAL POLICIES

The Group’s has adopted the gren hospital development

policy and implemented low carbon strategies in al aspects

of operations in compliance with the requirements by the PRC

government. The Group is comited to environmental protection

and energy conservation. In the course of investment, construction

and operation, the Group has consistently caried out the

operation objective of “Benefiting the society and the populace”

and focused on sustainable development. With reliability,

profesional and safety as its objective, the Group poseses

advanced IT program management and technical suport of

modern information network and strived to facilitate paperles

ofice and recycling.

主要供应商

于本年度，最大供应商的贡献低于本集团总

采购额

10%

。于本年度，五大供应商的总贡献

低于本集团总采购额

30%

。

据董事所深知，于本年度，概无董事或彼等之

任何紧密联系人（定义见

GEM

上市规则）或拥

有

5%

以上已发行股份的股东直接或间接拥有

本集团五大供应商的任何权益。

与主要持份者之关系

本集团之成功亦有赖于主要持份者（包括雇

员、客户、供应商、监管机构及股东）之支持。

雇员乃视为本集团之最重要及宝贵资产。于

本年度，本集团与其雇员维持良好关系及于

用工方面并无遭受任何主要困难，亦无遭受

任何人力方面之重大流失或遭遇任何重大劳

工纠纷。本集团亦明白为达致其短期及长期

目标而与其供应商及客户维持良好关系之重

要性。其与供应商及客户保持良好关系并致

力积极参与彼等经营所在社区之活动。

环境政策

本集团已遵照中国政府要求于营运之所有方

面采纳绿色医院发展政策及实施低碳策略。

本集团致力加强环境保护及节约资源。在投

资、建设和经营过程中，本集团始终贯彻「惠

予社会，好及百姓」的经营宗旨，注重可持续

发展。以可信赖、专业、安全为目标，本集团

拥有先进的资讯科技程序管理和现代资讯网

络技术支持，并致力于推行无纸化办公和环

保回收等事项。

---

金威医疗集团有限公司

2024/2025

年报

Report of the Directors

董事会报告

COMPLIANCE WITH LAWS AND REGULATIONS

The Group fuly complies with al laws and regulations and

regularly monitors and gathers information about changes in

laws, rules and regulations relevant to the Group’s busineses to

ensure the Group’s observance of those aplicable laws, rules and

regulations, especialy those which may have material impact on

the Group.

DIRECTORS

The Directors of the Company during the Year and up to the date

of this report were:

Executive Directors:

Mr. Ng Chi Lung (Chairman)

Mr. Wu Qiyou

Independent non-executive Directors:

Ms. Wong Ka Wai, Jeane

Mr. Lau Tak Kei Arthur

Mr. Lin Yaomin

In acordance with article 87 of the Articles of Asociation,

Mr. Ng Chi Lung, the executive Director and Ms. Wong Ka Wai,

Jeane, the independent non-executive Director, wil retire and,

being eligible, ofer themselves for re-election at the forthcoming

general meting.

The biographical details of the Directors and senior management

are set on pages 22 to 24 of this report. Details of the

emoluments of the directors and the five highest paid individuals

are set out in Note 12 to the consolidated financial statements,

respectively.

遵守法律及法规

本集团全面遵守各项法律法规、定期关注及

搜集与本集团业务有关之法律、法规及规则

的变动资讯，以确保本集团遵守（尤其是）对其

产生重大影响之该等适用法律、规则及法规。

董事

于本年度及直至本报告日期本公司之董事如

下：

执行董事：

吴志龙先生（主席）

吴其佑先生

独立非执行董事：

黄嘉慧女士

刘德基先生

林�先生

根据组织章程细则第

条，执行董事吴志龙

先生及独立非执行董事�女士将于应届

股东大会上轮值告退，惟符合资格并愿意膺

选连任。

董事及高级管理人员履历详情载于本报告第

至

页。董事及五名最高薪酬人士之酬金

详情分别载于综合财务报表附注

。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/202548

Report of the Directors

董事会报告

DIRECTORS’ SERVICES CONTRACTS

Mr. Ng Chi Lung has ben apointed as an executive Director by

way of a leter of apointment with the Company for a period

of one year comencing from 23 July 2018 which wil continue

thereafter until terminated by either party giving to the other

party not les than one month’s notice in writing.

Mr. Wu Qiyou has ben apointed as an executive Director by

way of a leter of apointment with the Company for a period of

one year comencing from 22 August 2023 which wil continue

thereafter until terminated by either party giving to the other

party not les than one month’s notice in writing.

Ms. Wong Ka Wai, Jeane has ben apointed as an independent

non-executive Director by way of a leter of apointment with the

Company for a period of one year comencing from 1 November

2007 which wil continue thereafter until terminated by either

party giving to the other party not les than one month’s notice in

writing.

Mr. Lau Tak Kei Arthur has ben apointed as an independent

non-executive Director by way of a leter of apointment with the

Company for a period of one year comencing from 4 October

2019 which wil continue thereafter until terminated by either

party giving to the other party not les than one month’s notice in

writing.

Mr. Lin Yaomin has ben apointed as an independent non-

executive Director by way of a leter of apointment with the

Company for a period of one year comencing from 17 April

2024 which wil continue thereafter until terminated by either

party giving to the other party not les than one month’s notice in

writing.

Save as disclosed above, none of the Directors has any service

contract with the Company or any of its subsidiaries which is not

determinable by the Group within one year without payment of

compensation, other than statutory compensation.

董事服务合约

吴志龙先生已获本公司以委任书委任为执行

董事，自二零一八年七月二十三日起计为期

一年，并将于其后续任，直至任何一方向另外

一方发出不少于一个月之书面通知终止聘任

为止。

吴其佑先生已获本公司以委任书委任为执行

董事，自二零二三年八月二十二日起计为期

一年，并将于其后续任，直至任何一方向另外

一方发出不少于一个月之书面通知终止聘任

为止。

黄嘉慧女士已获本公司以委任书委任为独立

非执行董事，自二零七年十一月一日起计

为期一年，并将于其后续任，直至任何一方向

另外一方发出不少于一个月之书面通知终止

聘任为止。

刘德基先生已获本公司以委任书委任为独立

非执行董事，自二零一九年十月四日起计为

期一年，并将于其后续任，直至任何一方向另

外一方发出不少于一个月之书面通知终止聘

任为止。

林�先生已获本公司以委任书委任为独立

非执行董事，自二零二四年四月十七日起计

为期一年，并将于其后续任，直至任何一方向

另外一方发出不少于一个月之书面通知终止

聘任为止。

除上文所披露者外，并无董事与本公司或其

任何附属公司订立本集团不得于一年内毋须

补偿（法定补偿除外）而终止之任何服务合约。

---

金威医疗集团有限公司

2024/2025

年报

Report of the Directors

董事会报告

DIRECTORS’ INTERESTS IN TRANSACTIONS,

ARANGEMENTS OR CONTRACTS OF

SIGNIFICANCE

Save as disclosed in the paragraph headed “Related party

transactions” below, no transaction, arangement or contracts

of significance in relation to the Group’s busines to which the

Company or any of its subsidiaries was a party and in which

a Director or his/her conected entity had a material interest,

whether directly or indirectly, subsisted at 31 March 2025 or at

any time during the Year.

CONTRACT OF SIGNIFICANCE

Save as disclosed in this report, at no time during the Year had

the Company or any of its subsidiaries entered into any contract

of significance with any controling Shareholder or any of its

subsidiaries, nor had any contract of significance ben entered

into for the services provided by any controling Shareholder or

any of its subsidiaries to the Company or any of its subsidiaries.

MANAGEMENT CONTRACTS

No contracts concerning the management and administration of

the whole or any substantial part of the busines of the Company

were entered into or existed during the Year.

CHARITABLE DONATIONS

During the Year, the Group did not make any charitable and other

donations (2024: nil).

董事于重大交易、安排或合约之

权益

除下文「关连方交易」一段所披露者外，本公司

或其任何附属公司概无订立于二零二五年三

月三十一日或于本年度任何时间仍然有效而

董事或其关连实体直接或间接拥有重大权益

之有关本集团业务之重大交易、安排或合约。

重要合约

除本报告所披露者外，本公司或其任何附属

公司于本年度任何时候均未与任何控股东

或其任何附属公司订立任何重要合约，亦未

就任何控股东或其任何附属公司向本公司

或其任何附属公司提供的服务订立任何重要

合约。

管理合约

于本年度概无订立或存有涉及管理及行政管

理本公司整个或任何主要部份业务之合约。

慈善捐款

于本年度，本集团并无作出任何慈善及其他

捐款（二零二四年：无）。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/202550

Report of the Directors

董事会报告

DIRECTORS’ AND CHIEF EXECUTIVE’S

INTERESTS IN SHARES, UNDERLYING SHARES

AND DEBENTURES OF THE COMPANY AND ITS

ASOCIATED CORPORATIONS

As at 31 March 2025, the interests and short positions of the

Directors and chief executive of the Company in the shares,

underlying shares and debentures of the Company or any of its

asociated corporation (within the meaning of Part XV of the

Securities and Futures Ordinance (“SFO”) which were recorded

in the register required to be kept by the Company under Section

352 of the SFO, or otherwise notified to the Company and the

Stock Exchange pursuant to the required standards of dealings by

directors of the Company as refered to in Rules 5.46 to 5.67 of

the GEM Listing Rules, were as folows:

Interests in shares and underlying shares of the

Company:

Name of DirectorNature of interest

Number

of shares and

underlying

sharesPosition

Aproximate

percentage

of the total

isued shares

董事姓名权益性质

股份及相关

股份数目仓位

占已发行

股份总数之

概约百分比

Mr. Ng Chi LungInterest in controled

corporation (Note)

316,391,892Long56.13%

吴志龙先生于受控制公司之权益（附注）好仓

Beneficial owner11,800,000Long2.09%

实益拥有人好仓

Note: Solar Star Global Limited is owned as to 50% by Mr. Ng Chi Lung,

25% by Ms. Ng Si Wing and 25% by Ms. Ng Yin. Mr. Ng Chi Lung

is demed to be interested in the shares in which Solar Star Global

Limited is interested in under Part XV of the SFO.

董事及主要行政人员于本公司及

其相联法团之股份、相关股份及债

权证之权益

于二零二五年三月三十一日，董事及本公司

主要行政人员于本公司或其任何相联法团（定

义见证券及期货条例（「证券及期货条例」）第

XV

部）之股份、相关股份及债权证中拥有根据

证券及期货条例第

条须由本公司存置之登

记册所记录之权益及淡仓，或根据

GEM

上市

规则第

5.46

至

5.67

条所述之本公司董事进行

买卖之规定标准须另行知会本公司及联交所

之权益及淡仓如下：

于本公司股份及相关股份之权益：

附注：

星阳环球有限公司由吴志龙先生、吴思颖

女士及吴燕女士分别拥有

50%

、

25%

及

25%

权益。根据证券及期货条例第

XV

部，

吴志龙先生被视为于星阳环球有限公司拥

有权益之股份中拥有权益。

---

金威医疗集团有限公司

2024/2025

年报

Report of the Directors

董事会报告

Save as disclosed above, as at 31 March 2025, none of the

Directors nor the chief executive of the Company had any

interests or short positions in any shares, underlying shares or

debentures of the Company or any of its asociated corporation

(within the meaning of Part XV of the SFO) as recorded in the

register required to be kept by the Company under Section 352

of the SFO, or otherwise notified to the Company and the Stock

Exchange pursuant to Rules 5.46 to 5.67 of the GEM Listing Rules.

SUBSTANTIAL SHAREHOLDERS’ INTERESTS

AND SHORT POSITIONS IN SHARES AND

UNDERLYING SHARES

As at 31 March 2025, other than the interests of a director or

chief executive of the Company as disclosed in the paragraph

headed “Directors’ and chief executive’s interests in shares,

underlying shares and debentures of the Company and its

asociated corporations” above, the interests and short positions

of persons in the shares and underlying shares of the Company as

recorded in the register required to be kept by the Company under

Section 336 of the SFO were as folows:

Name of shareholder

Number of

sharesPositionCapacity

Aproximate

percentage

of the total

isued shares

股东名称股份数目仓位身份

占已发行

股份总数之

概约百分比

Solar Star Global Limited (Note 1)316,391,892LongBeneficial owner56.13%

星阳环球有限公司（附注

）好仓实益拥有人

Ms. Cheng Wai Yin (Note 2)328,191,892LongInterest of spouse58.22%

郑慧贤女士（附注

）好仓配偶权益

New Hope International (Hong Kong)

Limited (Note 3)

68,643,507LongBeneficial owner12.18%

新希望国际（香港）有限公司

（附注

）

好仓实益拥有人

Southern Hope Enterprise Co., Ltd.

#

(Note 3)

68,643,507Long Interest in controled

corporation

12.18%

南方希望实业有限公司（附注

）好仓于受控制公司之权益

除上文所披露者外，于二零二五年三月

三十一日，董事及本公司主要行政人员概无

于本公司或其任何相联法团（定义见证券及期

货条例第

XV

部）之任何股份、相关股份或债权

证中拥有记录于根据证券及期货条例第

条须由本公司存置之登记册之任何权益或淡

仓，或根据

GEM

上市规则第

5.46

至

5.67

条须另

行知会本公司及联交所之任何权益或淡仓。

主要股东于股份及相关股份之权

益及淡仓

于二零二五年三月三十一日，除上文「董事

及主要行政人员于本公司及其相联法团之股

份、相关股份及债权证之权益」一段所披露本

公司董事或主要行政人员之权益外，以下人

士于本公司股份及相关股份中拥有记录于根

据证券及期货条例第

条须由本公司存置之

登记册之权益及淡仓：

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/202552

Report of the Directors

董事会报告

Name of shareholder

Number of

sharesPositionCapacity

Aproximate

percentage

of the total

isued shares

股东名称股份数目仓位身份

占已发行

股份总数之

概约百分比

Ningbo Zhuosheng Investment Co., Ltd.

#

(Note 3)

68,643,507Long Interest in controled

corporation

12.18%

宁波卓晟投资有限公司（附注

）好仓于受控制公司之权益

New Hope Group Co., Ltd.

#

(Note 3)68,643,507Long Interest in controled

corporation

12.18%

新希望集团有限公司（附注

）好仓于受控制公司之权益

New Hope Holdings Group Co., Ltd.

#

(Note 3)

68,643,507

Long Interest in controled

corporation

12.18%

新希望控股集团有限公司（附注

）

好仓于受控制公司之权益

New Hope Asia Pacific Investment Holdings

Co., Ltd.

#

(Note 3)

68,643,507

Long Interest in controled

corporation

12.18%

新希望亚太投资控股有限公司（附注

）

好仓于受控制公司之权益

Lhasa Economic Development Zone New

Hope Investment Co., Ltd.

#

(“Lhasa Economic”) (Note 3)

68,643,507

Long Interest in controled

corporation

12.18%

拉萨经济开发区新希望投资有限公司

（「拉萨经济」）（附注

）

好仓于受控制公司之权益

Mr. Liu Yonghao (Note 3)68,643,507Long Interest in controled

corporation

12.18%

刘永好先生（附注

）好仓于受控制公司之权益

---

金威医疗集团有限公司

2024/2025

年报

Report of the Directors

董事会报告

Notes:

• % by Mr. Ng

Chi Lung, 25% by Ms. Ng Si Wing and 25% by Ms. Ng Yin. Mr. Ng

Chi Lung is demed to be interested in al the shares in which Solar

Star is interested in under Part XV of the SFO.

(2) Ms. Cheng Wai Yin is the spouse of Mr. Ng Chi Lung. Ms. Cheng

Wai Yin is demed to be interested in al the shares and the

convertible preference shares (if any) in which Mr. Ng Chi Lung is

interested in under Part XV of the SFO.

• ,643,507 shares of

the Company. New Hope International is owned as to 75% by

Southern Hope which is in turn owned as to 51% by New Hope

Group and as to 49% by Ningbo Zhuosheng. New Hope Group

is owned as to 75% by New Hope Holdings, 14.60% by Mr. Liu

Yonghao and 9.09% by Ms. Liu Chang, New Hope Holdings is in

turn owned as to 100% by New Hope Asia Pacific and New Hope

Asia Pacific is owned as to 99% by Lhasa Economic and as to 1%

by Mr. Liu Yonghao. Lhasa Economic is then owned as to 100% by

Mr. Liu Yonghao. Mr. Liu Yonghao and Ms. Liu Chang are demed

to be interested in the shares in which New Hope International is

interested in under Part XV of the SFO.

附注：

(1)

星阳之已发行股本由吴志龙先生、吴思颖女

士及吴燕女士分别拥有

50%

、

25%

及

25%

。根

据证券及期货条例第

XV

部，吴志龙先生被视

为于星阳拥有权益之所有股份中拥有权益。

(2)

郑慧贤女士为吴志龙先生的配偶。根据证券

及期货条例第

XV

部，郑慧贤女士被视为于吴

志龙先生拥有权益之所有股份及可换股优先

股（如有）中拥有权益。

(3)

新希望国际于本公司之

68,643,507

股份中

拥有权益。新希望国际由南方希望拥有

75%

权益，而南方希望分别由新希望集团及宁波

卓晟拥有

51%

及

49%

权益。新希望集团由新

希望控股、刘永好先生及刘畅女士分别拥有

75%

、

14.60%

及

9.09%

权益；新希望控股由

新希望亚太拥有

100%

权益，而新希望亚太由

拉萨经济及刘永好先生分别拥有

99%

及

1%

权

益。拉萨经济当时由刘永好先生拥有

100%

权

益。根据证券及期货条例第

XV

部，刘永好先

生及刘畅女士被视为于新希望国际拥有权益

之股份中拥有权益。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/202554

Report of the Directors

董事会报告

DIRECTORS’ RIGHTS TO ACQUIRE SECURITIES

Save as disclosed in the paragraph headed “Directors’ and chief

executive’s interests in shares, underlying shares and debentures of

the Company and its asociated corporations” above, at no time

during the Year were rights to acquire benefits by means of the

acquisition of shares in or debentures of the Company or of any

other body corporate granted to any directors or their respective

spouse or children under 18 years of age, or were any such rights

exercised by them; or was the Company, its holding company or

any of its subsidiaries a party to any arangement to enable the

directors, their respective spouses or children under 18 years of

age to acquire such rights in any other body corporate.

Save as disclosed, at no time during the Year was the Company or

any of its subsidiaries, asociated companies, felow subsidiaries

or holding companies a party to any arangements to enable

the Directors or the chief executive of the Company to acquire

benefits by means of the acquisition of shares in, or debentures

of, the Company or any other body corporate.

SHARE OPTION SCHEME

The Company had adopted a share option scheme on 20 April

2002 (the “2002 Share Option Scheme”), which was terminated

by the shareholders at the anual general meting of the

Company held on 10 August 2011. For a sumary of the principal

terms of the 2002 Share Option Scheme, please refer to the

section headed “Sumary of terms of the Share Option Scheme”

in Apendix IV to the prospectus of the Company dated 29 April

2002.

As at the date of this anual report, no shares are available for

isue under the 2002 Share Option Scheme of the Company.

No share option was granted, exercised, canceled or lapsed under

the 2002 Share Option Scheme during the years ended 31 March

2025 and 2024.

As at 31 March 2025, no share option was outstanding under the

2002 Share Option Scheme (2023: Nil).

董事购买证券之权利

除上文「董事及主要行政人员于本公司及其相

联法团之股份、相关股份及债权证之权益」一

段所披露者外，于本年度，概无向任何董事或

彼等各自之配偶或未满十八岁之子女授出任

何权利，致使彼等可透过购入本公司或任何

其他法人团体的股份或债权证而获益，而彼

等亦概无行使该等权利；且本公司、其控股公

司或其任何附属公司亦概无订立任何安排，

致使董事、彼等各自之配偶或未满十八岁之

子女可获得任何其他法人团体之该等权利。

除所披露者外，于本年度，本公司或其任何附

属公司、联营公司、同系附属公司或控股公司

概无订立任何安排，致使董事或本公司主要

行政人员可于本年度透过收购本公司或任何

其他法人团体的股份或债权证方式获利。

购股权计划

本公司已于二零二年四月二十日采纳一项

购股权计划（「二零二年购股权计划」），其由

股东于本公司在二零一年八月十日举行之

股东周年大会上终止。二零二年购股权计

划之主要条款概要，请参阅本公司日期为二

零二年四月二十九日之招股章程附录四「购

股权计划之条款概要」一节。

于本年报日期，并无股份根据本公司二零

二年购股权计划可供发行。

于截至二零二五年及二零二四年三月三十一

日止年度，二零二年购股权计划项下并无

购股权获授出、行使、注销或失效。

于二零二五年三月三十一日，二零二年购

股权计划项下并无尚未行使购股权（二零二三

年：无）。

---

金威医疗集团有限公司

2024/2025

年报

Report of the Directors

董事会报告

Folowing the termination of the 2002 Share Option Scheme, no

further share option may be or has ben granted thereunder.

Folowing the termination of the 2002 Share Option Scheme, the

Company had adopted the share option scheme on 10 August

2011 (the “2011 Share Option Scheme”), which has expired on

the tenth aniversary of the adoption date. For a sumary of the

principal terms of the 2011 Share Option Scheme, please refer to

the circular of the Company dated 12 July 2011.

As at the date of this anual report, no shares are available for

isue under the 2011 Share Option Scheme.

No share option was granted, exercised, canceled or lapsed under

the 2011 Share Option Scheme during the years ended 31 March

2025 and 2024.

As at 31 March 2025, no share option was outstanding under the

2011 Share Option Scheme (2024: Nil).

Folowing the expiry of the 2011 Share Option Scheme, the

Company has conditionaly adopted a new share option scheme

(the “2025 Share Option Scheme”) at the extraordinary general

meting of the Company on 6 May 2025. The 2025 Share

Option Scheme has become unconditional on 13 May 2025 (the

“Adoption Date”). Since the adoption of the 2025 Share Option

Scheme and up to the date of this anual report, no share options

have ben granted pursuant to the 2025 Share Option Scheme.

二零二年购股权计划终止后，不可且并无

据其进一步授出购股权。

二零二年购股权计划终止后，本公司已于

二零一年八月十日采纳购股权计划（「二零

一年购股权计划」），其已于采纳日期第十周

年之日届满，二零一年购股权计划之主要

条款概要，请参阅本公司日期为二零一年

七月十二日之通函。

于本年报日期，并无股份根据二零一年购

股权计划可供发行。

于截至二零二五年及二零二四年三月三十一

日止年度，二零一年购股权计划项下并无

购股权获授出、行使、注销或失效。

于二零二五年三月三十一日，二零一年购

股权计划项下并无尚未行使购股权（二零二四

年：无）。

二零一年购股权计划届满后，本公司于二

零二五年五月六日的本公司股东特别大会上

有条件采纳一项新购股权计划（「二零二五年

购股权计划」）。二零二五年购股权计划已于二

零二五年五月十三日（「采纳日期」）成为无条

件。自二零二五年购股权计划获采纳以来及

直至本年度报告日期，并无根据二零二五年

购股权计划授出购股权。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/202556

Report of the Directors

董事会报告

以下为二零二五年购股权计划的主要条款概

要：

(a)

目的

二零二五年购股权计划旨在吸引及挽留

本集团现有最优秀人才，为合资格参与

者提供额外奖励，并促进本集团业务的

整体成功。二零二五年购股权计划将给

予合资格参与者于本公司拥有个人股权

的机会，这将有助于激励合资格参与者

优化其表现及效率，并吸引及挽留对本

集团长期增长及盈利能力作出重要贡献

的合资格参与者。

(b)

合资格参与者

合资格参与者包括

(i)

雇员参与者，包括

本集团任何成员公司之董事及雇员（不

论全职或兼职）（包括根据二零二五年购

股权计划获授购股权作为与本集团任何

成员公司订立雇佣合约的奖励之人士）；

(i)

关连实体参与者，包括本公司控股公

司、同系附属公司或联营公司的董事及

雇员（无论全职或兼职，但不包括任何

前雇员，另行符合资格参与者资格的

前雇员除外）；及

(i)

服务提供商，包括于

本集团的一般及日常业务过程中，持续

或经常性地向本集团任何成员公司提供

对本集团长期发展有利的服务的任何人

士，包括本集团任何业务领域或业务发

展的任何独立合约商、供应商、代理、咨

询师、顾问及╱或业务伙伴，但不包括

任何配售代理或为基金募集、合并或收

购提供咨询服务的财务顾问，以及其他

专业服务供应商，例如提供保证或必须

公正客观地执行其服务的核数师或估值

师。

The folowing is a sumary of the major terms of the 2025 Share

Option Scheme:

(a) Purpose

The purpose of the 2025 Share Option Scheme is to atract

and retain the best available and high calibre personel of

the Group, to provide aditional incentives to the Eligible

Participants and to promote the overal suces of the

busines of the Group. The 2025 Share Option Scheme

wil give the Eligible Participants an oportunity to have a

personal stake in the Company which wil help motivate

the Eligible Participants in optimising their performance and

eficiency and atract and retain the Eligible Participants

whose contributions are important to the long-term growth

and profitability of the Group.

(b) Eligible participants

Eligible participants include (i) employe participant(s)

including the director(s) and employe(s) (whether ful-

time or part-time) of any member of the Group (including

persons who are granted options under the 2025 Share

Option Scheme as inducement to enter into employment

contracts with any member of the Group); (i) related

entity participant(s) which include directors and employes

(whether ful time or part time but excludes any former

employe unles such former employe otherwise qualifies

as an eligible participant) of the holding companies, felow

subsidiaries or asociated companies of the Company; and

(i) service provider(s) including person(s) who provide

services to any member of the Group on a continuing or

recuring basis in its ordinary and usual course of busines

which are in the interests of the long term growth of the

Group, which include any independent contractor, suplier,

agent, consultant, adviser and/or busines partner to any

area of busines or busines development of the Group, but

excluding any placing agents or financial advisers providing

advisory services for fundraising, mergers or acquisitions,

and other profesional services provider such as auditors or

valuers who provide asurance, or are required to perform

their services with impartiality and objectivity.

---

金威医疗集团有限公司

2024/2025

年报

Report of the Directors

董事会报告

(c) Total number of shares available for isue’

(i) Subject to the GEM Listing Rules, the total number of

Shares which may be isued in respect of al options

which may be granted at any time under the 2025

Share Option Scheme together with options and

awards which may be granted under any other share

schemes for the time being of the Company shal not

exced 56,364,998 Shares, representing aproximately

10% of the isued share capital of the Company

(excluding treasury shares) as at the date of aproval

of the 2025 Share Option Scheme (the “Scheme

Mandate Limit”), unles Shareholders’ aproval has

ben obtained pursuant to sub-paragraphs (i) and (iv)

below. Options lapsed in acordance with the terms of

the 2025 Share Option Scheme wil not be regarded

as utilised for the purpose of calculating the Scheme

Mandate Limit and the Service Provider Sublimit (as

defined below). As at the date of this report, the

total number of shares available for isue under the

2025 Share Option Scheme was 56,364,998 Shares,

representing aproximately 10% of the isued share

capital of the Company (excluding treasury shares) as

at the date of this report.

(i) Subject to the limit mentioned in (i) above, within the

Scheme Mandate Limit, the total number of Shares

which may be isued in respect of al options which

may be granted at any time under the 2025 Share

Option Scheme together with options and awards

which may be granted under any other share schemes

for the time being of the Company to service providers

shal not exced 16,909,499 Shares, representing

aproximately 3% of the isued share capital of the

Company (excluding treasury shares) as at the date

of aproval of the 2025 Share Option Scheme (the

“Service Provider Sublimit”).

(c)

可供发行的股份总数

(i)

根据

GEM

上市规则，根据二零二五

年购股权计划可于任何时间授出

之所有购股权连同根据本公司当

时任何其他股份计划可授出之购

股权及奖励而可予发行之股份总

数不得超过

56,364,998

股份，

占本公司于二零二五年购股权计

划获批准日期已发行股本（不包括

库存股份）约

10%

（「计划授权限

额」），除非已根据下文第

(i)

及

(iv)

分段取得股东批准，则另当别论。

就计算计划授权限额及服务供应

商上限（定义见下文）而言，根据

二零二五年购股权计划之条款失

效之购股权将不会被视为已动用。

于本报告日期，根据二零二五年购

股权计划可供发行之股份总数为

56,364,998

股，占本公司于本报告

日期已发行股本（不包括库存股份）

约

10%

。

(i)

在上文

(i)

所述之限额之规限下，于

计划授权限额范围内，就根据二零

二五年购股权计划可能随时授出

的所有购股权连同可能根据本公

司当时之任何其他股份计划而向

服务提供商授出的购股权及奖励

而可能发行的股份总数，不得超过

16,909,499

股份，占本公司于批

准二零二五年购股权计划当日之

已发行股本（不包括库存股份）约

3%

（「服务提供商分项限额」）。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/202558

Report of the Directors

董事会报告

(i)

本公司可于采纳日期（或股东批准

最后一次更新日期）起计三

(3)

年

后，于股东大会上寻求股东批准更

新二零二五年购股权计划项下之

计划授权限额及╱或服务供应商

分项限额，惟如此更新之限额不得

超过于通过相关决议案之日期已

发行相关类别股份（不包括库存股

份）之

10%

。本公司须向股东寄发

通函，当中载有

GEM

上市规则规定

之有关资料。根据

GEM

上市规则第

23.03C(1)

条，计划授权限额及╱

或服务供应商分项限额于采纳日期

（或股东批准最后一次更新日期）

起计三

(3)

年内之任何更新须经独

立股东批准，方可作实，而任何控

股东及其联系人（或倘并无控股

股东，则为董事（不包括独立非执

行董事）及本公司最高行政人员及

彼等各自之联系人）须于股东大会

上放弃投票赞成有关决议。

(d)

每名参与者之最高配额

除非股东以二零二五年购股权计划规定

的方式批准，否则在任何十二个月期间

内，因行使根据二零二五年购股权计划

或本公司任何其他购股权计划授予每位

参与者之购股权及奖励而已发行及将予

发行之股份总数，不得超过本公司已发

行股份总数之

1%

。

(i) The Company may sek aproval of the Shareholders in

general meting to refresh the Scheme Mandate Limit

and/or the Service Provider Sublimit under the 2025

Share Option Scheme after thre (3) years from the

Adoption Date (or the date of Shareholders’ aproval

for the last refreshment), provided that the limit so

refreshed must not exced 10% of the relevant clas

of Shares in isue (excluding treasury shares) as at the

date of pasing the relevant resolution. The Company

must send a circular to the Shareholders containing

such information as required under the GEM Listing

Rules. Any refreshment of the Scheme Mandate Limit

and/or the Service Provider Sublimit to be made within

thre (3) years from the Adoption Date (or the date

of Shareholders’ aproval for the last refreshment)

shal be subject to independent Shareholders’ aproval

pursuant to Rule 23.03C(1) of the GEM Listing Rules

and any controling Shareholders and their asociates

(or if there is no controling Shareholder, Directors

(excluding independent non-executive Directors)

and the chief executive of the Company and their

respective asociates) must abstain from voting in

favour of the relevant resolution at the general

meting.

(d) Maximum entitlement of each participant

The total number of shares isued and to be isued upon

the exercise of the options and awards granted to each

participant under the 2025 Share Option Scheme or any

other option schemes of the Company in any 12-month

period must not exced 1% of the total number of shares of

the Company in isue, unles aproved by the Shareholders

in the maner stipulated in the 2025 Share Option Scheme.

---

金威医疗集团有限公司

2024/2025

年报

Report of the Directors

董事会报告

(e) Time of exercise of options

An option may be exercised in acordance with the terms of

the 2025 Share Option Scheme at any time during a period

as the Board may determine which shal not exced 10 years

from the date of grant subject to the provisions of early

termination thereof.

(f) Grant of options

An ofer for the grant of options shal remain open for

aceptance for a period of twenty-one days, including the

day in which the ofer was made. The amount payable by

the grante of an option to the Company on aceptance of

the ofer for the grant of the option is HK$1.0.

(g) Subscription price

The option subscription price for Shares to be subscribed

under the 2025 Share Option Scheme may be determined

by the Board at its absolute discretion, provided that it shal

not be les than the highest of: (a) the closing price of the

Shares as shown in the daily quotations shet of the Stock

Exchange on the ofer date, which must be a busines day;

(b) the average of the closing prices of the Shares as shown

in the daily quotations shets of the Stock Exchange for the

five (5) consecutive busines days imediately preceding the

ofer date; and (c) the nominal value of the Share on the

ofer date.

(h) Duration of the 2025 Share Option Scheme

The 2025 Share Option Scheme shal continue in force

for the period comencing from the Adoption Date, and

expiring at the close of busines on the date which fals ten

(10) years after the Adoption Date.

(e)

购股权之行使时间

购股权可根据二零二五年购股权计划的

条款于董事会可能厘定的期间（不得超

过授出日期起计

年）内随时行使，惟须

受有关提前终止的条文所规限。

(f)

授出购股权

授出购股权之要约须于二十一天（包括

提呈要约之日）期间内始终可供接纳。购

股权承授人于接纳授出购股权之要约时

应付本公司的金额为

1.0

港元。

(g)

认购价

根据二零二五年购股权计划将获认购股

份的购股权认购价可由董事会全权酌情

厘定，惟无论如何不得低于以下之最高

者：

(a)

于授出日期（须为营业日）联交所

发布的每日报价表所列的股份收市价；

(b)

于紧接授出日期前五

(5)

个连续营业日

联交所发布的每日报价表所列的股份平

均收市价；及

(c)

股份于授出日期之面值。

(h)

二零二五年购股权计划之期限

二零二五年购股权计划自采纳日期起持

续有效，并于采纳日期后第十

(10)

年当日

营业时间结束时届满。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/202560

Report of the Directors

董事会报告

EQUITY-LINKED AGREMENTS

Save for (i) the share option scheme adopted on 10 August 2011;

and (i) the 19,700,000 non-redemable convertible preference

shares aloted and isued in acordance with the sale and

purchase agrement dated 13 November 2009, no equity-linked

agrements that wil or may result in the Company isuing shares

were entered into by the Company during the year or subsisted at

the end of the year ended 31 March 2025.

PURCHASE, SALE OR REDEMPTION OF THE

COMPANY’S LISTED SHARES

During the year ended 31 March 2025, there was no purchase,

sale or redemption of the Company’s listed securities (including

sale of treasury shares) by the Company or any of its subsidiaries.

股票挂钩协议

除

(i)

于二零一年八月十日采纳之购股权计

划；及

(i)

根据日期为二零九年十一月十三

日之买卖协议配发及发行之

19,700,000

股不

可赎回可换股优先股，本公司于年内概无订

立或于截至二零二五年三月三十一日止年度

末仍有效之将会或可能会导致本公司发行股

份之股票挂钩协议。

购买、出售或赎回本公司上市股份

截至二零二五年三月三十一日止年度，本公

司或其任何附属公司并无购买、出售或赎回

本公司之上市证券（包括出售库存股份）。

---

金威医疗集团有限公司

2024/2025

年报

Report of the Directors

董事会报告

PRE-EMPTIVE RIGHTS

There are no provisions for pre-emptive rights under the Articles

of Asociation or the laws of the Cayman Islands, which would

oblige the Company to ofer new shares on a pro-rata basis to

existing shareholders.

FIVE YEAR FINANCIAL SUMARY

A sumary of the published results and of the asets, liabilities

and non-controling interests of the Group for the last five

financial years, as extracted from the audited consolidated

financial statements and restated as apropriate, is set out on

page 184. This sumary does not form part of the audited

consolidated financial statements.

RELATED PARTY TRANSACTIONS

Certain transactions which are undertaken in the normal course

of busines, are also disclosed as related party transactions (se

Note 34 to the consolidated financial statements), but none

of which constitutes a conected transaction or continuing

conected transaction that are not exempt from anual reporting

requirement in Chapter 20 of GEM Listing Rules.

DIVIDEND POLICY

The Board has adopted a dividend policy on 8 November 2018,

which sets out the aproach in recomending dividends, to

alow the Shareholders to participate in the Group’s profits and

for the Group to retain adequate reserves for future growth.

The Company’s ability to pay dividends wil depend upon,

among other things, the Group’s curent and future operations,

financial position, development pipeline, prevailing economic

environment, contractual restrictions, capital and other reserve

requirements, dividends received from the Company’s subsidiaries

and asociates, as wel as any other conditions or factors which

the Board dems relevant. The form, frequency and amount of

dividend payment by the Company are subject to any restrictions

under the memorandum and articles of asociation of the

Company, the aplicable laws and regulations of Hong Kong and

the Cayman Islands and any other laws and regulations aplicable

to the Company.

优先购股权

组织章程细则或开曼群岛法例并无有关本公

司须向现有股东按比例提呈新股份之优先购

股权之规定。

五年财务摘要

过往五个财政年度本集团已刊发之业绩及资

产、负债及非控股权益摘要载于第

页，有

关资料乃摘录自经审核综合财务报表，并于

适当情况下作出重列。此摘要并非经审核综

合财务报表之一部分。

关连人士交易

若干于日常业务过程中进行之交易亦已披露

为关连人士交易（见综合财务报表附注

），

惟概无构成未获豁免遵守

GEM

上市规则第

章之年度报告规定的关连交易或持续关连交

易。

股息政策

董事会已于二零一八年十一月八日采纳股息

政策，其中载列建议股息的方法，可让股东分

享本集团的溢利，以及供本集团为未来增长

保留充足储备。本公司支付股息的能力将取

决于（其中包括）本集团的现时及未来营运、

财务状况、发展渠道、现行经济环境、合约限

制、资本及其他储备要求、自本公司附属公司

及联营公司收取的股息，以及董事会认为相

关的任何其他条件或因素。本公司股息支付

的形式、频率及金额受本公司组织章程大纲

及细则、香港及开曼群岛适用法例及规例以

及本公司适用的任何其他法例及规例项下的

任何限制所规限。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/202562

Report of the Directors

董事会报告

BOARD DIVERSITY POLICY

The Board had adopted a board diversity policy (the “Board

Diversity Policy”) on 8 November 2018, which sets out the

aproach to achieve diversity on the Board. The Company

considered diversity of board members can be achieved through

consideration of a number of aspects, including but not limited

to gender, age, cultural and educational background, ethnicity,

integrity, management experience, technical skils, industry or

profesional knowledge and experience. As at the date of this

report, the gender ratio amongst members of the Board is 4 males

to 1 female. Al Board apointments are based on meritocracy,

and candidates are considered against objective criteria, having

due regard for the benefits of diversity on the Board. The ultimate

decision wil be made upon the merits and contribution that the

selected candidates wil bring to the Board.

The Nomination Comite had reviewed the Board Diversity

Policy to ensure its efectivenes and considered that the Group

had achieved board diversity for the year ended 31 March 2025.

NOMINATION POLICY

The Board had adopted a nomination policy (the “Nomination

Policy”) on 8 November 2018, which sets out the aproach to

determine the nomination of Directors, the procedure, proces

and criteria to be adopted for the purposes of selecting and

recomending candidates for directorship, and shal make

recomendations to the Board on the apointment or re-

apointment of Directors and sucesion planing for Directors,

in particular, the chairman of the Board and the chief executive

oficer.

The Company considered that, in asesing the suitability of a

proposed candidate, the nomination comite of the Board may

make reference to certain criteria, including but not limited to, the

experience in the Company principal busines and/or the industry

in which the Company operates, balance of skils, knowledge and

experience on the Board, and various aspects set out in the Board

Diversity Policy.

董事会多元化政策

董事会于二零一八年十一月八日采纳董事会

多元化政策（「董事会多元化政策」），其中载

列达致董事会多元化的方法。本公司认为，董

事会成员的多元化可透过考虑多个方面来实

现，包括（但不限于）性别、年龄、文化及教育

背景、种族、诚信、管理经验、技术技能、行业

或专业知识与经验。于本报告日期，董事会成

员的男女性别比例为

比

。所有董事会任命

均以唯贤是举为原则，而在甄选候选人时会

考虑客观标准并顾及董事会多元化带来的益

处。最终决定将根据所选候选人的优点及对

董事会的贡献作出。

提名委员会已审阅董事会多元化政策以确保

其效力，并认为本集团于截至二零二五年三

月三十一日止年度已实现董事会多元化。

提名政策

董事会已于二零一八年十一月八日采纳提名

政策（「提名政策」），其中载列确定董事提名的

方法、为甄选及推荐董事候选人而采纳的程

序、流程及标准，并就董事的委任或重新委任

及董事（尤其是董事会主席及行政总裁）的继

任计划向董事会提出建议。

本公司认为，在评估建议候选人的合适性时，

董事会提名委员会可参考若干标准，包括（但

不限于）于本公司主营业务及╱或本公司经营

所在行业的经验、董事会的技能、知识及经验

的平衡，以及董事会多元化政策中载列的各

个方面。

---

金威医疗集团有限公司

2024/2025

年报

Report of the Directors

董事会报告

The Nomination Comite had reviewed the Nomination Policy

to ensure its efectivenes and considered that the Board has

a balance of expertise, skils and experience required for the

busines of the Company for the year ended 31 March 2025.

REMUNERATION POLICY

The remuneration policy of the employes of the Group is set

up by the Remuneration Comite and is based on merit,

qualifications and competence of employes.

The remuneration policy of the Directors is decided by the

Remuneration Comite having regard to the Group’s operating

results, individual performance and comparable market statistics.

CORPORATE GOVERNANCE

The Company has aplied the code provisions set out in the Code

on Corporate Governance Practices (the “CG Code”) contained in

Apendix C1 to the Listing Rules. The Company has complied with

the code provisions of the CG Code for the year ended 31 March

2025.

SUFICIENCY OF PUBLIC FLOAT

Acording to the information that is publicly available to the

Company and to the best knowledge, information and belief of

the directors of the Company, the percentage of the shares which

are in the hands of the public exceds 25% of the total number of

isued shares as at the date of this report.

EVENTS AFTER THE END OF THE REPORTING

PERIOD

Details of significant event ocuring after the reporting period are

set out in Note 38 to the consolidated financial statement.

INDEMNITY OF DIRECTORS

A permited indemnity provision that provides for indemnity

against liability incured by Directors is curently in force and was

in force throughout the year ended 31 March 2025.

提名委员会已审阅提名政策以确保其效力，

并认为董事会于截至二零二五年三月三十一

日止年度拥有本公司业务所须的专业知识、

技能及经验的平衡。

薪酬政策

本集团之雇员薪酬政策由薪酬委员会制定，

并以雇员优点、资历及能力为基准。

董事之薪酬政策由薪酬委员会经计及本集团

之经营业绩、个别表现及可资比较市场统计

数据决定。

企业管治

本公司已应用载于上市规则附录

C1

之企业管

治常规守则（「企业管治守则」）所载之守则条

文。本公司已于截至二零二五年三月三十一

日止年度遵守企业管治守则之守则条文。

足够公众持股量

根据本公司公开可得之资料及就本公司董事

所深知、尽悉及确信，于本报告日期，公众人

士持有之股份百分比超过已发行股份总数之

25%

。

报告期末后事项

于报告期后发生之重大事项之详情载于综合

财务报表附注

。

董事弥偿

规定对董事所产生之责任进行弥偿之经批准

弥偿条文现仍有效及于截至二零二五年三月

三十一日止年度整年内均有效。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/202564

Report of the Directors

董事会报告

业务回顾

按（香港法例第

章）公司条例附表

规定对

该等业务所作之进一步讨论及分析，包括讨

论本集团面对之主要风险及不明朗因素，以

及本集团日后可能之业务发展之指示，载于

本报告「管理层讨论及分析」一节。上述章节构

成本董事会报告之一部分。

审核委员会审阅末期业绩

本集团截至二零二五年三月三十一日止年度

之经审核综合财务业绩已由审核委员会审

阅，并认为有关业绩之编制已遵守适用会计

准则及规定且已作出充足披露。

核数师

本集团截至二零二五年三月三十一日止年度

之综合财务报表经由国卫会计师事务所有限

公司审核，彼将于即将举行之股东周年大会

上退任，并符合资格及愿意接受续聘。

代表董事会

主席

吴志龙

香港，二零二五年六月二十六日

BUSINES REVIEW

Further discusion and analysis of these activities as required by

Schedule 5 to the Companies Ordinance (Chapter 622 of the laws

of Hong Kong), including a discusion of the principal risks and

uncertainties facing the Group and an indication of likely future

developments in the Group’s busines, can be found in the section

headed “Management Discusion and Analysis” in this report. The

above section form part of this Directors’ Report.

REVIEW OF THE FINAL RESULTS BY AUDIT

COMITE

The Group’s audited consolidated financial results for the year

ended 31 March 2025 were reviewed by the Audit Comite,

which was of the opinion that the preparation of such results

complied with the aplicable acounting standards and

requirements and that adequate disclosures have ben made.

AUDITORS

The consolidated financial statements of the Group for the year

ended 31 March 2025 were audited by HLB Hodgson Impey

Cheng Limited who wil retire at the forthcoming anual general

meting and being eligible, ofered themselves for reapointment.

On behalf of the Board

Ng Chi Lung

Chairman

Hong Kong, 26 June 2025

---

金威医疗集团有限公司

2024/2025

年报

Independent Auditors’ Report

独立核数师报告

kramdn

tertS red

l

gno

31/F, Gloucester Tower

aL ehT

deP 11

artneC

K gnoH

TO THE SHAREHOLDERS OF

GOD FELOW HEALTHCARE HOLDINGS LIMITED

(Incorporated in Cayman Islands with limited liability)

OPINION

We have audited the consolidated financial statements of God

Felow Healthcare Holdings Limited (the “Company”) and its

subsidiaries (colectively refered to as the “Group”) set out on

pages 73 to 183, which comprise the consolidated statement

of financial position as at 31 March 2025, and the consolidated

statement of profit or los and other comprehensive income, the

consolidated statement of changes in equity and the consolidated

statement of cash flows for the year then ended, and notes to the

consolidated financial statements, including material acounting

policy information.

In our opinion, the consolidated financial statements give a

true and fair view of the consolidated financial position of the

Group as at 31 March 2025, and of its consolidated financial

performance and its consolidated cash flows for the year then

ended in acordance with HKFRS Acounting Standards as isued

by the Hong Kong Institute of Certified Public Acountants

(“HKICPA”) and have ben properly prepared in compliance

with the disclosure requirements of the Hong Kong Companies

Ordinance.

致金威医疗集团有限公司全体股东

（于开曼群岛注册成立之有限公司）

意见

本核数师（以下简称「我们」）已审核列载于第

至

页的金威医疗集团有限公司（「贵公

司」）及其附属公司（以下统称「贵集团」）的综

合财务报表，此财务报表包括于二零二五年

三月三十一日的综合财务状况表与截至该日

止年度的综合损益及其他全面收益表、综合

权益变动表和综合现金流量表，以及综合财

务报表附注，包括重大会计政策资料。

我们认为，该等综合财务报表已根据香港会

计师公会（「香港会计师公会」）颁布的香港

财务报告准则会计准则真实而中肯地反映

了 贵集团于二零二五年三月三十一日的综

合财务状况及截至该日止年度的综合财务表

现及综合现金流量，并已遵照《香港公司条例》

的披露规定妥为拟备。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/202566

Independent Auditors’ Report

独立核数师报告

意见基准

我们已根据香港会计师公会颁布的香港审计

准则（「香港审计准则」）进行审计。我们在该

等准则下承担的责任已在本报告「核数师就审

计综合财务报表须承担的责任」部分中作进一

步阐述。根据香港会计师公会颁布的《专业会

计师道德守则》（以下简称「守则」），我们独立

于 贵集团，并已履行守则中的其他专业道德

责任。我们相信，我们所获得的审计凭证能充

足及适当地为我们的审计意见提供基础。

关键审计事项

关键审计事项是根据我们的专业判断，认为

对本期综合财务报表的审计最为重要的事

项。该事项是在我们审计整体综合财务报表

及出具意见时进行处理的。我们不会对该事

项提供单独的意见。

BASIS FOR OPINION

We conducted our audit in acordance with Hong Kong

Standards on Auditing (“HKSAs”) as isued by the HKICPA. Our

responsibilities under those standards are further described in

the Auditors’ Responsibilities for the Audit of the Consolidated

Financial Statements section of our report. We are independent

of the Group in acordance with the HKICPA’s Code of Ethics for

Profesional Acountants (the “Code”), and we have fulfiled our

other ethical responsibilities in acordance with the Code. We

believe that the audit evidence we have obtained is suficient and

apropriate to provide a basis for our opinion.

KEY AUDIT MATER

Key audit mater is the mater that, in our profesional judgment,

was of most significance in our audit of the consolidated financial

statements of the curent period. This mater was adresed in

the context of our audit of the consolidated financial statements

as a whole, and in forming our opinion thereon, and we do not

provide a separate opinion on this mater.

---

金威医疗集团有限公司

2024/2025

年报

Independent Auditors’ Report

独立核数师报告

KEY AUDIT MATER – continued

关键审计事项－续

Key audit materHow our audit adresed the key audit mater

关键审计事项我们进行审计时如何处理关键审计事项

Impairment of property, plant and equipment

物业、厂房及设备减值

Refer to Notes 15 to the consolidated financial

Statements

请参阅综合财务报表附注

As at 31 March 2025, the Group had property, plant

and equipment of aproximately HK$1,273,000 (net

of acumulated impairment los of aproximately

HK$2,000). We focused on this area because the

balance of property, plant and equipment was

significant and these asesment proceses are complex

and highly subjective which based on the selection

of apropriate comparables and asumptions such as

discount rate and future revenue.

于二零二五年三月三十一日， 贵集团拥有物业、厂房

及设备约

1,273,000

港元（经扣除累计减值亏损约

2,000

港元）。我们专注于该领域之原因为物业、厂房及设备

之结余庞大，而该等评估过程（基于选取恰当的比较数

据及假设，如折让率及未来收益）复杂及高度主观。

Our procedures in relation to management’s

impairment asesment of property, plant and

equipment included but were not limited to:

我们就管理层对物业、厂房及设备之减值评估采取之

程序包括但不限于：

• Engaging our valuation expert to evaluate the

asumption and methodologies used in the

calculation;

•

聘请估值专家评估计算所使用的假设及方法；

• Asesing the methodologies used and the

apropriatenes of the key asumptions based on

our knowledge of the relevant industry;

•

评估所使用的方法以及基于相关行业知识作出的

主要假设的适当性；

• Chalenging the reasonablenes of key asumption

based on our knowledge of the busines and

industry; and

•

质疑基于我们对业务及行业知识而作出的主要假

设的合理性；及

• , on a sampling basis, the acuracy and

relevance of the input data used.

•

抽样检查所使用输入数据的准确性及相关性。

We found the asumptions, methodologies, judgement

and estimates of the management were suported by

available evidence.

我们发现管理层的假设、方法、判断及估计获可得证据

所支持。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/202568

Independent Auditors’ Report

独立核数师报告

其他资料

董事需对其他资料负责。其他资料包括年报

中所包含的资料，但不包括综合财务报表及

我们的核数师报告（「其他资料」）。

我们对综合财务报表的意见并不涵盖其他资

料，我们亦不对该等其他资料发表任何形式

的鉴证结论。

结合我们对综合财务报表的审计，我们的责

任是阅读其他资料，在此过程中，考虑其他资

料是否与综合财务报表或我们在审计过程中

所了解的情况存在重大抵触或者似乎存在重

大错误陈述的情况。基于我们已执行的工作，

如果我们认为其他资料存在重大错误陈述，

我们需要报告该事实。在这方面，我们没有任

何报告。

董事及管治层就综合财务报表须

承担的责任

董事须负责根据香港会计师公会颁布的香港

财务报告准则会计准则及《香港公司条例》的

披露规定拟备真实而中肯的综合财务报表，

并对其认为使综合财务报表的拟备不存在

由于欺诈或错误而导致的重大错误陈述所需

的内部控制负责。

OTHER INFORMATION

The directors are responsible for the other information. The other

information comprises the information included in the anual

report, but does not include the consolidated financial statements

and our auditors’ report thereon (the “Other Information”).

Our opinion on the consolidated financial statements does not

cover the Other Information and we do not expres any form of

asurance conclusion thereon.

In conection with our audit of the consolidated financial

statements, our responsibility is to read the Other Information

and, in doing so, consider whether the Other Information is

materialy inconsistent with the consolidated financial statements

or our knowledge obtained in the audit or otherwise apears to

be materialy mistated. If, based on the work we have performed,

we conclude that there is a material mistatement of this Other

Information, we are required to report that fact. We have nothing

to report in this regard.

RESPONSIBILITIES OF THE DIRECTORS AND

THOSE CHARGED WITH GOVERNANCE FOR

THE CONSOLIDATED FINANCIAL STATEMENTS

The directors are responsible for the preparation of the

consolidated financial statements that give a true and fair view

in acordance with HKFRS Acounting Standards as isued by

the HKICPA and the disclosure requirements of the Hong Kong

Companies Ordinance and for such internal control as the

directors determine is necesary to enable the preparation of

consolidated financial statements that are fre from material

mistatement, whether due to fraud or eror.

---

金威医疗集团有限公司

2024/2025

年报

Independent Auditors’ Report

独立核数师报告

董事及管治层就综合财务报表须

承担的责任－续

在拟备综合财务报表时， 贵公司董事负责评

估 贵集团持续经营的能力，并在适用情况

下披露与持续经营有关的事项，以及使用持

续经营为会计基础，除非 贵公司董事有意

将 贵集团清盘或停止经营，或别无其他实际

的替代方案。

管治层须负责监督 贵集团的财务报告过程。

核数师就审计综合财务报表须承

担的责任

我们的目标，是对综合财务报表整体是否不

存在由于欺诈或错误而导致的重大错误陈

述取得合理保证，并根据协定的委聘条款仅

向 阁下（作为整体）出具包括我们意见的核

数师报告，除此之外，本报告别无其他用途。

我们不会就本报告内容向任何其他人士负上

或承担任何责任。合理保证是高水平的保证，

但不能保证按照香港审计准则进行的审计，

在某一重大错误陈述存在时总能发现。错误

陈述可以由欺诈或错误引起，如果合理预期

它们单独或汇总起来可能影响综合财务报表

使用者依赖该等综合财务报表所作出的经济

决定，则有关的错误陈述可被视作重大。

RESPONSIBILITIES OF THE DIRECTORS AND

THOSE CHARGED WITH GOVERNANCE FOR

THE CONSOLIDATED FINANCIAL STATEMENTS

– continued

In preparing the consolidated financial statements, the directors

of the Company are responsible for asesing the Group’s ability

to continue as a going concern, disclosing, as aplicable, maters

related to going concern and using the going concern basis of

acounting unles the directors of the Company either intend to

liquidate the Group or to cease operations, or have no realistic

alternative but to do so.

Those charged with governance are responsible for overseing the

Group’s financial reporting proces.

AUDITORS’ RESPONSIBILITIES FOR THE

AUDIT OF THE CONSOLIDATED FINANCIAL

STATEMENTS

Our objectives are to obtain reasonable asurance about whether

the consolidated financial statements as a whole are fre from

material mistatement, whether due to fraud or eror, and to isue

an auditors’ report that includes our opinion solely to you, as a

body, in acordance with our agred terms of engagement, and

for no other purpose. We do not asume responsibility towards

or acept liability to any other person for the contents of this

report. Reasonable asurance is a high level of asurance, but

is not a guarante that an audit conducted in acordance with

HKSAs wil always detect a material mistatement when it exists.

Mistatements can arise from fraud or eror and are considered

material if, individualy or in the agregate, they could reasonably

be expected to influence the economic decisions of users taken on

the basis of these consolidated financial statements.

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/202570

Independent Auditors’ Report

独立核数师报告

核数师就审计综合财务报表须承

担的责任－续

作为根据香港审计准则进行审计的一部份，

在整个审计的过程中，我们运用了专业判断，

保持了专业怀疑态度。我们亦：

•

识别和评估由于欺诈或错误而导致综

合财务报表存在重大错误陈述的风险，

设计及执行审计程序以应对这些风险，

以及获取充足及适当的审计凭证，作为

我们意见的基础。由于欺诈可能涉及串

谋、伪造、蓄意遗漏、虚假陈述，或凌驾

于内部控制之上，因此未能发现因欺诈

而导致出现重大错误陈述的风险高于未

能发现因错误而导致出现重大错误陈述

的风险。

•

了解与审计相关的内部控制，以设计适

当的审计程序，但目的并非对 贵集团

内部控制的有效性发表意见。

•

评价董事所采用会计政策的恰当性及作

出会计估计和相关披露的合理性。

•

对董事采用持续经营会计基础的恰当性

作出结论。根据所获取的审计凭证，确

定是否存在与事项或情况有关的重大不

确定性，从而可能导致对 贵集团的持

续经营能力产生重大疑虑。如果我们认

为存在重大不确定性，则有必要在核数

师报告中提请使用者注意综合财务报表

中的相关披露。假若有关的披露不足，

则我们应当发表非无保留意见。我们的

结论是基于核数师报告日止所取得的审

计凭证。然而，未来事项或情况可能导

致 贵集团不能持续经营。

AUDITORS’ RESPONSIBILITIES FOR THE

AUDIT OF THE CONSOLIDATED FINANCIAL

STATEMENTS – continued

As part of an audit in acordance with HKSAs, we exercise

profesional judgment and maintain profesional scepticism

throughout the audit. We also:

• Identify and ases the risks of material mistatement of the

consolidated financial statements, whether due to fraud

or eror, design and perform audit procedures responsive

to those risks, and obtain audit evidence that is suficient

and apropriate to provide a basis for our opinion. The

risk of not detecting a material mistatement resulting

from fraud is higher than for one resulting from eror, as

fraud may involve colusion, forgery, intentional omisions,

misrepresentations, or the overide of internal control.

• Obtain an understanding of internal control relevant to

the audit in order to design audit procedures that are

apropriate in the circumstances, but not for the purpose

of expresing an opinion on the efectivenes of the Group’s

internal control.

• Evaluate the apropriatenes of acounting policies used

and the reasonablenes of acounting estimates and related

disclosures made by the directors.

• ’ use of the

going concern basis of acounting and, based on the audit

evidence obtained, whether a material uncertainty exists

related to events or conditions that may cast significant

doubt on the Group’s ability to continue as a going concern.

If we conclude that a material uncertainty exists, we are

required to draw atention in our auditors’ report to the

related disclosures in the consolidated financial statements

or, if such disclosures are inadequate, to modify our opinion.

Our conclusions are based on the audit evidence obtained up

to the date of our auditors’ report. However, future events

or conditions may cause the Group to cease to continue as a

going concern.

---

金威医疗集团有限公司

2024/2025

年报

Independent Auditors’ Report

独立核数师报告

核数师就审计综合财务报表须承

担的责任－续

•

评价综合财务报表的整体列报方式、结

构和内容，包括披露，以及综合财务报

表是否中肯反映相关交易和事项。

•

计划及执行集团审计，以就集团内实体

或业务单位的财务信息获取充足、适当

的审计凭证，作为对集团财务报表形成

意见的基础。我们负责指导、监督及审

查为集团审计之目的而进行的审计工

作。我们为审计意见承担全部责任。

除其他事项外，我们与管治层沟通了计划的

审计范围、时间安排、重大审计发现等，包括

我们在审计中识别出内部控制的任何重大缺

陷。

我们还向管治层提交声明，说明我们已符合

有关独立性的相关专业道德要求，并与他们

沟通有可能合理地被认为会影响我们独立性

的所有关系和其他事项，以及在适用的情况

下，采取措施消除威胁或采取相关防范措施。

从与管治层沟通的事项中，我们确定哪些事

项对本期综合财务报表的审计最为重要，因

而构成关键审计事项。我们在核数师报告中

描述这些事项，除非法律法规不允许公开披

露这些事项，或在极端罕见的情况下，如果合

理预期在我们报告中沟通某事项造成的负面

后果超过产生的公众利益，我们决定不应在

报告中沟通该事项。

AUDITORS’ RESPONSIBILITIES FOR THE

AUDIT OF THE CONSOLIDATED FINANCIAL

STATEMENTS – continued

• , structure and content

of the consolidated financial statements, including the

disclosures, and whether the consolidated financial

statements represent the underlying transactions and events

in a maner that achieves fair presentation.

• Plan and perform the group audit to obtain suficient

apropriate audit evidence regarding the financial

information of the entities or busines units within the group

as a basis for forming an opinion on the group financial

statements. We are responsible for the direction, supervision

and review of the audit work performed for purposes of

the group audit. We remain solely responsible for our audit

opinion.

We comunicate with those charged with governance regarding,

among other maters, the planed scope and timing of the audit

and significant audit findings, including any significant deficiencies

in internal control that we identify during our audit.

We also provide those charged with governance with a statement

that we have complied with relevant ethical requirements

regarding independence, and to comunicate with them al

relationships and other maters that may reasonably be thought to

bear on our independence, and where aplicable, actions taken to

eliminate threats or safeguard aplied.

From the maters comunicated with those charged with

governance, we determine those maters that were of most

significance in the audit of the consolidated financial statements

of the curent period and are therefore the key audit maters.

We describe these maters in our auditors’ report unles law or

regulation precludes public disclosure about the mater or when,

in extremely rare circumstances, we determine that a mater

should not be comunicated in our report because the adverse

consequences of doing so would reasonably be expected to

outweigh the public interest benefits of such comunication.

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/202572

Independent Auditors’ Report

独立核数师报告

核数师就审计综合财务报表须承

担的责任－续

出具本独立核数师报告的审计项目董事为

田新杰。

国卫会计师事务所有限公司

执业会计师

田新杰

执业证书编号：

P07364

香港，二零二五年六月二十六日

AUDITORS’ RESPONSIBILITIES FOR THE

AUDIT OF THE CONSOLIDATED FINANCIAL

STATEMENTS – continued

The engagement director on the audit resulting in this

independent auditors’ report is Tien Sun Kit, Jack.

HLB Hodgson Impey Cheng Limited

Certified Public Acountants

Tien Sun Kit, Jack

Practising Certificate Number: P07364

Hong Kong, 26 June 2025

---

2025
二零二五年 HK$’000
千港元
16,120
(7,751)
8,369
987
(7,819)
(1,089)
10,458
(3,105)
(15,060)
81
–
(7,178)
(190)
(7,368)
11
(7,357)
(305)
(500)

金威医疗集团有限公司

2024/2025

年报

Consolidated Statement of Profit or Los and Other Comprehensive Income

综合损益及其他全面收益表

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

二零二四年

NotesHK$’000

附注千港元

Revenue

收益

538,962

Cost of sales

销售成本

(20,288)

Gros profit

毛利

18,674

Other revenue

其他收益

Other los

其他亏损

8(2,075)

(Alowance for)/reversal of expected

credit loses on other receivables and

deposits, net

其他应收款项及按金之

预期信贷亏损（拨备）╱

拨回净额

Gain on disposal of subsidiaries

出售附属公司收益

34–

Seling and distribution expenses

销售及分销费用

(8,918)

Administrative expenses

行政开支

(20,271)

Fair value gain/(los) on financial asets

at fair value through profit or los

按公平值计入损益之

金融资产之公平值

收益╱（亏损）

22(441)

Impairment los on non-financial asets

非金融资产减值亏损

18(3,526)

Los from operations

经营业务亏损

(16,036)

Finance costs

财务费用

9(308)

Los before taxation

除税前亏损

(16,344)

Taxation

税项

10(1,043)

Los for the year

本年度亏损

11(17,387)

Other comprehensive expense

for the year

本年度其他全面开支

Items that may be reclasified

subsequently to profit or los:

其后可重新分类至损益之

项目：

Exchange diferences on translating

foreign operations

换算海外经营业务之

汇兑差额

(581)

Reclasification of cumulative

translation reserve upon

disposal of subsidiaries

于出售附属公司后

重新分类累计换算储备

–

---

2025
二零二五年 HK$’000
千港元
(805)
(8,162)
(10,127)
2,770
(7,357)
(10,866)
2,704
(8,162)
(1.80)

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/202574

Consolidated Statement of Profit or Los and Other Comprehensive Income

综合损益及其他全面收益表

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

随附之附注为该等综合财务报表之一部分。

二零二四年

NotesHK$’000

附注千港元

Other comprehensive expense

for the year

本年度其他全面开支

(581)

Total comprehensive expense

for the year

本年度全面开支总额

(17,968)

Los for the year atributable to:

应占本年度亏损：

Owners of the Company

本公司拥有人

(17,110)

Non-controling interests

非控股权益

(277)

(17,387)

Total comprehensive expense

for the year atributable to:

应占本年度全面开支总额：

Owners of the Company

本公司拥有人

(17,833)

Non-controling interests

非控股权益

(135)

(17,968)

Los per share

每股亏损

– Basic and diluted

(HK cents per share)

–

基本及摊薄

（每股港仙）

14(3.04)

The acompanying notes form an integral part of these

consolidated financial statements.

---

2025
二零二五年 HK$’000
千港元
1,273
–
–
1,273
–
4,414
316
3,829
8,559
6,053
–
10,529
5
16,587
(8,028)
(6,755)

金威医疗集团有限公司

2024/2025

年报

Consolidated Statement of Financial Position

综合财务状况表

At 31 March 2025

于二零二五年三月三十一日

二零二四年

NotesHK$’000

附注千港元

Non-curent asets

非流动资产

Property, plant and equipment

物业、厂房及设备

1516,035

Right-of-use asets

使用权资产

164,138

Rental deposits

租赁按金

20,441

Curent asets

流动资产

Inventories

存货

201,063

Trade and other receivables

贸易及其他应收款项

213,761

Financial asets at fair value

through profit or los

按公平值计入损益之

金融资产

Cash and bank balances

现金及银行结余

233,644

8,705

Curent liabilities

流动负债

Trade and other payables

贸易及其他应付款项

2415,510

Lease liabilities

租赁负债

253,006

Borowings

借款

267,099

Tax payables

应付税项

–

25,615

Net curent liabilities

流动负债净值

(16,910)

Total asets les curent liabilities

资产总值减流动负债

3,531

---

2025
二零二五年 HK$’000
千港元
–
–
(6,755)
29,168
(35,677)
(6,509)
(246)
(6,755)

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/202576

Consolidated Statement of Financial Position

综合财务状况表

At 31 March 2025

于二零二五年三月三十一日

综合财务报表于二零二五年六月二十六日由

董事会批准及授权刊发，并由下列董事代表

签署：

随附之附注为该等综合财务报表之一部分。

二零二四年

NotesHK$’000

附注千港元

Non-curent liabilities

非流动负债

Lease liabilities

租赁负债

252,124

2,124

Net (liabilities)/asets

（负债）╱资产净值

1,407

Capital and reserves

资本及储备

Share capital

股本

2729,168

Reserves

储备

(24,811)

Equity atributable to owners

of the Company

本公司拥有人应占权益

4,357

Non-controling interests

非控股权益

(2,950)

Total equity

权益总额

1,407

The consolidated financial statements were aproved and

authorised for isue by the Board of Directors on 26 June 2025

and are signed on its behalf by:

Ng Chi LungWu Qiyou

吴志龙吴其佑

DirectorDirector

董事董事

The acompanying notes form an integral part of these

consolidated financial statements.

---

金威医疗集团有限公司

2024/2025

年报

Consolidated Statement of Changes in Equity

综合权益变动表

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

Atributable to the owners of the Company

本公司拥有人应占

Share

capital

Share

premium

Capital

reserve

Other

reserve

Special

reserve

Translation

reserve

Statutory

reserve

Acumulated

losesSub-total

Non-

controling

interestsTotal equity

股本股份溢价资本储备其他储备特别储备汇兑储备法定储备累计亏损小计非控股权益权益总额

HK$’000HK$’000HK$’000HK$’000HK$’000HK$’000HK$’000HK$’000HK$’000HK$’000HK$’000

千港元千港元千港元千港元千港元千港元千港元千港元千港元千港元千港元

(Note (a)(Note (b)(Note (c)(Note (d)

（附注

(a)

）（附注

(b)

）（附注

(c)

）（附注

(d)

）

At 1 April 2023

于二零二三年四月一日

29,168440,289295,610(7,457)(31,315)(1,555)1,608(704,158)22,190(2,815)19,375

Los for the year

本年度亏损

–(17,110)(17,110)(277)(17,387)

Exchange diference on translating

foreign operations

换算海外业务之汇兑差额

–(723)–(723)142(581)

Total comprehensive expense

for the year

本年度全面开支总额

–(723)–(17,110)(17,833)(135)(17,968)

At 31 March 2024

于二零二四年三月三十一日

29,168440,289295,610(7,457)(31,315)(2,278)1,608(721,268)4,357(2,950)1,407

Los for the year

本年度亏损

–

（

10,127

）（

10,127

）

2,770

（

7,357

）

Exchange diference on translating

foreign operations

换算海外业务之汇兑差额

–

（

）

–

（

）

(66)(305)

Reclasification of cumulative

translation reserve upon

disposal of a foreign operation

于出售海外经营业务后

重新分类累计换算储备

–(500)–(500)–(500)

Total comprehensive expense

for the year

本年度全面开支总额

–(739)–

（

10,127

）

(10,866)2,704(8,162)

Disposal of subsidiaries (Note 34)

出售附属公司（附注

）

–7,457–(26)(7,431)–

At 31 March 2025

于二零二五年三月三十一日

29,168440,289295,610–(31,315)(3,017)1,582(738,826)(6,509)(246)(6,755)

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/202578

Consolidated Statement of Changes in Equity

综合权益变动表

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

Notes:

(a) Other reserve represents the diference betwen the consideration

paid for aditional equity interest in a subsidiary without the overal

change in the control in that subsidiary and the carying amount of

share of net liabilities/asets.

(b) Special reserve represents the diference betwen the Company’s

shares of nominal value of the paid-up capital of subsidiaries

acquired over the Company’s cost of acquisition of the subsidiaries

under comon control upon change in ownership interests in

subsidiaries.

(c) Translation reserve comprises al foreign exchange diferences

arising from the translation of the financial statements of operations

outside Hong Kong. The reserve is dealt with in acordance with the

acounting policies set out in Note 3.

(d) As stipulated by the relevant People’s Republic of China (“PRC”)

laws and regulations, the subsidiaries of the Company established

in the PRC shal set aside 10% of its net profit after taxation for the

statutory surplus reserve fund (except where the reserve balance

has reached 50% of the subsidiaries’ paid-up capital). The reserve

fund can only be used, upon aproval by the board of directors and

by the relevant authority, to ofset acumulated loses or increase

capital.

The acompanying notes form an integral part of these

consolidated financial statements.

附注：

(a)

其他储备指就附属公司额外股权（并无导致于

该附属公司控制权之整体变动）已付代价与应

占净负债／资产之账面值两者间之差额。

(b)

特别储备指本公司占所收购之附属公司的已

缴股本的面值与本公司于附属公司拥有权

益变动后的共同控制下收购附属公司成本之

差额。

(c)

汇兑储备包括换算于香港境外之业务之财务

报表而产生之所有外汇差额。该储备乃根据

附注

所载之会计政策处理。

(d)

根据中华人民共和国（「中国」）相关法律及

法规之规定，于中国成立之本公司附属公司

须拨出

10%

除税后纯利为法定盈余储备基金

（除非储备结余已达至附属公司缴足资本之

50%

）。待董事会及有关政府当局批准后，储

备基金仅可用作抵销累计亏损或增加资本。

随附之附注为该等综合财务报表之一部分。

---

2025
二零二五年 HK$’000
千港元
(7,368)
(1)
615
7,819
190
6,934
2,105
(81)
1,089
–
(904)
(10,458)
(60)
445
(1,676)
1,503
2,394
2,606
16
2,622

金威医疗集团有限公司

2024/2025

年报

Consolidated Statement of Cash Flows

综合现金流量表

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

二零二四年

NotesHK$’000

附注千港元

CASH FLOWS FROM OPERATING

ACTIVITIES

经营业务之现金流量

Los before taxation

除税前亏损

(16,344)

Adjustments for:

调整项目：

Bank interest income

银行利息收入

7(28)

Writen of of inventories

撇销存货

Los on disposal of property,

plant and equipment

出售物业、厂房及

设备之亏损

82,075

Interest expenses

利息开支

Depreciation of property,

plant and equipment

物业、厂房及设备折旧

152,782

Depreciation of right-of-use asets

使用权资产折旧

163,136

Fair value (gain)/los on financial asets

at fair value through profit or los

按公平值计入损益之

金融资产之公平值

（收益）╱亏损

Reversal of alowance

for expected credit loses on

other receivables and deposits

其他应收款项及按金之

预期信贷亏损拨备拨回

(372)

Impairment los on non-financial asets

非金融资产减值亏损

183,526

Gain on early termination of leases

提前终止租赁之收益

–

Gain on disposal of subsidiaries

出售附属公司之收益

34–

Operating cash flows before movements

in working capital

营运资金变动前之经营

现金流量

(3,949)

Decrease/(increase) in inventories

存货减少╱（增加）

(8)

(Increase)/decrease in trade and other

receivables

贸易及其他应收款项

（增加）╱减少

3,181

Decrease in restricted cash

受限制现金减少

2,453

Increase/(decrease) in trade and

other payables

贸易及其他应付款项

增加╱（减少）

(1,466)

Cash generated from operations

业务所得现金

PRC Enterprise Income Tax refund/(paid)

已退还╱（已付）中国企业

所得税

(1,065)

Net cash generated from/(used in)

operating activities

经营业务所得╱（所用）现金

净额

(854)

---

2025
二零二五年 HK$’000
千港元
1
(41)
(1,534)
(1,574)
–
5,600
(2,159)
(2,382)
1,059
2,107
2,141
(419)
3,829

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/202580

Consolidated Statement of Cash Flows

综合现金流量表

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

随附之附注为该等综合财务报表之一部分。

二零二四年

NotesHK$’000

附注千港元

CASH FLOWS FROM INVESTING

ACTIVITIES

投资活动之现金流量

Interest received

已收利息

Purchase of property,

plant and equipment

购买物业、厂房及设备

15(14,491)

Net cash outflow on disposal of

subsidiaries

出售附属公司之现金流出净额

34–

Net cash used in investing activities

投资活动所用现金净额

(14,463)

CASH FLOWS FROM FINANCING

ACTIVITIES

融资活动之现金流量

Interest paid

已付利息

(34)

Proceds from borowings

借款所得款项

10,419

Repayment of borowings

偿还借款

(3,288)

Repayment of lease liabilities

偿还租赁负债

(2,739)

Net cash generated from financing

activities

融资活动所得现金净额

4,358

Net increase/(decrease) in cash and

cash equivalents

现金及现金等值项目

增加／（减少）净额

(10,959)

Cash and cash equivalents

at begining of the year

年初之现金及现金等值项目

13,541

Efect of foreign exchange rate changes

外汇率变动之影响

(441)

Cash and cash equivalents at end of

the year

年末之现金及现金等值项目

232,141

The acompanying notes form an integral part of these

consolidated financial statements.

---

金威医疗集团有限公司

2024/2025

年报

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

1. GENERAL INFORMATION

God Felow Healthcare Holdings Limited (the “Company”)

was incorporated in the Cayman Islands on 28 May 2001

as an exempted company with limited liability. The shares

of the Company are listed on GEM (“GEM”) of The Stock

Exchange of Hong Kong Limited (the “Stock Exchange”).

Its imediate holding company is Solar Star Global Limited

and ultimate controling party is Mr. Ng Chi Lung, who is

also the chairman and Executive Director of the Company.

The registered ofice of the Company is P.O. Box 31119

Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand

Cayman, KY1-1205, Cayman Islands. The head ofice and

principal place of busines of the Company in Hong Kong is

located at Rom 2101, 21/F, China Merchants Tower, Shun

Tak Centre, 168-200 Conaught Road Central, Hong Kong.

The consolidated financial statements are presented in Hong

Kong dolars (“HK$”), which is the functional curency of

the Company, and the functional curency of most of its

subsidiaries is Renminbi (“RMB”). The consolidated financial

statements are presented in thousands of units of HK$

(HK$’000), unles otherwise stated.

The Company acts as an investment holding company while

its subsidiaries (together with the Company, the “Group”)

are principaly engaged in the provision of general hospital

services in the People’s Republic of China (the “PRC”). The

principal activities of its subsidiaries are set out in Note 36 to

the consolidated financial statements.

1.

一般资料

金威医疗集团有限公司（「本公司」）于

二零一年五月二十八日在开曼群岛注

册成立为一家获豁免有限公司。本公司

股份在香港联合交易所有限公司（「联交

所」）

GEM

（「

GEM

」）上市。其直接控股公

司为星阳环球有限公司及最终控股方乃

亦为本公司主席兼执行董事之吴志龙先

生。本公司注册办事处为

P.O. Box 31119

Grand Pavilion, Hibiscus Way, 802 West

Bay Road, Grand Cayman, KY1-1205,

Cayman Islands

。本公司于香港之总办

事处及主要营业地点位于香港干诺道

中

168-200

号信德中心招商局大厦

楼

室。

综合财务报表乃以本公司之功能货币港

元（「港元」）呈列，而其大部份附属公司

之功能货币为人民币（「人民币」）。除另

有指明外，综合财务报表以千港元（千港

元）呈列。

本公司为一间投资控股公司，而其附属

公司（连同本公司统称为「本集团」）主要

于中华人民共和国（「中国」）从事提供综

合性医院服务。其附属公司之主要业务

载于综合财务报表附注

。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/202582

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

2. APLICATION OF NEW AND

AMENDMENTS TO HKFRS ACOUNTING

STANDARDS

Amendments to HKFRS Acounting Standards that

are mandatorily efective for the curent year

In the curent year, the Group has aplied the folowing

amendments to HKFRS Acounting Standards isued by

the Hong Kong Institute of Certified Public Acountants

(“HKICPA”) for the first time, which are mandatorily

efective for the Group’s anual period begining on 1

April 2024 for the preparation of the consolidated financial

statements:

Amendments to HKFRS 16Lease Liability in a Sale and

Leaseback

Amendments to HKAS 1Clasification of Liabilities as

Curent or Non-curent and

related amendments

to Hong Kong

Interpretation 5 (2020)

Amendments to HKAS 1Non-curent Liabilities with

Covenants

Amendments to HKAS 7

and HKFRS 7

Suplier Finance Arangements

The aplication of the amendments to HKFRS Acounting

Standards in the curent year has had no material impact

on the Group’s financial positions and performance for the

curent and prior years and/or on the disclosures set out in

these consolidated financial statements.

2.

应用新订香港财务报告准则会

计准则及其修订本

于本年度强制生效的香港财务报告

准则会计准则修订本

于本年度，本集团已首次应用以下由香

港会计师公会（「香港会计师公会」）颁布

且于本集团于二零二四年四月一日开始

之年度期间强制生效之香港财务报告准

则会计准则修订本编制综合财务报表：

香港财务报告准则

第

号修订本

售后租回的租赁

负债

香港会计准则

第

号修订本

流动或非流动负债

分类以及香港诠释

第

号相关修订本

（二零二零年）

香港会计准则

第

号修订本

附带契诺的非流动

负债

香港会计准则

第

号及香港财务

报告准则第

号

修订本

供应商融资安排

于本年度应用香港财务报告准则会计准

则修订本对本集团于本年度及过往年度

之财务状况及表现及╱或于该等综合财

务报表内所载之披露资料并无重大影

响。

---

金威医疗集团有限公司

2024/2025

年报

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

2. APLICATION OF NEW AND

AMENDMENTS TO HKFRS ACOUNTING

STANDARDS – continued

New and amendments to HKFRS Acounting

Standards in isue but not yet efective

The Group has not early aplied the folowing new and

amendments to HKFRS Acounting Standards that have ben

isued but are not yet efective:

Amendments to HKFRS 9

and HKFRS 7

Amendments to the Clasification

and Measurement of Financial

Instruments

Amendments to HKFRS 10

and HKAS 28

Sale or Contribution of Asets

betwen an Investor and its

Asociate or Joint Venture

Amendments to HKFRS

Acounting Standards

Anual Improvements to HKFRS

Acounting Standards – Volume

Amendments to HKAS 21Lack of Exchangeability

HKFRS 18Presentation and Disclosure in

Financial Statements

Efective for anual periods begining on or after a date to be

determined.

Efective for anual periods begining on or after 1 January

2025.

Efective for anual periods begining on or after 1 January

2026.

Efective for anual periods begining on or after 1 January

2027.

The directors anticipate that the aplication of the new and

amendments to HKFRS Acounting Standards wil have no

material impact on the consolidated financial statements in

the foreseable future.

2.

应用新订香港财务报告准则会

计准则及其修订本－续

已颁布但尚未生效之新订香港财务

报告准则会计准则及其修订本

本集团并未提早应用下列已颁布但尚未

生效之新订香港财务报告准则会计准则

及其修订本：

香港财务报告准则

第

号及香港财务

报告准则第

号

修订本

金融工具的分类及

计量修订本

香港财务报告准则

第

号及香港会

计准则第

号

修订本

投资者及其联营公司

或合营企业之间的

资产出售或投入

香港财务报告准则

会计准则修订本

香港财务报告准则

会计准则的年度改

进－第

册

香港会计准则

第

号修订本

缺乏可兑换性

香港财务报告准则

第

号

财务报表的呈列及

披露

于待厘定之日期或之后开始之年度期

间生效。

于二零二五年一月一日或之后开始之

年度期间生效。

于二零二六年一月一日或之后开始之

年度期间生效。

于二零二七年一月一日或之后开始之

年度期间生效。

董事预期，应用新订香港财务报告准则

会计准则及其修订本于可见未来将不会

对综合财务报表产生重大影响。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/202584

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

3. BASIS OF PREPARATION OF

CONSOLIDATED FINANCIAL STATEMENTS

AND MATERIAL ACOUNTING POLICY

INFORMATION

Basis of preparation of consolidated financial

statements

The consolidated financial statements have ben prepared

in acordance with HKFRS Acounting Standards isued by

the HKICPA and acounting principles generaly acepted

in Hong Kong. For the purpose of preparation of the

consolidated financial statements, information is considered

material if such information is reasonably expected to

influence decisions made by primary users. In adition,

the consolidated financial statements include aplicable

disclosures required by the Rules Governing the Listing of

Securities on GEM of The Stock Exchange of Hong Kong

Limited (the “Listing Rules”) and by the Hong Kong

Companies Ordinance.

The consolidated financial statements have ben prepared

on the historical cost basis, except for certain financial

instruments which are measured at fair values at the end

of each reporting period, as explained in the acounting

policies set out below. Historical cost is generaly based on

the fair value of the consideration given in exchange for

gods and services.

As at 31 March 2025, the Group had net liabilities of

aproximately HK$6,755,000 and incured a net los of

aproximately HK$7,357,000 during the year.

In light of the prevailing circumstances, the Group’s rights

isue is anticipated for completion in June 2025. The

directors regard the funds anticipated to be raised through

this initiative as crucial to enhancing the Group’s liquidity

position.

3.

综合财务报表编制基准及重大

会计政策资料

综合财务报表编制基准

综合财务报表已按照香港会计师公会颁

布的香港财务报告准则会计准则及香

港公认会计原则编制。就编制综合财务

报表而言，倘资料被合理地预期会影响

主要使用者的决策，则该资料被视为重

要。此外，综合财务报表包括香港联合

交易所有限公司

GEM

证券上市规则（「上

市规则」）及香港公司条例规定的适用披

露。

如以下会计政策所述，综合财务报表乃

按历史成本基准编制，惟若干金融工具

乃按各报告期末之公平值计量。历史成

本一般根据交换货品及服务时支付代价

之公平值计算。

于二零二五年三月三十一日，本集团之

负债净额约为

6,755,000

港元及年内产生

亏损净额约

7,357,000

港元。

鉴于当前情况，本集团的供股预期于二

零二五年六月完成。董事认为预期透过

此举筹集的资金对提升本集团的流动资

金状况至关重要。

---

金威医疗集团有限公司

2024/2025

年报

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

3. BASIS OF PREPARATION OF

CONSOLIDATED FINANCIAL STATEMENTS

AND MATERIAL ACOUNTING POLICY

INFORMATION – continued

Basis of preparation of consolidated financial

statements – continued

The directors have reviewed the Group’s cash flow

projections cover a period of not les than twelve months

from the end of the reporting period. In the opinion of the

directors, the Group wil have suficient working capital to

finance its operations and to met its financial obligations

when they fal due within the next twelve months from the

end of the reporting period. As such, the estimates and

underlying asumptions are reviewed on an ongoing basis.

Material acounting policy information

Basis of consolidation

The consolidated financial statements incorporate the

financial statements of the Company and entities (including

structured entities) controled by the Company and its

subsidiaries. Control is achieved when the Company:

• ;

• , or has rights, to variable returns from its

involvement with the investe; and

• has the ability to use its power to afect its returns.

The Group reaseses whether or not it controls an investe

if facts and circumstances indicate that there are changes to

one or more of the thre elements of control listed above.

3.

综合财务报表编制基准及重大

会计政策资料－续

综合财务报表编制基准－续

董事已审阅本集团涵盖不少于报告期末

起计未来十二个月期间的现金流量预

测。董事认为，本集团将具有充裕营运

资金为其自报告期末起计十二个月内之

营运提供资金并履行到期之财务责任。

因此，估计及相关假设乃按持续基准审

阅。

重大会计政策资料

综合基准

综合财务报表编入本公司及由本公司及

其附属公司所控制实体（包括结构性实

体）之财务报表。当本公司属以下情况时

则取得控制权：

•

可对受投资实体行使权力；

•

对来自参与受投资实体之可变回

报承担风险或享有权利；及

•

有能力使用其权力影响其回报。

倘有事实及情况显示上述三项控制因素

中，有一项或以上出现变数，本集团会

重新评估其是否控制受投资实体。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/202586

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

3. BASIS OF PREPARATION OF

CONSOLIDATED FINANCIAL STATEMENTS

AND MATERIAL ACOUNTING POLICY

INFORMATION – continued

Material acounting policy information

– continued

Basis of consolidation – continued

Consolidation of a subsidiary begins when the Group obtains

control over the subsidiary and ceases when the Group loses

control of the subsidiary. Specificaly, income and expenses

of a subsidiary acquired or disposed of during the year are

included in the consolidated statement of profit or los and

other comprehensive income from the date the Group gains

control until the date when the Group ceases to control the

subsidiary.

Profit or los and each component of other comprehensive

income are atributed to the owners of the Company and to

the non-controling interests even if this results in the non-

controling interests having a deficit balance.

When necesary, adjustments are made to the financial

statements of subsidiaries to bring their acounting policies

into line with the Group’s acounting policies.

Al intragroup asets and liabilities, equity, income, expenses

and cash flows relating to transactions betwen members of

the Group are eliminated in ful on consolidation.

Non-controling interests in subsidiaries are presented

separately from the Group’s equity therein, which represent

present ownership interests entitling their holders to a

proportionate share of net asets of the relevant subsidiaries

upon liquidation.

3.

综合财务报表编制基准及重大

会计政策资料－续

重大会计政策资料－续

综合基准－续

综合一家附属公司账目之时间从本集团

取得该附属公司之控制权起至本集团失

去该附属公司之控制权止。尤其是，于

年内所收购或出售之一家附属公司之收

入及开支，自本集团取得该附属公司之

控制权之日起至本集团失去该附属公司

之控制权之日止计入综合损益及其他全

面收益表。

损益及其他全面收益之各项归属于本公

司拥有人及非控股权益，即使此将导致

非控股权益出现亏绌结余。

如有需要，将对附属公司之财务报表作

出调整，以使其会计政策与本集团之会

计政策一致。

集团内公司间之所有资产及负债、权

益、收入及开支以及与本集团成员公司

间之交易有关之现金流量均于综合账目

时悉数对销。

附属公司非控股权益与本集团于其中的

权益分开呈列，指赋予其持有人权利于

清盘时按比例分占相关附属公司资产净

值之现时所有权益。

---

金威医疗集团有限公司

2024/2025

年报

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

3. BASIS OF PREPARATION OF

CONSOLIDATED FINANCIAL STATEMENTS

AND MATERIAL ACOUNTING POLICY

INFORMATION – continued

Material acounting policy information

– continued

Changes in the Group’s ownership interests in existing

subsidiaries

When the Group loses control of a subsidiary, the asets and

liabilities of that subsidiary and non-controling interests (if

any) are derecognised, a gain or los is recognised in profit

or los and is calculated as the diference betwen (i) the

agregate of the fair value of the consideration received and

the fair value of any retained interest and (i) the carying

amount of the asets (including godwil), and liabilities of

the subsidiary atributable to the owners of the Company.

Al amounts previously recognised in other comprehensive

income in relation to that subsidiary are acounted for as

if the Group had directly disposed of the related asets or

liabilities of the subsidiary (i.e. reclasified to profit or los

or transfered to another category of equity as specified/

permited by aplicable HKFRS Acounting Standards). The

fair value of any investment retained in the former subsidiary

at the date when control is lost is regarded as the fair value

on initial recognition for subsequent acounting under

HKFRS 9 Financial Instruments or, when aplicable, the cost

on initial recognition of an investment in an asociate or a

joint venture.

3.

综合财务报表编制基准及重大

会计政策资料－续

重大会计政策资料－续

本集团于现有附属公司所有权益之变

动

当本集团丧失对附属公司的控制权时，

即终止确认该附属公司之资产及负债以

及非控股权益（如有），并于损益内确认

收益或亏损，计算为

(i)

所收到的代价的

公平值和任何保留权益的公平值总额与

(i)

本公司拥有人应占附属公司资产（包

括商誉）和负债的账面金额之间的差额。

此前与附属公司相关并于其他全面收益

确认的全部金额应视同本集团已直接处

置该附属公司的相关资产或负债进行核

算（即按照适用香港财务报告准则会计

准则规定╱允许，重新分类到损益或结

转到另一权益类别）。在前附属公司中保

留的投资在丧失控制权之日的公平值于

其后入账时应作为按照香港财务报告准

则第

号金融工具进行初始确认的公平

值，或作为在联营公司或合营企业中的

投资的初始确认成本（如适用）。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/202588

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

3. BASIS OF PREPARATION OF

CONSOLIDATED FINANCIAL STATEMENTS

AND MATERIAL ACOUNTING POLICY

INFORMATION – continued

Material acounting policy information

– continued

Godwil

Godwil arising on an acquisition of a busines is caried at

cost as established at the date of acquisition of the busines

les acumulated impairment loses.

For the purposes of impairment testing, godwil is alocated

to each of the Group’s cash-generating units (“CGUs”)

(or groups of CGUs) that is expected to benefit from the

synergies of the combination,which represents the lowest

level at which the godwil is monitored for internal

management purposes and not larger than an operating

segment.

A CGU to which godwil has ben alocated is tested for

impairment anualy, or more frequently when there is an

indication that the unit may be impaired. If the recoverable

amount of the CGU is les than its carying amount, the

impairment los is alocated first to reduce the carying

amount of any godwil alocated to the unit and then to

the other asets of the unit on a pro-rate basis based on the

carying amount of each aset in the unit. Any impairment

los for godwil is recognised directly in profit or los

in the consolidated statement of profit or los and other

comprehensive income. An impairment los recognised for

godwil is not reversed in subsequent periods.

On disposal of the relevant CGU, the atributable amount of

godwil is included in the determination of the profit or los

on disposal.

3.

综合财务报表编制基准及重大

会计政策资料－续

重大会计政策资料－续

商誉

收购一项业务所产生的商誉以于收购该

业务当日确立之成本减累计减值亏损计

量。

就减值测试而言，商誉将被分配到预期

从合并的协同效应中受益的本集团各有

关现金产生单位（「现金产生单位」）或现

金产生单位的组别，即就内部管理而言

监察商誉的最低层面且该层面不大于经

营分部。

已获分配商誉的现金产生单位每年或当

其有可能出现减值的迹象时更频密地进

行减值测试。倘现金产生单位的可收回

金额少于其账面值，减值亏损首先将被

分配以削减任何分配到该单位的商誉账

面值，其后按该单位内各资产的账面值

按比例分配至该单位的其他资产。商誉

的任何减值亏损直接于综合损益及其他

全面收益表的损益中确认。就商誉确认

的减值亏损于其后期间不予拨回。

于出售相关现金产生单位时，会计入商

誉应占金额以厘定出售损益。

---

金威医疗集团有限公司

2024/2025

年报

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

3. BASIS OF PREPARATION OF

CONSOLIDATED FINANCIAL STATEMENTS

AND MATERIAL ACOUNTING POLICY

INFORMATION – continued

Material acounting policy information

– continued

Revenue from contracts with customers

Under HKFRS 15, the Group recognises revenue when (or as)

a performance obligation is satisfied, i.e. when “control” of

the gods or services underlying the particular performance

obligation is transfered to the customer.

A performance obligation represents a god or service (or

a bundle of gods or services) that is distinct or a series of

distinct gods or services that are substantialy the same.

Control is transfered over time and revenue is recognised

over time by reference to the progres towards complete

satisfaction of the relevant performance obligation if one of

the folowing criteria is met:

• the customer simultaneously receives and consumes

the benefits provided by the Group’s performance as

the Group performs;

• ’s performance creates and enhances

an aset that the customer controls as the Group

performs; or

• ’s performance does not create an aset

with an alternative use to the Group and the Group

has an enforceable right to payment for performance

completed to date.

Otherwise, revenue is recognised at a point in time when the

customer obtains control of the distinct god or service.

3.

综合财务报表编制基准及重大

会计政策资料－续

重大会计政策资料－续

来自客户合约收益

根据香港财务报告准则第

号，本集团

于完成履约责任时（或就此）确认收益，

即于特定履约责任相关之货品或服务的

「控制权」转让予客户时。

履约责任指可区分的单一货品或服务

（或一批货品或服务）或一系列大致相

同的可区分货品或服务。

倘符合下列其中一项标准，控制权随时

间转移，而收益会参考已完成相关履约

责任的进度随时间确认：

•

于本集团履约时，客户同时取得并

耗用本集团履约所提供的利益；

•

本集团的履约产生及加强一项资

产，而该项资产于本集团履约时由

客户控制；或

•

本集团的履约并未产生对本集团

有替代用途的资产，且本集团对迄

今已完成履约的付款具有可强制

执行的权利。

否则，收益会在客户获得可区分的货品

或服务的控制权时在某一时点确认。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/202590

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

3. BASIS OF PREPARATION OF

CONSOLIDATED FINANCIAL STATEMENTS

AND MATERIAL ACOUNTING POLICY

INFORMATION – continued

Material acounting policy information

– continued

Revenue from contracts with customers

– continued

A contract aset represents the Group’s right to

consideration in exchange for gods or services that

the Group has transfered to a customer that is not yet

unconditional. It is asesed for impairment in acordance

with HKFRS 9. In contrast, a receivable represents the

Group’s unconditional right to consideration, i.e. only

the pasage of time is required before payment of that

consideration is due.

A contract liability represents the Group’s obligation to

transfer gods or services to a customer for which the Group

has received consideration (or an amount of consideration is

due) from the customer.

A contract aset and a contract liability relating to a contract

are acounted for and presented on a net basis.

Provision of general hospital services

Revenue from the provision of general hospital services,

which is mainly derived from hospital services provided at

the hospitals, is recognised at a point in time, i.e. when the

related services have ben rendered to patients.

3.

综合财务报表编制基准及重大

会计政策资料－续

重大会计政策资料－续

来自客户合约收益－续

合约资产指本集团就交换本集团已向客

户转让的货品或服务而收取代价的权

利，有关权利并非无条件，并须根据香

港财务报告准则第

号评估减值。相反，

应收款项指本集团收取代价的无条件权

利，即只需待时间过去代价即需到期支

付。

合约负债指本集团因已向客户收取代价

（或代价金额到期），而须向客户转让货

品或服务的责任。

与合约有关的合约资产及合约负债按净

额基准入账及呈列。

提供综合性医院服务

提供综合性医院服务所得收益主要来自

于医院提供的医院服务，收益于向病人

提供相关服务时的某一个时点确认。

---

金威医疗集团有限公司

2024/2025

年报

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

3. BASIS OF PREPARATION OF

CONSOLIDATED FINANCIAL STATEMENTS

AND MATERIAL ACOUNTING POLICY

INFORMATION – continued

Material acounting policy information

– continued

Leases

Definition of a lease

A contract is, or contains, a lease if the contract conveys the

right to control the use of an identified aset for a period of

time in exchange for consideration.

For contracts entered into or modified, the Group aseses

whether a contract is or contains a lease based on the

definition under HKFRS 16 at inception, modification date,

as apropriate. Such contract wil not be reasesed unles

the terms and conditions of the contract are subsequently

changed.

The Group as lese

Alocation of consideration to components of a contract

For a contract that contains a lease component and one or

more aditional lease or non-lease components, the Group

alocates the consideration in the contract to each lease

component on the basis of the relative stand-alone price of

the lease component and the agregate stand-alone price of

the non-lease components.

The Group aplies practical expedient not to separate non-

lease components from lease component, and instead

acount for the lease component and any asociated non-

lease components as a single lease component.

3.

综合财务报表编制基准及重大

会计政策资料－续

重大会计政策资料－续

租赁

租赁的定义

倘合约为换取代价而给予在一段时间内

控制已识别资产使用的权利，则该合约

属于或包含租赁。

就已订立或修改的合约而言，本集团根

据香港财务报告准则第

号的定义于开

始、修订日期（如适用）评估该合约是否

属于或包含租赁。除非合约的条款及条

件其后出现变动，否则有关合约将不予

重新评估。

本集团作为承租人

将代价分配至合约组成部分

对于包含一项租赁组成部分及一项或多

项额外租赁或非租赁组成部分的合约，

本集团根据租赁组成部分的相对单独价

格及非租赁组成部分的单独价格总和将

合约代价分配至各个租赁组成部分。

本集团采用可行权宜方法，不将非租赁

组成部分从租赁组成部分区分开来，而

是将租赁组成部分及任何相关非租赁组

成部分作为一项单独的租赁组成部分进

行入账。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/202592

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

3. BASIS OF PREPARATION OF

CONSOLIDATED FINANCIAL STATEMENTS

AND MATERIAL ACOUNTING POLICY

INFORMATION – continued

Material acounting policy information

– continued

Leases – continued

The Group as lese – continued

Short-term leases

The Group aplies the short-term lease recognition

exemption to leases of ofice that have a lease term of 12

months or les from the comencement date and do not

contain a purchase option. Lease payments on short-term

leases and leases of low-value asets are recognised as

expense on a straight-line basis or another systematic basis

over the lease term.

Right-of-use asets

The cost of right-of-use aset includes:

• the amount of the initial measurement of the lease

liability;

• any lease payments made at or before the

comencement date, les any lease incentives

received;

• ; and

• an estimate of costs to be incured by the Group

in dismantling and removing the underlying asets,

restoring the site on which it is located or restoring the

underlying aset to the condition required by the terms

and conditions of the lease.

Right-of-use asets are measured at cost, les any

acumulated depreciation and impairment loses, and

adjusted for any remeasurement of lease liabilities.

3.

综合财务报表编制基准及重大

会计政策资料－续

重大会计政策资料－续

租赁－续

本集团作为承租人－续

短期租赁

本集团将短期租赁确认豁免应用于租期

为自开始当日起计为期十二个月或以下

之办公室租赁，及不包含购买选择权。

短期租赁及低价值资产租赁之租赁付款

于租期内按直线基准或其他系统基准确

认为开支。

使用权资产

使用权资产的成本包括：

•

租赁负债的初始计量金额；

•

于开始日期或之前所作的任何租

赁付款，减去所得的任何租赁奖

励；

•

本集团产生的任何初始直接成本；

及

•

本集团拆除及移除相关资产、修复

相关资产所在场地或将相关资产

恢复至租赁条款及条件所规定状

态将予产生的估计成本。

使用权资产按成本减任何累计折旧及减

值亏损计量，并就租赁负债的任何重新

计量作出调整。

---

金威医疗集团有限公司

2024/2025

年报

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

3. BASIS OF PREPARATION OF

CONSOLIDATED FINANCIAL STATEMENTS

AND MATERIAL ACOUNTING POLICY

INFORMATION – continued

Material acounting policy information

– continued

Leases – continued

The Group as lese – continued

Right-of-use asets – continued

Right-of-use asets in which the Group is reasonably certain

to obtain ownership of the underlying leased asets at the

end of the lease term are depreciated from comencement

date to the end of the useful life. Otherwise, right-of-

use asets are depreciated on a straight-line basis over the

shorter of its estimated useful life and the lease term.

The Group presents right-of-use asets as a separate line

item on the consolidated statement of financial position.

Refundable rental deposits

Refundable rental deposits paid are acounted under HKFRS

9 Financial Instruments (“HKFRS 9”) and initialy measured

at fair value. Adjustments to fair value at initial recognition

are considered as aditional lease payments and included in

the cost of right-of-use asets.

Lease liabilities

At the comencement date of a lease, the Group recognises

and measures the lease liability at the present value of

lease payments that are unpaid at that date. In calculating

the present value of lease payments, the Group uses the

incremental borowing rate at the lease comencement

date if the interest rate implicit in the lease is not readily

determinable.

Lease payments includes:

• ,

les any lease incentives receivable;

3.

综合财务报表编制基准及重大

会计政策资料－续

重大会计政策资料－续

租赁－续

本集团作为承租人－续

使用权资产－续

倘本集团合理确信在租赁期届满时取得

相关租赁资产的拥有权，则使用权资产

自开始日期起至可使用年期届满期间折

旧。否则，使用权资产按其估计可使用

年期及租期的较短者以直线法折旧。

本集团于综合财务状况表内将使用权资

产呈列为一项单独项目。

可退回租赁按金

已付可退回租赁按金根据香港财务报告

准则第

号金融工具（「香港财务报告准

则第

号」）入账并初始按公平值计量。于

初始确认时之公平值之调整被视为额外

租赁款项并计入使用权资产之成本。

租赁负债

于租赁开始日期，本集团按当日未付租

赁款项现值确认及计量租赁负债。倘租

赁隐含的利率难以厘定，则本集团会使

用租赁开始日期的增额借款利率计算租

赁款项的现值。

租赁付款包括：

•

固定付款（包括实质固定付款）减任

何应收租赁优惠；

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/202594

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

3. BASIS OF PREPARATION OF

CONSOLIDATED FINANCIAL STATEMENTS

AND MATERIAL ACOUNTING POLICY

INFORMATION – continued

Material acounting policy information

– continued

Leases – continued

The Group as lese – continued

Lease liabilities – continued

• variable lease payments that depend on an index or

rate, initialy measured using the index or rate at the

comencement date;

• amount expected to be payable by the Group under

residual value guarantes;

• , if the Group is

reasonably certain to exercise the options; and

• , if the

lease term reflects the Group exercising an option to

terminate the lease.

After the comencement date, lease liabilities are adjusted

by interest acretion and lease payments.

The Group remeasures lease liabilities (and makes a

coresponding adjustment to the related right-of-use asets)

whenever:

• the lease term has changed or there is a change in

the asesment of exercise of a purchase option, in

which case the related lease liabilities remeasured by

discounting the revised lease payments using a revised

discount rate at the date of reasesment.

• the lease payments change due to changes in market

rental rates folowing a market rent review in which

cases the related lease liability is remeasured by

discounting the revised lease payments using the initial

discount rate.

The lease liability is presented as a separate line in the

consolidated statement of financial position.

3.

综合财务报表编制基准及重大

会计政策资料－续

重大会计政策资料－续

租赁－续

本集团作为承租人－续

租赁负债－续

•

基于指数或利率的可变租赁款项，

使用开始日期的指数或利率初始

计量；

•

剩余价值担保下的预期本集团应

付款项；

•

倘本集团合理确定将予行使购买

选择权，则购买选择权之行使价；

及

•

支付终止租赁的罚款（倘租赁条

款反映本集团行使选择权终止租

赁）。

于开始日期后，租赁负债按利息增长及

租赁款项调整。

本集团于以下情况重新计量租赁负债

（并就有关使用权资产作相应调整）：

•

租期有变或有关行使购买权的评

估有变，于此情况下，相关租赁负

债透过使用于重新评估日期的经

修订贴现率贴现经修订租赁付款

而重新计量。

•

租赁付款因进行市场租金调查后

市场租金变动而出现变动，在此情

况下，相关租赁负债透过使用初始

贴现率贴现经修订租赁付款而重

新计量。

租赁负债在综合财务状况表中单独呈

列。

---

金威医疗集团有限公司

2024/2025

年报

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

3. BASIS OF PREPARATION OF

CONSOLIDATED FINANCIAL STATEMENTS

AND MATERIAL ACOUNTING POLICY

INFORMATION – continued

Material acounting policy information

– continued

Property, plant and equipment

Property, plant and equipment are tangible asets that are

held for use in the services, or for administrative purposes.

Property, plant and equipment are stated in the consolidated

statement of financial position at cost les subsequent

acumulated depreciation and subsequent acumulated

impairment loses, if any.

Depreciation is recognised so as to write of the cost of

asets les their residual values over their estimated useful

lives, using the straight-line method. The estimated useful

lives, residual values and depreciation method are reviewed

at the end of each reporting period, with the efect of any

changes in estimate acounted for on a prospective basis.

An item of property, plant and equipment is derecognised

upon disposal or when no future economic benefits are

expected to arise from the continued use of the asets.

Any gain or los arising on disposal and retirement of an

item of property, plant and equipment is determined as

the diference betwen the sales proceds and the carying

amount of the aset and is recognised in profit or los.

3.

综合财务报表编制基准及重大

会计政策资料－续

重大会计政策资料－续

物业、厂房及设备

物业、厂房及设备乃持作服务用途或作

为行政用途的有形资产。物业、厂房及

设备乃按成本减其后累计折旧及其后累

计减值亏损（如有）于综合财务状况表内

入账。

折旧以直线法确认，以于估计使用年期

内撇销资产的成本减剩余价值。估计使

用年期、剩余价值及折旧方法于各报告

期末审核，任何估计变动的影响按前瞻

基准入账。

物业、厂房及设备项目于出售或预期持

续使用该资产将不会产生未来经济利益

时终止确认。出售及报废物业、厂房及

设备项目产生的任何收益或亏损确定为

该资产出售所得款项与账面值之间的差

额，并于损益中确认。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/202596

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

3. BASIS OF PREPARATION OF

CONSOLIDATED FINANCIAL STATEMENTS

AND MATERIAL ACOUNTING POLICY

INFORMATION – continued

Material acounting policy information

– continued

Impairment on property, plant and equipment

and right of use asets

At the end of the reporting period, the Group reviews the

carying amounts of its property, plant and equipment

and right-of-use asets, to determine whether there is any

indication that these asets have sufered an impairment

los. If any such indication exists, the recoverable amount

of the relevant aset is estimated in order to determine the

extent of the impairment los, if any.

The recoverable amount of property, plant and equipment

and right-of-use asets are estimated individualy. When it is

not posible to estimate the recoverable amount individualy,

the Group estimates the recoverable amount of the cash-

generating unit to which the aset belongs.

In testing a cash-generating unit for impairment, corporate

asets are alocated to the relevant cash-generating unit

when a reasonable and consistent basis of alocation can be

established, or otherwise they are alocated to the smalest

group of cash generating units for which a reasonable

and consistent alocation basis can be established. The

recoverable amount is determined for the cash-generating

unit or group of cash-generating units to which the

corporate aset belongs, and is compared with the carying

amount of the relevant cash-generating unit or group of

cash-generating units.

3.

综合财务报表编制基准及重大

会计政策资料－续

重大会计政策资料－续

物业、厂房及设备及使用权资产减

值

于报告期末，本集团审阅本身之物业、

厂房及设备以及使用权资产之账面值，

借以决定是否有迹象显示此等资产出现

减值亏损。倘显示任何出现减值亏损之

迹象，则会估计该相关资产之可收回金

额，以厘定减值亏损（如有）之程度。

物业、厂房及设备及使用权资产可个别

地估计可收回金额。倘不可个别地估计

可收回金额，则本集团估计该资产所属

之现金产生单位之可收回金额。

在测试现金产生单位之减值时，企业资

产分配至相关现金产生单位可以建立合

理和一致的分配基础，否则分配至可以

建立合理和一致的分配基础的最小的现

金产生单位组别。可收回金额是针对企

业资产所属现金产生单位或现金产生单

位组别确定，并与相关现金产生单位或

现金产生单位组别的账面值进行比较。

---

金威医疗集团有限公司

2024/2025

年报

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

3. BASIS OF PREPARATION OF

CONSOLIDATED FINANCIAL STATEMENTS

AND MATERIAL ACOUNTING POLICY

INFORMATION – continued

Material acounting policy information

– continued

Impairment on property, plant and equipment and right

of use asets – continued

Recoverable amount is the higher of fair value les costs

of disposal and value in use. In asesing value in use, the

estimated future cash flows are discounted to their present

value using a pre-tax discount rate that reflects curent

market asesments of the time value of money and the risks

specific to the aset (or a CGU) for which the estimates of

future cash flows have not ben adjusted.

If the recoverable amount of an aset (or a CGU) is estimated

to be les than its carying amount, the carying amount of

the aset (or a CGU) is reduced to its recoverable amount.

For corporate asets or portion of corporate asets which

canot be alocated on a reasonable and consistent basis to

a CGU, the Group compares the carying amount of a group

of CGUs, including the carying amounts of the corporate

asets or portion of corporate asets alocated to that group

of CGUs, with the recoverable amount of the group of

CGUs. In alocating the impairment los, the impairment

los is alocated first to reduce the carying amount of any

godwil (if aplicable) and then to the other asets on a

pro-rata basis based on the carying amount of each aset

in the unit or the group of CGUs. The carying amount of

an aset is not reduced below the highest of its fair value

les costs of disposal (if measurable), its value in use (if

determinable) and zero. The amount of the impairment

los that would otherwise have ben alocated to the

aset is alocated pro rata to the other asets of the unit

or the group of CGUs. An impairment los is recognised

imediately in profit or los.

3.

综合财务报表编制基准及重大

会计政策资料－续

重大会计政策资料－续

物业、厂房及设备及使用权资产减

值－续

可收回金额为公平值减去销售成本与

使用价值之间的较高者。评估使用价值

时，会采用反映现时市场对货币时间价

值及针对该资产（或现金产生单位）的风

险（并未调整对未来现金流量的估计）评

估的税前贴现率，将估计未来现金流量

贴现至其现有价值。

倘估计资产（或现金产生单位）的可收回

金额低于其账面值，则资产（或现金产生

单位）账面值扣减至其可收回金额。就未

能按合理一致的基准分配至现金产生单

位的企业资产或部分企业资产，本集团

会比较一个组别的现金产生单位账面值

（包括已分配至该组现金产生单位的企

业资产或部分企业资产的账面值）与该

组现金产生单位的可收回金额。于分配

减值亏损时，减值亏损按比例根据该单

位或现金产生单位组别各资产的账面值

首先分配至减少任何商誉的账面值（倘

适用）及其后分配至其他资产。资产账面

值不得减少至低于其公平值减出售成本

（如可计量）、其使用价值（如可厘定）及

零之中的最高值。已另行分配至资产之

减值亏损数额按比例分配至该单位或现

金产生单位组别其他资产。减值亏损即

时于损益中确认。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/202598

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

3. BASIS OF PREPARATION OF

CONSOLIDATED FINANCIAL STATEMENTS

AND MATERIAL ACOUNTING POLICY

INFORMATION – continued

Material acounting policy information

– continued

Impairment on property, plant and equipment and right

of use asets – continued

Where an impairment los subsequently reverses, the

carying amount of the aset (or CGU or a group of CGUs) is

increased to the revised estimate of its recoverable amount,

but so that the increased carying amount does not exced

the carying amount that would have ben determined

had no impairment los ben recognised for the aset (or

a CGU or a group of CGUs) in prior years. A reversal of an

impairment los is recognised imediately in profit or los.

Inventories

Inventories are stated at the lower of cost and net realisable

value. Cost, which comprises al costs of purchase and,

where aplicable, other costs that have ben incured

in bringing the inventories to their present location and

condition, is calculated using the first-in, first-out method.

Net realisable value represents the estimated seling price

in the ordinary course of busines les al estimated costs

necesary to make the sale. Costs necesary to make the sale

include incremental costs directly atributable to the sale and

non-incremental costs which the Group must incur to make

the sale.

Taxation

Income tax expense represents the sum of the tax curently

payable and defered tax.

The tax curently payable is based on taxable profit for the

year. Taxable profit difers from los before tax because of

income or expense that are taxable or deductible in other

years and items that are never taxable or deductible. The

Group’s liability for curent tax is calculated using tax rates

that have ben enacted or substantively enacted by the end

of the reporting period.

3.

综合财务报表编制基准及重大

会计政策资料－续

重大会计政策资料－续

物业、厂房及设备及使用权资产减

值－续

倘随后拨回减值亏损，资产（或现金产生

单位或现金产生单位组别）之账面值可

调高至重新估计之可收回金额，惟因此

而增加之账面值不可高于该资产（或现

金产生单位或现金产生单位组别）于过

往年度未经确认减值亏损前厘定之账面

值。拨回之减值亏损即时于损益中确认。

存货

存货按成本及可变现净值两者中之较低

者入账。成本按先入先出法计算，包括

一切购货成本及（如适用）将存货运至目

前地点及达致现状产生之其他成本。可

变现净值乃按日常业务内估计售价减达

致出售该等存货之一切估计成本计算。

销售所需的成本包括销售直接应占增量

成本及本集团就销售必须产生的非增量

成本。

税项

所得税开支指本期应付税项与递延税项

之总和。

本期应付税项乃按年度应课税溢利计

算。由于在其他年度应课税或可扣减之

收入或支出以及永不课税或扣减之项

目，应课税溢利与除税前亏损不同。本

集团就即期税项的负债使用于报告期末

前已颁布或实质上已颁布的税率计算。

---

金威医疗集团有限公司

2024/2025

年报

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

3. BASIS OF PREPARATION OF

CONSOLIDATED FINANCIAL STATEMENTS

AND MATERIAL ACOUNTING POLICY

INFORMATION – continued

Material acounting policy information

– continued

Taxation – continued

Defered tax is recognised on temporary diferences

betwen the carying amounts of asets and liabilities in the

consolidated financial statements and the coresponding tax

bases used in the computation of taxable profit. Defered tax

liabilities are generaly recognised for al taxable temporary

diferences. Defered tax asets are generaly recognised for

al deductible temporary diferences to the extent that it is

probable that taxable profits wil be available against which

those deductible temporary diferences can be utilised. Such

defered tax asets and liabilities are not recognised if the

temporary diference arises from the initial recognition (other

than in a busines combination) of asets and liabilities in

a transaction that afects neither the taxable profit nor the

acounting profit and at the time of the transaction does

not give rise to equal taxable and deductible temporary

diferences. In adition, defered tax liabilities are not

recognised if the temporary diference arises from the initial

recognition of godwil.

Defered tax liabilities are recognised for taxable temporary

diferences asociated with investments in subsidiaries and

asociates, and interests in joint ventures, except where

the Group is able to control the reversal of the temporary

diference and it is probable that the temporary diference

wil not reverse in the foreseable future. Defered tax asets

arising from deductible temporary diferences asociated

with such investments and interests are only recognised to

the extent that it is probable that there wil be suficient

taxable profits against which to utilise the benefits of the

temporary diferences and they are expected to reverse in

the foreseable future.

The carying amount of defered tax asets is reviewed at the

end of each reporting period and reduced to the extent that

it is no longer probable that suficient taxable profits wil be

available to alow al or part of the aset to be recovered.

3.

综合财务报表编制基准及重大

会计政策资料－续

重大会计政策资料－续

税项－续

递延税项乃按于综合财务报表内资产及

负债账面值与用于计算应课税溢利之相

应税基两者之临时差额确认。递延税项

负债通常会就所有应课税暂时差异确

认。递延税项资产一般就所有可抵扣暂

时差额确认，而递延税项资产乃于可能

出现应课税溢利抵销有关可动用可扣税

暂时差额时确认。若暂时差异因于一项

既不影响应课税溢利亦不影响会计溢利

之交易（不包括业务合并）中开始确认资

产及负债而引致，且于交易时并未产生

等额应课税及可扣减暂时差额，则不会

确认该等递延税项资产及负债。此外，

倘暂时性差异产生自商誉初始确认，则

不确认递延税项负债。

递延税项负债就与于附属公司及联营公

司投资以及合营企业权益有关之应课税

临时差额确认，惟倘本集团能控制临时

差额拨回且临时差额于可见未来不会拨

回则作别论。与该等投资及权益相关的

可抵扣暂时差额所产生的递延税项资产

仅在动用暂时差额利益时有足够的应课

税溢利且预期在可见将来其将被拨回

时，方可确认。

递延税项资产之账面值会于各报告期末

均作检讨，并在不大可能再有足够应课

税溢利收回全部或部份资产时减少。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/2025100

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

3. BASIS OF PREPARATION OF

CONSOLIDATED FINANCIAL STATEMENTS

AND MATERIAL ACOUNTING POLICY

INFORMATION – continued

Material acounting policy information

– continued

Taxation – continued

Defered tax asets and liabilities are measured at the tax

rates that are expected to aply in the period in which

the liability is setled or the aset is realised, based on tax

rate (and tax laws) that have ben enacted or substantively

enacted by the end of the reporting period.

The measurement of defered tax liabilities and asets

reflects the tax consequences that would folow from the

maner in which the Group expects, at the end of the

reporting period, to recover or setle the carying amount of

its asets and liabilities.

For the purposes of measuring defered tax for leasing

transactions in which the Group recognises the right-of-

use asets and the related lease liabilities, the Group first

determines whether the tax deductions are atributable to

the right-of-use asets or the lease liabilities.

For leasing transactions in which the tax deductions are

atributable to the lease liabilities, the Group aplies HKAS

12 requirements to the lease liabilities, and the related

asets separately. The Group recognises a defered tax aset

related to lease liabilities to the extent that it is probable that

taxable profit wil be available against which the deductible

temporary diference can be utilised and a defered tax

liability for al taxable temporary diferences.

3.

综合财务报表编制基准及重大

会计政策资料－续

重大会计政策资料－续

税项－续

递延税项资产及负债以负债被清偿或资

产被变现的期间内预期适用的税率衡

量，并根据于报告期末已制订或实际上

已制订的税率（及税务法例）计量。

递延税项负债及资产之计量反映随本集

团预期于报告期末时收回或偿还资产及

负债账面值所产生之税务后果。

就计量本集团确认使用权资产及相关租

赁负债之租赁交易之递延税项而言，本

集团首先厘定税项减免是否归属于使用

权资产或租赁负债。

就税项扣减归因于租赁负债之租赁交易

而言，本集团分别就租赁负债及相关资

产应用香港会计准则第

号的规定。本

集团就所有应课税暂时性差异，以可能

获得可抵扣暂时性差异的应课税溢利为

限，确认与租赁负债相关的递延税项资

产及递延税项负债。

---

金威医疗集团有限公司

2024/2025

年报

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

3. BASIS OF PREPARATION OF

CONSOLIDATED FINANCIAL STATEMENTS

AND MATERIAL ACOUNTING POLICY

INFORMATION – continued

Material acounting policy information

– continued

Taxation – continued

Defered tax asets and liabilities are ofset when there is a

legaly enforceable right to set of curent tax asets against

curent tax liabilities and when they relate to income taxes

levied to the same taxable entity by the same taxation

authority.

Curent and defered tax are recognised in profit or los,

except when they relate to items that are recognised in other

comprehensive income or directly in equity, in which case,

the curent and defered tax are also recognised in other

comprehensive income or directly in equity respectively.

Where curent tax or defered tax arises from the initial

acounting for a busines combination, the tax efect is

included in the acounting for the busines combination.

Foreign curencies

In preparing the financial statements of each individual

group entity, transactions in curencies other than the

entity’s functional curency (foreign curencies) are

recognised at the rates of exchange prevailing at the dates

of the transactions. At the end of the reporting period,

monetary items denominated in foreign curencies are

retranslated at the rates prevailing at that date. Non-

monetary items caries at fair value that are denominated in

foreign curencies are retranslated at the rates prevailing at

the date when the fair value was determined. Non-monetary

items that are measured in terms of historical cost in a

foreign curency are not retranslated.

Exchange diferences arising on the setlement of monetary

items, and on the retranslating of monetary items, are

recognised in profit or los in the period in which they arise

except for:

3.

综合财务报表编制基准及重大

会计政策资料－续

重大会计政策资料－续

税项－续

当有法定可执行权利将当期税项资产抵

销当期税项负债时，以及当他们与同一

税务机关对同一应课税实体征收的所得

税有关时，递延税项资产及负债均予以

抵销。

即期及递延税项乃于损益中确认，惟倘

其与于其他全面收益或直接于权益中

确认之项目有关者除外，在此情况下，

即期及递延税项亦会分别于其他全面收

益或直接于权益中确认。当因业务合并

之初始会计处理而产生即期或递延税项

时，有关税务影响会计入业务合并之会

计处理内。

外币

于编制各个别集团实体之财务报表时，

以该实体功能货币以外之货币（外币）进

行之交易乃按于交易日期当时之汇率确

认。于报告期末，以外币结算之货币项

目按当日之汇率重新换算。按公平值列

账且以外币结算之非货币项目按厘定公

平值当日之现行汇率重新换算。按过往

成本以外币计算之非货币项目不予重新

换算。

结算货币项目及换算货币项目时产生之

汇兑差额于产生期间在损益内确认，惟

以下各项除外：

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/2025102

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

3. BASIS OF PREPARATION OF

CONSOLIDATED FINANCIAL STATEMENTS

AND MATERIAL ACOUNTING POLICY

INFORMATION – continued

Material acounting policy information

– continued

Foreign curencies – continued

• exchange diferences on foreign curency borowings

relating to asets under construction for future

productive use, productive use, which are included in

the cost of those asets when they are regarded as an

adjustment to interest costs on those foreign curency

borowings;

• exchange diferences on transactions entered into in

order to hedge certain foreign curency risks; and

• exchange diferences on monetary items receivable

from or payable to a foreign operation for which

setlement is neither planed nor likely to ocur

(therefore forming part of the net investment in the

foreign operation), which are recognised initialy in

other comprehensive income and reclasified from

equity to profit or los on repayment of the monetary

items.

For the purpose of presenting the consolidated financial

statements, the asets and liabilities of the Group’s foreign

operations are translated into the presentation curency of

the Group (i.e. Hong Kong dolars) using exchange rates

prevailing at the end of each reporting period. Income and

expense items are translated at the average exchange rates

for the period, unles exchange rates fluctuate significantly

during the period, in which case the exchange rates at the

dates of the transactions are used. Exchange diferences

arising, if any, are recognised in other comprehensive

income and acumulated in equity under the heading of

translation reserve (atributed to non-controling interests as

apropriate).

3.

综合财务报表编制基准及重大

会计政策资料－续

重大会计政策资料－续

外币－续

•

有关用作未来生产用途之在建资

产之外币借贷之汇兑差额，该等差

额于被视为外币借贷利息成本之

调整时计入该等资产之成本；

•

为对冲若干外币风险而订立之交

易之汇兑差额；及

•

应收或应付海外业务之货币项目

之汇兑差额，而其既无计划结算或

不大可能结算（因此为海外业务净

投资之一部份），并初步于其他全

面收入确认及于偿还货币项目时

由权益重新分类至损益。

就呈列综合财务报表之目的而言，本集

团海外业务之资产及负债均按各报告期

间末汇率换算为本集团之呈报货币（即

港元）。收入及开支项目乃按期间平均

汇率换算，除非汇率于期内出现重大波

幅，则于此情况下，将采用交易日期之

汇率。所产生之汇兑差额（如有）于其

他全面收入中确认并于权益中汇兑储备

（视情况归入非控股权益）项下累计。

---

金威医疗集团有限公司

2024/2025

年报

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

3. BASIS OF PREPARATION OF

CONSOLIDATED FINANCIAL STATEMENTS

AND MATERIAL ACOUNTING POLICY

INFORMATION – continued

Material acounting policy information

– continued

Foreign curencies – continued

On the disposal of a foreign operation (that is, a disposal

of the Group’s entire interest in a foreign operation, or

a disposal involving los of control over a subsidiary that

includes a foreign operation), al of the exchange diferences

acumulated in equity in respect of that operation

atributable to the owners of the Company are reclasified to

profit or los.

Godwil and fair value adjustments to identifiable asets

and liabilities asumed through acquisition of a foreign

operation are treated as asets and liabilities of the foreign

operation and translated at the rate of exchange prevailing

at the end of each reporting period. Exchange diferences

arising are recognised in other comprehensive income.

Contingent liabilities

A contingent liability is a present obligation arising from past

events but is not recognised because it is not probable that

an outflow of resources embodying economic benefits wil

be required to setle the obligation or the amount of the

obligation canot be measured with suficient reliability.

Where the Group is jointly and severaly liable for an

obligation, the part of the obligation that is expected to be

met by other parties is treated as a contingent liability and it

is not recognised in the consolidated financial statements.

3.

综合财务报表编制基准及重大

会计政策资料－续

重大会计政策资料－续

外币－续

出售海外业务（即出售本集团于海外业

务之全部权益，或涉及丧失对包括海外

业务在内之附属公司控制权之出售事

项）时，就本公司拥有人应占该项业务于

权益中累计之所有汇兑差额会重新分类

至损益。

透过收购海外业务之可识别资产及所承

担之负债之商誉及公平值调整将被视作

该海外业务之资产及负债，并按各报告

期末之汇率换算。由此产生之汇兑差额

乃于其他全面收入内确认。

或然负债

或然负债乃因过往事件产生但未确认的

现有责任，原因是不大可能须流出具有

经济利益之资源以清偿责任或责任金额

不能以足够的可靠性计量。

倘本集团对某项责任负有连带责任，预

计将由其他方履行的部分责任被视为或

然负债，且并无于综合财务报表内确认。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/2025104

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

3. BASIS OF PREPARATION OF

CONSOLIDATED FINANCIAL STATEMENTS

AND MATERIAL ACOUNTING POLICY

INFORMATION – continued

Material acounting policy information

– continued

Contingent liabilities – continued

The Group aseses continualy to determine whether an

outflow of resources embodying economic benefits has

become probable. If it becomes probable that an outflow

of future economic benefits wil be required for an item

previously dealt with as a contingent liability, a provision is

recognised in the consolidated financial statements in the

reporting period in which the change in probability ocurs,

except in the extremely rare circumstances where no reliable

estimate can be made.

Cash and cash equivalents

Cash and cash equivalents presented on the consolidated

statement of financial position include:

(a) cash, which comprises of cash on hand and demand

deposits, excluding bank balances that are subject to

regulatory restrictions that result in such balances no

longer meting the definition of cash; and

(b) cash equivalents, which comprises of short-term

(generaly with original maturity of thre months

or les), highly liquid investments that are readily

convertible to a known amount of cash and which

are subject to an insignificant risk of changes in

value. Cash equivalents are held for the purpose of

meting short-term cash comitments rather than for

investment or other purposes.

Bank balances for which use by the Group is subject to third

party contractual restrictions are included as part of cash

unles the restrictions result in a bank balance no longer

meting the definition of cash. Contractual restrictions

afecting use of bank balances are disclosed in note 36.

3.

综合财务报表编制基准及重大

会计政策资料－续

重大会计政策资料－续

或然负债－续

本集团持续评估以厘定流出具有经济利

益之资源是否可能发生。倘过往作为或

然负债处理的项目可能需要未来经济利

益流出，则于变动可能发生的报告期内

于综合财务报表内确认拨备，惟于极端

罕见的情况下无法作出可靠估计则除

外。

现金及现金等值项目

于综合财务状况表呈列之现金及现金等

值项目包括：

(a)

现金，其包括手头现金及活期存

款，不包括受监管限制而导致有关

结余不再符合现金定义的银行结

余；及

(b)

现金等值项目，其包括短期（通常

原到期日为三个月或更短）、可随

时转换为已知数额现金且价值变

动风险不大的高流动性投资。现金

等值项目持作满足短期现金承担，

而非用于投资或其他目的。

本集团的使用受第三方合约限制的银行

结余计入现金的一部分，除非有关限制

导致银行结余不再符合现金的定义。影

响银行结余使用的合约限制于附注

披

露。

---

金威医疗集团有限公司

2024/2025

年报

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

3. BASIS OF PREPARATION OF

CONSOLIDATED FINANCIAL STATEMENTS

AND MATERIAL ACOUNTING POLICY

INFORMATION – continued

Material acounting policy information

– continued

Provisions

Provisions are recognised when the Group has a present

obligation (legal or constructive) as a result of a past event,

it is probable that the Group wil be required to setle that

obligation, and a reliable estimate can be made of the

amount of the obligation.

The amount recognised as a provision is the best estimate

of the consideration required to setle the present obligation

at the end of the reporting period, taking into acount the

risks and uncertainties surounding the obligation. When

a provision is measured using the cash flows estimated to

setle the present obligation, its carying amount is the

present value of those cash flows (where the efect of the

time value of money is material).

When some or al of the economic benefits required to setle

a provision are expected to be recovered from a third party,

a receivable is recognised as an aset if it is virtualy certain

that reimbursement wil be received and the amount of the

receivable can be measured reliably.

3.

综合财务报表编制基准及重大

会计政策资料－续

重大会计政策资料－续

拨备

倘本集团因过往事件而须承担现有法定

或推定责任，本集团可能将须清偿该责

任，并能对责任金额作出可靠估计时，

则确认拨备。

确认为拨备的金额为清偿报告期末的现

时责任并计入该责任的风险及不明朗因

素所需代价的最佳估计。倘使用现金流

量估计清偿现时责任而计量拨备，其账

面值为该等现金流量的现值（倘货币时

间价值影响属重大）。

当须用于清偿拨备的部分或全部经济利

益预期可自第三方收回时，则应收款项

会在实际确定将获偿付且能可靠计量应

收款项金额时确认为资产。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/2025106

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

3. BASIS OF PREPARATION OF

CONSOLIDATED FINANCIAL STATEMENTS

AND MATERIAL ACOUNTING POLICY

INFORMATION – continued

Material acounting policy information

– continued

Employe benefits

Retirement benefit costs

The Group’s contributions to the defined contribution

retirement benefit plans are charged to profit or los in the

year incured and are reduced by contributions forfeited by

those employes who leave the scheme prior to vesting fuly

in the contributions. The Group has no further payment

obligations once the contributions have ben paid.

For long serve payment (“LSP”) obligation, the Group

acounts for the employer MPF contributions expected to

be ofset as a demed employe contribution towards the

LSP obligation in terms of HKAS 19.93(a) and it is measure

on a net basis. The estimated amount of future benefit

is determined after deducting the negative service cost

arising from the acrued benefits derived from the Group’s

MPF contributions that have ben vested with employes,

which are demed to be contributions from the relevant

employes.

Termination benefits

A liability for a termination benefit is recognised at the

earlier of when the Group entity can no longer withdraw the

ofer of the termination benefit and when it recognises any

related restructuring costs.

3.

综合财务报表编制基准及重大

会计政策资料－续

重大会计政策资料－续

雇员福利

退休福利成本

本集团对定额供款退休福利计划作出的

供款于产生年度自损益扣除，并扣减雇

员于供款悉数归属前退出计划所没收供

款。缴付供款后，本集团并无进一步付

款责任。

就长期服务金（「长期服务金」）义务而

言，本集团根据香港会计准则第

19.93(a)

条，将预期抵销之雇主强积金供款入账

列作视作雇员对长期服务金义务之供款

及按净额基准计量。未来福利的估计金

额乃经扣除本集团已归属于雇员的强积

金供款所产生的应计福利的负服务成本

后厘定，有关供款被视为来自有关雇员

的供款。

离职福利

离职福利负债于本集团实体无法再撤回

离职福利要约及当其确认任何相关重组

成本（以较早发生者为准）时确认。

---

金威医疗集团有限公司

2024/2025

年报

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

3. BASIS OF PREPARATION OF

CONSOLIDATED FINANCIAL STATEMENTS

AND MATERIAL ACOUNTING POLICY

INFORMATION – continued

Material acounting policy information

– continued

Employe benefits – continued

Short-term and other long-term employe benefits

Short-term employe benefits are recognised at the

undiscounted amount of the benefits expected to be paid

as and when employes rendered the services. Al short

term employe benefits are recognised as an expense unles

another HKFRS requires or permits the inclusion of the

benefit in the cost of an aset.

A liability is recognised for benefits acruing to employes

(such as wages and salaries, anual leave and sick leave)

after deducting any amount already paid.

Liabilities recognised in respect of other long-term

employe benefits are measured at the present value of

the estimated future cash outflows expected to be made

by the Group in respect of services provided by employes

up to the reporting date. Any changes in the liabilities’

carying amounts resulting from service cost, interest and

remeasurements are recognised in profit or los except to the

extent that another HKFRS requires or permits their inclusion

in the cost of an aset.

3.

综合财务报表编制基准及重大

会计政策资料－续

重大会计政策资料－续

雇员福利－续

短期及其他长期雇员福利

短期雇员福利按预期于雇员提供服务时

支付的福利的未贴现金额确认。所有短

期雇员福利确认为开支，除非其他香港

财务报告准则规定或允许将福利计入资

产成本。

就扣除任何已付金额后的应付雇员福利

（例如工资及薪金、年假及病假）确认作

负债。

就其他长期雇员福利确认的负债按本集

团预计就雇员于截至报告日期止所提供

服务的估计未来现金流出的现值计量。

任何因服务费用、利息及重新计量而导

致的负债账面值变动均于损益中确认，

惟其他香港财务报告准则规定或允许将

其计入资产成本除外。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/2025108

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

3. BASIS OF PREPARATION OF

CONSOLIDATED FINANCIAL STATEMENTS

AND MATERIAL ACOUNTING POLICY

INFORMATION – continued

Material acounting policy information

– continued

Share-based payments

Equity-setled share-based payments to employes and

others providing similar services are measured at the fair

value of the equity instruments at the grant date.

The fair value of the equity-setled share-based payments

determined at the grant date without taking into

consideration al non-market vesting conditions is expensed

on a straight-line basis over the vesting period, based on the

Group’s estimate of equity instruments that wil eventualy

vest, with a coresponding increase in equity (share options

reserve). At the end of each reporting period, the Group

revises its estimate of the number of equity instruments

expected to vest based on asesment of al relevant non-

market vesting conditions. The impact of the revision of the

original estimates, if any, is recognised in profit or los such

that the cumulative expense reflects the revised estimate,

with a coresponding adjustment to the share options

reserve. For share options that vest imediately at the

date of grant, the fair value of the share options granted is

expensed imediately to profit or los.

When share options are exercised, the amount previously

recognised in share options reserve wil be transfered to

share capital and share premium. When the share options

are forfeited after the vesting date or are stil not exercised

at the expiry date, the amount previously recognised in share

options reserve wil be transfered to acumulated loses.

3.

综合财务报表编制基准及重大

会计政策资料－续

重大会计政策资料－续

以股份为基础之付款

向雇员及提供类似服务之其他人士作出

之以权益结算以股份为基础之付款乃于

授出日期按股本工具之公平值计算。

以权益结算以股份为基础之付款于授出

日期厘定的公平值（并无考虑所有非市

埸归属条件），根据本集团对最终归属的

权益工具的估计，按归属期以直线法基

准支销，并于权益内作相应增加（购股权

储备）。于各报告期末，本集团根据对所

有相关非市场归属条件的评估修订预期

归属的权益工具数目的估计。修订原有

估计的影响（如有）于损益中确认，以致

累计开支反映修订后的估计，并对购股

权储备作相应调整。就于授出日期立即

归属的购股权而言，所授出购股权的公

平值随即于损益中列支。

当购股权获行使时，过往于购股权储备

中确认的金额将转拨至股本及股份溢

价。倘购股权于归属日后被没收或于届

满日仍未获行使，则过往于购股权储备

中确认的金额将转拨至累计亏损。

---

金威医疗集团有限公司

2024/2025

年报

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

3. BASIS OF PREPARATION OF

CONSOLIDATED FINANCIAL STATEMENTS

AND MATERIAL ACOUNTING POLICY

INFORMATION – continued

Material acounting policy information

– continued

Borowing costs

Borowing costs directly atributable to the acquisition,

construction or production of qualifying asets that

necesarily take a substantial period of time to get ready for

their intended use or sale, are aded to the cost of those

asets until such time as the asets are substantialy ready for

their intended use or sale.

Al other borowing costs are recognised in profit or los in

the period in which they are incured.

Segment reporting

Operating segments, and the amounts of each segment item

reported in the financial statements, are identified from the

financial information provided regularly to the Group’s most

senior executive management for the purposes of alocating

resources to, and asesing the performance of, the Group’s

various lines of busines and geographical locations.

3.

综合财务报表编制基准及重大

会计政策资料－续

重大会计政策资料－续

借款成本

收购、建造或生产合资格资产（需要较长

期间才可供拟定用途或销售）直接应占

借贷成本乃计入该等资产的成本，直至

该等资产绝大部分已达致可供拟定用途

或销售为止。

所有其他借贷成本于其产生期间内于损

益中确认。

分类报告

经营分类及于财务报表呈报之各分类金

额乃依据向本集团最高行政管理层定期

报告以便彼等分配资源予各业务部门及

地区及评定其表现之财务资料而划分。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/2025110

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

3. BASIS OF PREPARATION OF

CONSOLIDATED FINANCIAL STATEMENTS

AND MATERIAL ACOUNTING POLICY

INFORMATION – continued

Material acounting policy information

– continued

Segment reporting – continued

Individualy material operating segments are not agregated

for financial reporting purposes unles the segments have

similar economic characteristics and are similar economic

characteristics and are similar in respect of the nature of

products and services, the nature of production proceses,

the type of clas of customers, the methods used to

distribute the products or provide the services, and the

nature of the regulatory environment. Operating segments

which are not individualy material may be agregated if they

share a majority of these criteria.

Segment revenue, expenses, results and asets include items

directly atributable to a segment as wel as those that can

be alocated on a reasonable basis to that segment, but

exclude exceptional items. Segment capital expenditure is

the total cost incured during the year to acquire segment

asets (both tangible and intangible) that are expected to be

used for more than one year. Corporate portions of expenses

and asets mainly comprise corporate administrative

and financing expenses and corporate financial asets

respectively.

3.

综合财务报表编制基准及重大

会计政策资料－续

重大会计政策资料－续

分类报告－续

就财务申报而言，个别重要之经营分类

并不予合并计算，除非各分类拥有类似

经济特点，并在产品及服务、生产过程、

客户类别、分销产品或提供服务所用方

法，以及规管环境均有类似性质。个别

不重要之经营分类倘符合以上大部分条

件，则予合并计算。

分类收益、开支、业绩及资产包括分类

直接应占之项目及可合理分配至该分类

之项目，惟特殊项目除外。分类资本开

支为年内就收购预期将使用一年以上之

分类资产（有形及无形）所产生之总成

本。企业开支及资产部份分别主要包括

企业行政及融资开支及企业金融资产。

---

金威医疗集团有限公司

2024/2025

年报

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

3. BASIS OF PREPARATION OF

CONSOLIDATED FINANCIAL STATEMENTS

AND MATERIAL ACOUNTING POLICY

INFORMATION – continued

Material acounting policy information

– continued

Related parties

A person or an entity is be related to the Group if:

(a) A person or a close member of that person’s family is

related to the Group if that person:

(i) has control or joint control over the Group;

(i) has significant influence over the Group; or

(i) is a member of the key management personel of

the Group or of a parent of the Group.

(b) An entity is related to the Group if any of the folowing

conditions aplies:

(i) The entity and the Group are members of the

same group (which means that each parent,

subsidiary and felow subsidiary is related to the

others).

(i) One entity is an asociate or joint venture of the

other entity (or an asociate or joint venture of a

member of a group of which the other entity is a

member).

(i) Both entities are joint ventures of the same third

party.

(iv) One entity is a joint venture of a third entity and

the other entity is an asociate of the third entity.

3.

综合财务报表编制基准及重大

会计政策资料－续

重大会计政策资料－续

关连人士

与本集团有关连之人士或实体指：

(a)

倘一名人士或该人士家庭的近亲

成员符合下列条件，则与本集团有

关连：

(i)

控制或共同控制本集团；

(i)

对本集团有重大影响；或

(i)

属本集团或本集团母公司主

要管理人员的成员。

(b)

倘属下列情况，一间实体属与本集

团有关连：

(i)

该实体与本集团为同一集团

的成员公司（代表各自之母公

司、附属公司及同系附属公

司均互相关连）。

(i)

一间实体属另一间实体的联

营公司或合营公司（或为一集

团成员公司之联营公司或合

营公司，而另一实体为该集

团之成员公司）。

(i)

两间实体皆为同一名第三方

的合营公司。

(iv)

一间实体为第三方实体的合

营公司及另一实体为第三方

实体的联营公司。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/2025112

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

3. BASIS OF PREPARATION OF

CONSOLIDATED FINANCIAL STATEMENTS

AND MATERIAL ACOUNTING POLICY

INFORMATION – continued

Material acounting policy information

– continued

Related parties – continued

(b) An entity is related to the Group if any of the folowing

conditions aplies: – continued

(v) The entity is a post-employment benefit plan for

the benefit of employes of either the Group or

an entity related to the Group. If the Group is

itself such a plan, the sponsoring employers are

also related to the Group.

(vi) The entity is controled or jointly controled by a

person identified in (a).

(vi) A person identified in (a) (i) has significant

influence over the entity or is a member of the

key management personel of the entity (or of a

parent of the entity).

(vi) The entity, or any member of a group of which

it is a part, provides key management personel

services to the Group or to the Group’s parent.

Close family members of an individual are those family

members who may be expected to influence, or be

influenced by, that person in their dealings with the entity.

3.

综合财务报表编制基准及重大

会计政策资料－续

重大会计政策资料－续

关连人士－续

(b)

倘属下列情况，一间实体属与本集

团有关连：－续

(v)

该实体乃以本集团或本集团

关连实体之雇员为受益人的

雇员退休后福利计划。倘本

集团本身属有关计划，提供

资助之雇主亦与本集团有关

连。

(vi)

该实体受属

(a)

项的人士控制

或共同控制。

(vi)

属

(a)(i)

项的人士对该实体有

重大影响或属该实体（或属该

实体的母公司）主要管理人员

的成员。

(vi)

实体或身为其中一员之任何

集团成员公司向本集团或本

集团母公司提供主要管理层

人员服务。

某一人士之密切家族成员指预期可影响

该人士与实体进行买卖或于买卖时受该

人士影响的有关家族成员。

---

金威医疗集团有限公司

2024/2025

年报

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

3. BASIS OF PREPARATION OF

CONSOLIDATED FINANCIAL STATEMENTS

AND MATERIAL ACOUNTING POLICY

INFORMATION – continued

Material acounting policy information

– continued

Financial instruments

Financial asets and financial liabilities are recognised when

a group entity becomes a party to the contractual provisions

of the instrument. Al regular way purchases or sales of

financial asets are recognised and derecognised on a trade

date basis. Regular way purchases or sales are purchases or

sales of financial asets that require delivery of asets within

the time frame established by regulation or convention in

the market place.

Financial asets and financial liabilities are initialy measured

at fair value except for trade receivables arising from

contracts with customers which are initialy measured in

acordance with HKFRS 15. Transaction costs that are

directly atributable to the acquisition or isue of financial

asets and financial liabilities (other than financial asets

or financial liabilities at fair value through profit or los

(“FVTPL”) are aded to or deducted from the fair value of

the financial asets or financial liabilities, as apropriate, on

initial recognition. Transaction costs directly atributable to

the acquisition of financial asets or financial liabilities at

FVTPL are recognised imediately in profit or los.

The efective interest method is a method of calculating

the amortised cost of a financial aset or financial liability

and of alocating interest income and interest expense over

the relevant period. The efective interest rate is the rate

that exactly discounts estimated future cash receipts and

payments (including al fes and points paid or received

that form an integral part of the efective interest rate,

transaction costs and other premiums or discounts) through

the expected life of the financial aset or financial liability,

or, where apropriate, a shorter period, to the net carying

amount on initial recognition.

Interest income which are derived from the financial asets

are presented as “other income”.

3.

综合财务报表编制基准及重大

会计政策资料－续

重大会计政策资料－续

金融工具

当本集团成为工具合约条文之一方，则

确认金融资产及金融负债。所有一般购

买或出售之金融资产乃按交易日基准确

认及终止确认。一般购买或出售指对须

按市场所在地规则或惯例所确定时限内

交付资产之金融资产之购买或出售。

金融资产及金融负债初步按公平值计

量，惟根据香港财务报告准则第

号初

步计量之客户合约产生的贸易应收款项

除外。收购或发行金融资产及金融负债

直接应占之交易成本（按公平值透过损

益列账（「按公平值透过损益列账」）之金

融资产及金融负债除外）乃于初步确认

时加入金融资产或金融负债之公平值，

或从金融资产或金融负债之公平值内扣

除（如适当）。收购按公平值透过损益列

账之金融资产或金融负债直接应占之交

易成本，即时于损益内确认。

实际利率法乃计算金融资产或金融负债

摊销成本以及于相关期间分配利息收入

及利息开支之方法。实际利率乃在金融

资产或金融负债之预计年期或（如适用）

较短期间内，将估计未来现金收入及付款

（包括构成实际利率部份之所有已付或

已收费用及利率差价、交易成本及其他

溢价或折让）准确贴现至初步确认时之

账面净值之利率。

金融资产所得之利息收入呈列为「其他

收入」。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/2025114

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

3. BASIS OF PREPARATION OF

CONSOLIDATED FINANCIAL STATEMENTS

AND MATERIAL ACOUNTING POLICY

INFORMATION – continued

Material acounting policy information

– continued

Financial instruments – continued

Financial asets

Clasification and subsequent measurement of financial

asets

Financial asets that met the folowing conditions are

subsequently measured at amortised cost:

• the financial aset is held within a busines model

whose objective is to colect contractual cash flows;

and

• the contractual terms give rise on specified dates to

cash flows that are solely payments of principal and

interest on the principal amount outstanding.

Financial asets that met the folowing conditions

are subsequently measured at fair value through other

comprehensive income (“FVTOCI”):

• the financial aset is held within a busines model

whose objective is achieved by both colecting

contractual cash flows and seling the financial aset;

and

• the contractual terms give rise on specified dates to

cash flows that are solely payments of principal and

interest on the principal amount outstanding.

Al other financial asets are subsequently measured at

FVTPL, except that at the date of initial recognition of a

financial aset the Group may irevocably elect to present

subsequent changes in fair value of an equity investment

in other comprehensive income if that equity investment

is neither held for trading nor contingent consideration

recognised by an acquirer in a busines combination to

which HKFRS 3 Busines Combinations aplies.

3.

综合财务报表编制基准及重大

会计政策资料－续

重大会计政策资料－续

金融工具－续

金融资产

金融资产之分类及其后计量

符合以下条件的金融资产其后按摊销成

本计量：

•

于目的是收取合约现金流量的业

务模式内持有的金融资产；及

•

合约条款于指定日期产生现金流

量仅为支付本金及尚未偿还本金

额之利息。

符合以下条件的金融资产其后按公平值

透过其他全面收益列账（「按公平值透过

其他全面收益列账」）计量：

•

于目的是收取合约现金流量及出

售金融资产的业务模式内持有的

金融资产；及

•

合约条款于指定日期产生现金流

量仅为支付本金及尚未偿还本金

额之利息。

所有其他金融资产随后会按公平值透

过损益列账，惟于初始确认金融资产之

日，倘股权投资并非持作买卖用途或收

购方于香港财务报告准则第

号业务合

并所适用的业务合并中确认的或然代

价，则本集团可不可撤销地选择于其他

全面收益中呈列有关股权投资公平值的

其后变动。

---

金威医疗集团有限公司

2024/2025

年报

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

3. BASIS OF PREPARATION OF

CONSOLIDATED FINANCIAL STATEMENTS

AND MATERIAL ACOUNTING POLICY

INFORMATION – continued

Material acounting policy information

– continued

Financial instruments – continued

Financial asets – continued

Clasification and subsequent measurement of financial

asets – continued

A financial aset is held for trading if:

• it has ben acquired principaly for the purpose of

seling in the near term; or

• on initial recognition it is a part of a portfolio of

identified financial instruments that the Group

manages together and has a recent actual patern of

short-term profit-taking; or

• it is a derivative that is not designated and efective as

a hedging instrument.

In adition, the Group may irevocably designate a financial

aset that are required to be measured at the amortised cost

or FVTOCI as measured at FVTPL if doing so eliminates or

significantly reduces an acounting mismatch.

3.

综合财务报表编制基准及重大

会计政策资料－续

重大会计政策资料－续

金融工具－续

金融资产－续

金融资产之分类及其后计量－续

倘属下列情况，金融资产乃分类为持作

买卖：

•

收购该金融资产之目的主要是在

不久将来出售；或

•

于初始确认时，该金融资产为本集

团共同管理之已识别金融工具组

合之一部分，并且具有最近实际短

期获利模式；或

•

该金融资产为非指定之衍生工具

及可有效作为对冲工具。

此外，本集团可不可撤回地将须按摊销

成本计量或按公平值透过其他全面收益

列账之金融资产指定为按公平值透过损

益列账之方式计量，前提是此举能消除

或大幅减少会计错配情况。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/2025116

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

3. BASIS OF PREPARATION OF

CONSOLIDATED FINANCIAL STATEMENTS

AND MATERIAL ACOUNTING POLICY

INFORMATION – continued

Material acounting policy information

– continued

Financial instruments – continued

Financial asets – continued

Clasification and subsequent measurement of financial

asets – continued

Amortised cost and interest income

Interest income is recognised using the efective interest

method for financial asets measured subsequently at

amortised cost. Interest income is calculated by aplying

the efective interest rate to the gros carying amount

of a financial aset, except for financial asets that have

subsequently become credit-impaired (se below). For

financial asets that have subsequently become credit-

impaired, interest income is recognised by aplying the

efective interest rate to the amortised cost of the financial

aset from the next reporting period. If the credit risk on the

credit– impaired financial instrument improves so that the

financial aset is no longer credit-impaired, interest income is

recognised by aplying the efective interest rate to the gros

carying amount of the financial aset from the begining

of the reporting period folowing the determination that the

aset is no longer credit impaired.

Financial asets at FVTPL

Financial asets that do not met the criteria for being

measured at amortised cost or FVTOCI or designated as

FVTOCI are measured at FVTPL.

Financial asets at FVTPL are measured at fair value at the

end of each reporting period, with any fair value gains

or loses recognised in profit or los. The net gain or los

recognised in profit or los excludes any dividend or interest

earned on the financial aset and is included in the “other

gains and loses” line item.

3.

综合财务报表编制基准及重大

会计政策资料－续

重大会计政策资料－续

金融工具－续

金融资产－续

金融资产之分类及其后计量－续

摊销成本及利息收入

其后按摊销成本计量的金融资产的利息

收入运用实际利率法确认。利息收入透

过应用实际利率于金融资产的总账面值

计算，其后已信贷减值的金融资产除外

（见下文）。就其后已信贷减值的金融资

产而言，利息收入自下一报告期间起透

过应用实际利率于金融资产的摊销成本

确认。倘已信贷减值的金融工具的信贷

风险有所改善，继而令金融资产不再信

贷减值，利息收入则自厘定该资产并无

信贷减值后的报告期间初起透过应用实

际利率于金融资产的总账面值确认。

按公平值透过损益列账之金融资产

不符合按摊销成本计量或按公平值透过

其他全面收益列账或指定为按公平值透

过其他全面收益列账标准的金融资产按

公平值透过损益列账之方式计量。

按公平值透过损益列账之金融资产按各

报告期末的公平值计量，任何公平值收

益或亏损于损益中确认。于损益确认之

收益或亏损净额不包括金融资产所赚取

的任何股息或利息，并计入「其他收益及

亏损」一栏。

---

金威医疗集团有限公司

2024/2025

年报

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

3. BASIS OF PREPARATION OF

CONSOLIDATED FINANCIAL STATEMENTS

AND MATERIAL ACOUNTING POLICY

INFORMATION – continued

Material acounting policy information

– continued

Financial instruments – continued

Financial asets – continued

Impairment of financial asets

The Group recognises a los alowance for ECL on financial

asets which are subject to impairment asesment under

HKFRS 9 (including trade receivables, other receivables and

deposits). The amount of ECL is updated at each reporting

date to reflect changes in credit risk since initial recognition.

Lifetime ECL represents the ECL that wil result from al

posible default events over the expected life of the relevant

instrument. In contrast, 12-month ECL (“12m ECL”)

represents the portion of lifetime ECL that is expected to

result from default events that are posible within 12 months

after the reporting date. Asesment are done based on the

Group’s historical credit los experience, adjusted for factors

that are specific to the debtors, general economic conditions

and an asesment of both the curent conditions at the

reporting date as wel as the forecast of future conditions.

For al other instruments, the Group measures the los

alowance equal to 12m ECL, unles when there has ben a

significant increase in credit risk since initial recognition, the

Group recognises lifetime ECL. The asesment of whether

lifetime ECL should be recognised is based on significant

increases in the likelihod or risk of a default ocuring since

initial recognition.

3.

综合财务报表编制基准及重大

会计政策资料－续

重大会计政策资料－续

金融工具－续

金融资产－续

金融资产减值

本集团就根据香港财务报告准则第

号

面临减值评估的金融资产（包括贸易应

收款项、其他应收款项及按金）的预期信

贷亏损确认亏损拨备。预期信贷亏损的

金额于各报告日期更新，以反映自初始

确认起的信贷风险变动。

全期预期信贷亏损指于相关工具之预计

年期内所有可能之违约事件而产生的预

期信贷亏损。相反，

个月预期信贷亏损

（「

个月预期信贷亏损」）指于报告日

期后

个月内因可能发生的违约事件而

预期产生的部分全期预期信贷亏损。评

估已根据本集团过往信贷亏损经验，并

就债务人特定因素、整体经济状况以及

对于报告日期之当前状况及未来状况预

测的评估作出调整。

就所有其他工具而言，本集团计量的亏

损拨备等于

个月预期信贷亏损，惟

倘信贷风险自初始确认以来出现显著

上升，则本集团会确认全期预期信贷亏

损。应否确认全期预期信贷亏损的评估

乃基于自初始确认以来发生违约的机率

或风险的显著上升而作出。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/2025118

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

3. BASIS OF PREPARATION OF

CONSOLIDATED FINANCIAL STATEMENTS

AND MATERIAL ACOUNTING POLICY

INFORMATION – continued

Material acounting policy information

– continued

Financial instruments – continued

Financial asets – continued

Impairment of financial asets – continued

(i) Significant increase in credit risk

In asesing whether the credit risk has increased

significantly since initial recognition, the Group

compares the risk of a default ocuring on the

financial instrument as at the reporting date with the

risk of a default ocuring on the financial instrument

as at the date of initial recognition. In making this

asesment, the Group considers both quantitative

and qualitative information that is reasonable and

suportable, including historical experience and

forward-loking information that is available without

undue cost or efort.

In particular, the folowing information is taken into

acount when asesing whether credit risk has

increased significantly:

• an actual or expected significant deterioration in

the financial instrument’s external (if available) or

internal credit rating;

• significant deterioration in external market

indicators of credit risk, e.g. a significant increase

in the credit spread, the credit default swap prices

for the debtor;

3.

综合财务报表编制基准及重大

会计政策资料－续

重大会计政策资料－续

金融工具－续

金融资产－续

金融资产减值－续

(i)

信贷风险大幅增加

于评估信贷风险是否自初始确认

以来已大幅增加时，本集团比较金

融工具于报告日期出现违约的风

险与该金融工具于初始确认日期

出现违约的风险。作此评估时，本

集团均会考虑合理及有理据的定

量及定性资料，包括历史经验及毋

须花费不必要成本或精力即可获

得的前瞻性资料。

尤其是，评估信贷风险是否大幅增

加时会考虑下列资料：

•

金融工具外部（如有）或内部

信贷评级的实际或预期重大

恶化；

•

信贷风险的外界市场指标的

重大恶化，例如信贷息差大

幅增加、债务人的信贷违约

掉期价；

---

金威医疗集团有限公司

2024/2025

年报

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

3. BASIS OF PREPARATION OF

CONSOLIDATED FINANCIAL STATEMENTS

AND MATERIAL ACOUNTING POLICY

INFORMATION – continued

Material acounting policy information

– continued

Financial instruments – continued

Financial asets – continued

Impairment of financial asets – continued

(i) Significant increase in credit risk – continued

• ,

financial or economic conditions that are

expected to cause a significant decrease in the

debtor’s ability to met its debt obligations;

• an actual or expected significant deterioration in

the operating results of the debtor;

• an actual or expected significant adverse change

in the regulatory, economic, or technological

environment of the debtor that results in a

significant decrease in the debtor’s ability to met

its debt obligations.

Irespective of the outcome of the above asesment,

the Group presumes that the credit risk has increased

significantly since initial recognition when contractual

payments are more than 30 days past due, unles the

Group has reasonable and suportable information

that demonstrates otherwise.

The Group regularly monitors the efectivenes of the

criteria used to identify whether there has ben a

significant increase in credit risk and revises them as

apropriate to ensure that the criteria are capable of

identifying significant increase in credit risk before the

amount becomes past due.

3.

综合财务报表编制基准及重大

会计政策资料－续

重大会计政策资料－续

金融工具－续

金融资产－续

金融资产减值－续

(i)

信贷风险大幅增加－续

•

预期将导致债务人履行其债

务责任的能力大幅下降的业

务、财务或经济状况的现有

或预测不利变动；

•

债务人经营业绩的实际或预

期重大恶化；

•

导致债务人履行其债务责任

的能力大幅下降的债务人监

管、经济或技术环境的实际

或预期重大不利变动。

不论上述评估结果，本集团假设自

合约付款初始确认到期超过

天，

信贷风险已大幅增加，惟本集团有

合理且可支持的资料证明其他情

况则除外。

本集团定期监察用以确定信贷风

险曾否显著增加的标准的成效，并

于适当时候作出修订，从而确保有

关标准能够于款项逾期前确定信

贷风险大幅增加。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/2025120

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

3. BASIS OF PREPARATION OF

CONSOLIDATED FINANCIAL STATEMENTS

AND MATERIAL ACOUNTING POLICY

INFORMATION – continued

Material acounting policy information

– continued

Financial instruments – continued

Financial asets – continued

Impairment of financial asets – continued

(i) Definition of default

For internal credit risk management, the Group

considers an event of default ocurs when information

developed internaly or obtained from external sources

indicates that the debtor is unlikely to pay its creditors,

including the Group, in ful (without taking into

acount any colaterals held by the Group).

Irespective of the above, the Group considers that

default has ocured when a financial aset is more

than 90 days past due unles the Group has reasonable

and suportable information to demonstrate that a

more laging default criterion is more apropriate.

(i) Credit-impaired financial asets

A financial aset is credit-impaired when one or more

events of default that have a detrimental impact on

the estimated future cash flows of that financial aset

have ocured. Evidence that a financial aset is credit-

impaired includes observable data about the folowing

events:

(a) significant financial dificulty of the isuer or the

borower;

(b) a breach of contract, such as a default or past

due event;

3.

综合财务报表编制基准及重大

会计政策资料－续

重大会计政策资料－续

金融工具－续

金融资产－续

金融资产减值－续

(i)

违约定义

就内部信贷风险管理而言，本集团

认为，倘内部生成或自外部来源

获得的资料显示债务人不太可能

向其债权人（包括本集团）悉数付

款（不考虑本集团持有的任何抵押

品），则发生违约事件。

尽管以上所述，本集团认为，倘金

融资产逾期超过

天时则发生违

约，除非本集团有合理可靠的资料

证明较宽松的违约标准属更合适

则当别论。

(i)

信贷减值的金融资产

当发生一项或多项对金融资产估

计未来现金流量有不利影响的违

约事件时，金融资产出现信贷减

值。金融资产信贷减值的证据包括

有关以下事件的可观察数据：

(a)

发行人或借款人出现重大财

政困难；

(b)

违约，例如拖账或逾期事项；

---

金威医疗集团有限公司

2024/2025

年报

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

3. BASIS OF PREPARATION OF

CONSOLIDATED FINANCIAL STATEMENTS

AND MATERIAL ACOUNTING POLICY

INFORMATION – continued

Material acounting policy information

– continued

Financial instruments – continued

Financial asets – continued

Impairment of financial asets – continued

(i) Credit-impaired financial asets – continued

(c) the lender(s) of the borower, for economic or

contractual reasons relating to the borower’s

financial dificulty, having granted to the

borower concesion(s) that the lender(s) would

not otherwise consider;

(d) it is becoming probable that the borower

wil enter bankruptcy or other financial

reorganisation; or

(e) the disapearance of an active market for that

financial aset because of financial dificulties.

(iv) Write-of policy

The Group writes of a financial aset when there

is information indicating that the counterparty is

in severe financial dificulty and there is no realistic

prospect of recovery, for example, when the

counterparty has ben placed under liquidation or has

entered into bankruptcy procedings, or in the case

of trade receivables, when the amounts are over two

years past due, whichever ocurs soner. Financial

asets writen of may stil be subject to enforcement

activities under the Group’s recovery procedures, taking

into acount legal advice where apropriate. A write-

of constitutes a derecognition event. Any subsequent

recoveries are recognised in profit or los.

3.

综合财务报表编制基准及重大

会计政策资料－续

重大会计政策资料－续

金融工具－续

金融资产－续

金融资产减值－续

(i)

信贷减值的金融资产－续

(c)

借款人的放款人因与借款人

出现财务困难有关之经济或

合约理由而给予借款人在其

他情况下放款人不予考虑之

优惠条件；

(d)

借款人有可能破产或进行其

他财务重组；或

(e)

由于财务困难致使金融资产

的活跃市场消失。

(iv)

撇销政策

倘有资料显示对手方陷入严重财

务困难且无实际可收回之期望（如

对手方已进行清盘或进入破产程

序，或如属贸易应收款项，该款项

已逾期超过两年）（以较早发生者

为准），本集团则撇销金融资产。经

考虑法律意见（如适用）后，已撇销

之金融资产仍可能受制于本集团

收回程序下之执法活动。撇销构成

终止确认事件。其后的任何收回均

在损益确认。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/2025122

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

3. BASIS OF PREPARATION OF

CONSOLIDATED FINANCIAL STATEMENTS

AND MATERIAL ACOUNTING POLICY

INFORMATION – continued

Material acounting policy information

– continued

Financial instruments – continued

Financial asets – continued

Impairment of financial asets – continued

(v) Measurement and recognition of ECL

The measurement of ECL is a function of the

probability of default, los given default (i.e. the

magnitude of the los if there is a default) and the

exposure at default. The asesment of the probability

of default and los given default is based on historical

data and forward loking information. Estimation of

ECL reflects an unbiased and probability-weighted

amount that is determined with the respective risks

of default ocuring as the weights. The Group uses

a practical expedient in estimating ECL on trade

receivables using a provision matrix taking into

consideration historical credit los experience, adjusted

for forward loking information that is available

without undue cost or efort.

Generaly, the ECL is the diference betwen al

contractual cash flows that are due to the Group

in acordance with the contract and the cash flows

that the Group expects to receive, discounted at the

efective interest rate determined at initial recognition.

Lifetime ECL for certain trade receivables are

considered on a colective basis taking into

consideration past due information and relevant credit

information such as forward-loking macroeconomic

information.

3.

综合财务报表编制基准及重大

会计政策资料－续

重大会计政策资料－续

金融工具－续

金融资产－续

金融资产减值－续

(v)

计量及确认预期信贷亏损

预期信贷亏损之计量为违约概率、

违约亏损（即违约亏损程度）及违约

风险的函数。违约概率及违约亏损

之评估乃基于历史数据及前瞻性

资料作出。预期信贷风险的估计反

映不偏不倚及概率加权金额，以各

自发生违约的风险为权重厘定。本

集团经考虑过往信贷亏损经验后

使用拨备矩阵并采用可行权宜方

法估计贸易应收款项的预期信贷

亏损，并按无须花费不必要成本或

精力即可获取的前瞻性资料进行

调整。

一般而言，预期信贷亏损为根据合

约应付本集团的所有合约现金流

与本集团预期将收取的所有现金

流量之间的差额，并按初始确认时

厘定的实际利率贴现。

经计及过往逾期资料及相关信贷

资料（例如前瞻性宏观经济资料），

若干贸易应收款项的全期预期信

贷亏损乃按集体基准予以考虑。

---

金威医疗集团有限公司

2024/2025

年报

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

3. BASIS OF PREPARATION OF

CONSOLIDATED FINANCIAL STATEMENTS

AND MATERIAL ACOUNTING POLICY

INFORMATION – continued

Material acounting policy information

– continued

Financial instruments – continued

Financial asets – continued

Impairment of financial asets – continued

(v) Measurement and recognition of ECL – continued

For colective asesment, the Group takes into

consideration the folowing characteristics when

formulating the grouping:

• ;

• , size and industry of debtors; and

• External credit ratings where available.

The grouping is regularly reviewed by management

to ensure the constituents of each group continue to

share similar credit risk characteristics.

Interest income is calculated based on the gros

carying amount of the financial aset unles the

financial aset is credit impaired, in which case interest

income is calculated based on amortised cost of the

financial aset.

The Group recognises an impairment gain or los in

profit or los for al financial instruments by adjusting

their carying amount, with the exception of trade

receivables and other receivables and deposits where

the coresponding adjustment is recognised through a

los alowance acount.

3.

综合财务报表编制基准及重大

会计政策资料－续

重大会计政策资料－续

金融工具－续

金融资产－续

金融资产减值－续

(v)

计量及确认预期信贷亏损－续

本集团为集体评估制定组别时，将

考虑以下特点：

•

逾期状况；

•

债务人之性质、规模及行业；

及

•

外部信贷评级（如有）。

管理层定期检讨分组，以确保各组

之组成继续具有类似之信贷风险

特征。

利息收入乃根据金融资产之账面

总值计算，除非金融资产作出信贷

减值，在此情况下，利息收入根据

金融资产之摊销成本计算。

本集团透过调整所有金融工具之

账面值于损益确认该等金融工具

之减值收益或亏损，惟贸易应收款

项及其他应收款项以及按金乃透

过亏损拨备账确认相应调整除外。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/2025124

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

3. BASIS OF PREPARATION OF

CONSOLIDATED FINANCIAL STATEMENTS

AND MATERIAL ACOUNTING POLICY

INFORMATION – continued

Material acounting policy information

– continued

Financial instruments – continued

Financial asets – continued

Derecognition of financial asets

The Group derecognises a financial aset only when the

contractual rights to the cash flows from the aset expire,

or when it transfers the financial aset and substantialy al

the risks and rewards of ownership of the aset to another

entity. If the Group neither transfers nor retains substantialy

al the risks and rewards of ownership and continues to

control the transfered aset, the Group recognises its

retained interest in the aset and an asociated liability

for amounts it may have to pay. If the Group retains

substantialy al the risks and rewards of ownership of a

transfered financial aset, the Group continues to recognise

the financial aset and also recognises a colateralised

borowing for the proceds received.

On derecognition of a financial aset measured at amortised

cost, the diference betwen the aset’s carying amount

and the sum of the consideration received and receivable is

recognised in profit or los.

3.

综合财务报表编制基准及重大

会计政策资料－续

重大会计政策资料－续

金融工具－续

金融资产－续

终止确认金融资产

仅于资产现金流量之合约权利届满时，

或转让金融资产及将该资产所有权之绝

大部分风险及回报转让予另一实体时，

本集团方会终止确认金融资产。倘本集

团并未转让亦未保留所有权之绝大部分

风险及回报，并继续控制已转让资产，

则本集团确认其于资产之保留利益及其

须支付之相联负债金额。倘本集团保留

已转让金融资产所有权之绝大部分风险

及回报，则本集团继续确认该金融资产

并确认已收所得款项之有抵押借贷。

于终止确认按摊销成本计量之金融资产

时，资产账面值与已收及应收代价总额

之差额乃于损益确认。

---

金威医疗集团有限公司

2024/2025

年报

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

3. BASIS OF PREPARATION OF

CONSOLIDATED FINANCIAL STATEMENTS

AND MATERIAL ACOUNTING POLICY

INFORMATION – continued

Material acounting policy information

– continued

Financial liabilities and equity instruments

Clasification as debt or equity

Debt and equity instruments isued by a group entity

are clasified as either financial liabilities or as equity

in acordance with the substance of the contractual

arangements and the definitions of a financial liability and

an equity instrument.

Equity instruments

An equity instrument is any contract that evidences a

residual interest in the asets of an entity after deducting al

of its liabilities. Equity instruments isued by a group entity

are recognised at the proceds received, net of direct isue

costs.

Financial liabilities

Al financial liabilities are subsequently measured at

amortised cost using the efective interest method.

Financial liabilities at amortised cost

Financial liabilities (including trade and other payables and

lease liabilities) are subsequently measured at amortised cost

using the efective interest method.

Derecognition of financial liabilities

The Group derecognises financial liabilities when, and only

when, the Group’s obligations are discharged, canceled or

they expire. The diference betwen the carying amount

of the financial liability derecognised and the consideration

paid and payable is recognised in profit or los.

3.

综合财务报表编制基准及重大

会计政策资料－续

重大会计政策资料－续

金融负债及股本工具

分类为债务或股本

集团实体发行之债务及股本工具乃根据

合约安排之性质及金融负债及股本工具

之定义分类为金融负债或股本。

股本工具

股本工具乃证明实体资产于扣除其所有

负债后之剩余权益之任何合约。一间集

团实体发行之股本工具乃按已收取所得

款项扣除直接发行成本确认。

金融负债

所有金融负债其后使用实际利率法按摊

销成本计量。

按摊销成本计量之金融负债

金融负债（包括贸易及其他应付款项及

租赁负债）其后使用实际利率法按摊销

成本计量。

终止确认金融负债

本集团仅于其责任已被解除、注销或届

满时方会终止确认金融负债。终止确认

之金融负债账面值与已付及应付代价之

差额乃于损益内确认。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/2025126

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

4. KEY SOURCES OF ESTIMATION

UNCERTAINTY

In the aplication of the Group’s acounting policies, which

are described in note 3, the directors of the Company are

required to make judgements, estimates and asumptions

about the carying amounts of asets and liabilities that are

not readily aparent from other sources. The estimates and

underlying asumptions are based on historical experience

and other factors that are considered to be relevant. Actual

results may difer from these estimates.

The estimates and underlying asumptions are reviewed on

an on-going basis. Revisions to acounting estimates are

recognised in the period in which the estimate is revised

if the revision afects only that period, or in the period of

the revision and future periods if the revision afects both

curent and future periods.

The folowing are the key asumptions concerning the

future, and other key sources of estimation uncertainty at

the end of the reporting period that may have a significant

risk of causing a material adjustment to the carying

amounts of asets and liabilities within the next financial

year.

4.

估计不确定因素之主要来源

在采用本集团的会计政策（见附注

概

述）时，本公司董事须就无法从其他来

源即时获取之资产和负债之账面值作出

判断、估计和假设。估计和有关假设乃

基于其过往经验和其他被认为相关的因

素。实际结果与该等估计可能出现误差。

估计和有关假设将持续予以检讨。对会

计估计作出之修订如只影响该修订之期

间，则会于该期间确认，如该修订影响

现时及将来之期间，则同时于修订期间

及将来期间确认。

以下为于报告期末有关未来之主要假

设，以及其他估计不确定因素之主要来

源，彼等带有导致须对下一财政年度之

资产及负债账面值作重大调整之重大风

险。

---

金威医疗集团有限公司

2024/2025

年报

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

4. KEY SOURCES OF ESTIMATION

UNCERTAINTY – continued

(a) Estimated impairment of property, plant and

equipment and right-of use asets

Property, plant and equipment and right-of-use asets

are stated at costs les acumulated depreciation and

impairment, if any. In determining whether an aset

is impaired, the Group has to exercise judgement and

make estimation, particularly in asesing: (1) whether

an event has ocured or any indicators that may afect

the aset value; (2) whether the carying value of an

aset can be suported by the recoverable amount,

in the case of value in use, the net present value of

future cash flows which are estimated based upon the

continued use of the aset; and (3) the apropriate

key asumptions to be aplied in estimating the

recoverable amounts including cash flow projections

and an apropriate discount rate. When it is not

posible to estimate the recoverable amount of an

individual aset (including right-of-use asets), the

Group estimates the recoverable amount of the cash

generating unit to which the asets belongs, including

alocation of corporate asets when a reasonable

and consistent basis of alocation can be established,

otherwise recoverable amount is determined at the

smalest group of cash generating units, for which

the relevant corporate asets have ben alocated.

Changing the asumptions and estimates, including

the discount rates or the growth rate in the cash flow

projections, could materialy afect the recoverable

amounts. Furthermore, the cash flows projections,

growth rate and discount rate are subject to greater

uncertainties due to uncertainty on how the volatility

in financial and foreign curency markets may progres

and evolve.

4.

估计不确定因素之主要来源

－续

(a)

物业、厂房及设备以及使用权

资产的估计减值

物业、厂房及设备以及使用权资产

按成本减累计折旧及减值（如有）列

账。于厘定资产是否减值时，本集

团须作出判断及估计，尤其需要评

估：

(1)

是否发生可能影响资产价值

的事件或任何迹象；

(2)

资产账面值

是否能够以可收回金额（如为使用

价值）支持，即按照持续使用资产

估计的未来现金流量的净现值；及

(3)

将应用于估计可收回金额的适

当关键假设（包括现金流量预测及

适当的贴现率）。当无法估计个别

资产（包括使用权资产）的可收回金

额时，本集团估计资产所属现金产

生单位的可收回金额，包括当可设

立合理及持续分配基准的公司资

产分配，否则可收回金额按现金产

生单位最小组合厘定，而其相关公

司资产已予分配。更改有关假设及

估计（包括现金流预测中的贴现率

或增长率），可显著影响可收回金

额。此外，现金流量预测、增长率

及贴现率受限于更大不确定性，原

因为金融及外汇市场波动会如何

发展及演变的不确定性。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/2025128

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

4. KEY SOURCES OF ESTIMATION

UNCERTAINTY – continued

(a) Estimated impairment of property, plant and

equipment – continued

As at 31 March 2025, the carying amounts of

property, plant and equipment subjected to impairment

asesment were of aproximately HK$1,273,000

(net of acumulated impairment los of aproximately

HK$2,000) (2024: aproximately HK$16,035,000 (net

of acumulated impairment los of aproximately

HK$2,777,000). Details of the impairment testing of

non-financial asets including godwil are disclosed in

Note 18.

(b) Provision of ECL for trade and other

receivables

The los alowances for financial asets are based

on asumption about risk of default and expected

los rates. The Group use judgment in making these

asumptions and selecting the inputs to the impairment

calculation, based on the Group’s past history, existing

market conditions as wel as forward-loking estimates

at the end of each reporting period.

The provision of ECL is sensitive to changes in

estimates. The information about the ECL and the

Group’s for trade and other receivables are disclosed in

Notes 32(b).

4.

估计不确定因素之主要来源

－续

(a)

物业、厂房及设备的估计减值

－续

于二零二五年三月三十一日，接受

减值评估的物业、厂房及设备的账

面值约为

1,273,000

港元（经扣除

累计减值亏损约

2,000

港元）（二零

二四年：约为

16,035,000

港元（经

扣除累计减值亏损约

2,777,000

港

元）。有关非金融资产（包括商誉）

减值测试的详情于附注

披露。

(b)

贸易及其他应收款项之预期信

贷亏损拨备

金融资产之亏损拨备乃基于与违

约风险及预期亏损率有关之假设。

本集团于作出该等假设及选定减

值计算之输入数据时根据本集团

之过往历史、当前市况以及于各报

告期末之前瞻性估计使用判断。

预期信贷亏损之拨备对估计变动

较为敏感。有关预期信贷亏损以及

本集团之贸易及其他应收款项之

资料于附注

32(b)

披露。

---

2025
二零二五年 HK$’000
千港元
16,120
10,945
5,175
16,120

金威医疗集团有限公司

2024/2025

年报

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

5. REVENUE

An analysis of the Group’s revenue for the year is as folows:

二零二四年

HK$’000

千港元

Revenue from contract with customers:

客户合约收益：

Provision of general hospital services and

related services

提供综合性医院服务及相关服务

38,962

Timing of recognition of revenue from

contracts with customers:

客户合约收益确认时间：

At a point in time

于某个时点

38,962

Over time

随时间

–

38,962

Revenue from the provision of general hospital services,

which is mainly derived from hospital services provided at

the hospitals, is recognised at a point in time, i.e. when the

related services have ben rendered to patients.

Al revenue contracts are for one year or les. As permited

by practical expedient under HKFRS 15, the transaction price

alocated to unsatisfied contracts is not disclosed.

5.

收益

本集团本年度收益之分析如下：

提供综合性医院服务的收益主要来自所

提供的医院住院服务，并于某个时点（即

于向患者提供相关服务时）确认。

所有收益合约为期一年或以下。根据香

港财务报告准则第

号实际适宜方法许

可，分配至未履行合约的交易价格不予

披露。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/2025130

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

6. SEGMENT INFORMATION

Information reported internaly to the chief operating

decision maker (“CODM”), for the purpose of resource

alocation and asesment of segment performance focuses

on types of gods sold or services rendered. The Group is

principaly engaged in provision of general hospital services

in the PRC.

Acordingly, the Group does not present separately segment

information. No analysis of the Group’s results by types of

works nor asets and liabilities is regularly provided to the

CODM for review. In adition, al of the Group’s revenue is

generated in PRC and al of the Group’s asets and liabilities

are mainly located in PRC. Acordingly, no busines or

geographical segment information is presented.

Geographical information

The Group principaly operates in the PRC (place of domicile

of the Group entities that derived the revenue). Al of the

Group’s revenue was derived from the PRC based on the

location of services delivered and the Group’s property, plant

and equipment are mainly located in PRC.

Information about major customers

No information about major customers is presented as no

single customer contributed over 10% of total revenue of

the Group during the years ended 31 March 2025 and 2024.

6.

分类资料

就资源分配及分类表现评估而向主要营

运决策者（「主要经营决策者」）作内部报

告之资料著重所出售之货品或所提供服

务之类型。本集团主要在中国从事提供

综合性医院服务。

因此，本集团并无单独呈列分部资料。

并无向主要经营决策者定期提供按工程

类别划分的本集团业绩或资产及负债分

析以作审阅。此外，本集团的所有收益

均源自中国，而本集团的所有资产及负

债主要位于中国。因此，概无呈列任何

业务或地区分类资料。

地区资料

本集团主要在中国（本集团实体产生收

益之存册地点）经营。本集团所有收益基

于所提供服务的地点均源自中国，而本

集团的物业、厂房及设备主要位于中国。

主要客户的资料

由于在截至二零二五年及二零二四年三

月三十一日止年度内，概无任何单一客

户对本集团总收益的贡献超过

10%

，因

此并无提供有关主要客户的资料。

---

2025
二零二五年 HK$’000
千港元
1
904
82
987

2025
二零二五年 HK$’000
千港元
7,819

金威医疗集团有限公司

2024/2025

年报

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

7. OTHER REVENUE

二零二四年

HK$’000

千港元

Bank interest income

银行利息收入

Gain on early termination of lease

提前终止租赁之收益

–

Sundry income

杂项收入

8. OTHER LOS

二零二四年

HK$’000

千港元

Los on disposal of property,

plant and equipment

出售物业、厂房及设备之亏损

2,075

7.

其他收益

8.

其他亏损

---

2025
二零二五年 HK$’000
千港元
–
190
190

2025
二零二五年 HK$’000
千港元
5
(16)
–
(11)

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/2025132

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

9. FINANCE COSTS

二零二四年

HK$’000

千港元

Interest on:

以下项目之利息：

– borowings

－借款

– lease liabilities

－租赁负债

10. TAXATION

The Group is subject to income tax on an entity basis on

profits arising or derived from the jurisdictions in which

members of the Group are domiciled and operate. Provision

on profits asesable elsewhere has ben calculated at the

rates of tax prevailing in the countries in which the Group

operates, based on existing legislation, interpretations and

practices in respect thereof.

二零二四年

HK$’000

千港元

PRC Enterprise Income Tax:

中国企业所得税：

– Curent tax

－即期税项

–

– Over-provision in prior years

－过往年度超额拨备

–

– Under-provision in prior years

－过往年度拨备不足

1,043

1,043

9.

财务费用

10.

税项

本集团乃按实体自本集团成员公司所在

及经营司法权区产生或源自该司法权区

之溢利为基准缴纳所得税。其他地区之

应课税溢利拨备乃根据本集团业务经营

所在国家之现有法例、诠释及惯例按当

地现行税率计算。

---

2025
二零二五年 HK$’000
千港元
(7,368)
(2,194)
(1,922)
1,832
2,289
(16)
(11)

金威医疗集团有限公司

2024/2025

年报

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

10. TAXATION – continued

A reconciliation of the income tax expense aplicable to los

before taxation using the statutory rate for the location in

which the Company and its subsidiaries are domiciled to the

tax expense at the efective tax rate are as folows:

二零二四年

HK$’000

千港元

Los before taxation

除税前亏损

(16,344)

Notional tax on los before tax,

calculated at rates aplicable to

profits in the tax jurisdiction concerned

按适用于相关税务司法权区

溢利之税率计算之除税前

亏损之名义税项

(3,200)

Tax efect of income not taxable

for tax purpose

毋须缴税之收入之税务影响

(85)

Tax efect of expense not deductible

for tax purpose

不可扣税开支之税务影响

2,834

Tax efect of tax loses not recognised

未确认税项亏损之税务影响

(Over)/under-provision in prior years

过往年度（超额拨备）╱拨备不足

1,043

Taxation

税项

1,043

10.

税项－续

按本公司及其附属公司显示所在地的法

定税率计算适用于除税前亏损的所得税

开支与按实际税率计算的税项开支的对

账如下：

---

2025
二零二五年 HK$’000
千港元
9,157
1,764
–
2,247
3,236
–
16,404

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/2025134

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

10. TAXATION – continued

At the end of the reporting period, the Group has unused

tax loses of aproximately HK$16,404,000 (2024:

HK$20,392,000) available for ofset against future profits.

No defered tax aset has ben recognised in respect of the

unutilised tax loses and the deductible temporary diference

due to the unpredictability of future profit streams. Included

in unrecognised tax loses of aproximately HK$16,404,000

(2024: HK$20,392,000) with expiry dates as disclosed in the

folowing table.

二零二四年

HK$’000

千港元

二零三零年

–

二零二九年

1,782

二零二八年

二零二七年

4,915

二零二六年

8,954

二零二五年

4,005

20,392

10.

税项－续

于报告期末，本集团可用作抵销未来溢

利之尚未动用税项亏损约为

16,404,000

港元（二零二四年：

20,392,000

港元）。由

于日后溢利来源之不可预测性，故并无

就尚未动用之税项亏损及可扣减暂时性

差额确认递延税项资产。未确认税项亏

损包括约

16,404,000

港元（二零二四年：

20,392,000

港元），其届满日期如下表所

披露。

---

金威医疗集团有限公司

2024/2025

年报

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

10. TAXATION – continued

Acording to the PRC Enterprise Income Tax Law (“EIT

Law”), 10% witholding income tax is imposed on dividend

declared relating to profits earned by the subsidiaries

established in the PRC from 1 January 2008 onwards to

their foreign shareholders. For investors incorporated in

Hong Kong which hold at least 25% of equity interest of

those PRC companies, a preferential rate of 5% wil be

aplied. The Group has aplied the preferential rate of 5%

as the Group’s subsidiaries in the PRC are directly held by an

investment holding company incorporated in Hong Kong.

Under the EIT Law and Implementation Regulation of the

EIT Law, the tax rate of the PRC subsidiaries is 25% for both

years.

Under the two-tiered profits tax rates regime of Hong Kong

Profits Tax, the first HK$2 milion of profits of the qualifying

group entities wil be taxed at 8.25%, and profits above

HK$2 milion wil be taxed at 16.5%. The profits of group

entities not qualifying for the two-tiered profits tax rates

regime wil continue to be taxed at a flat rate of 16.5%.

Acordingly, the Hong Kong Profits Tax of the qualifying

group entity is calculated at 8.25% on the first HK$2 milion

of the estimated asesable profits and at 16.5% on the

estimated asesable profits above HK$2 milion.

No provision of Hong Kong Profits Tax, Bermuda and BVI

Income Tax has ben made, as the Group did not generate

any asesable profits in these jurisdictions during the years

ended 31 March 2025 and 2024.

10.

税项－续

根据中国企业所得税法（「企业所得税

法」），自二零八年一月一日起，就在

中国成立的附属公司赚取的溢利向其境

外股东宣派的股息征收

10%

的预扣所得

税。对于在香港注册成立且持有该等中

国公司至少

25%

股权的投资者，将实施

5%

的优惠税率。由于本集团在中国的附

属公司均由一间在香港注册成立的投资

控股公司直接持有，故本集团按

5%

的优

惠税率缴纳税项。

根据企业所得税法及企业所得税法实施

条例，中国附属公司于两个年度之税率

均为

25%

。

根据香港利得税率两级制，合资格

集团实体的首

2,000,000

港元溢利将按

8.25%

征税，而超过

2,000,000

港元的溢

利则须按

16.5%

征税。不符合利得税

率两级制的集团实体的溢利将继续按

固定税率

16.5

％征税。因此，合资格集

团实体的估计应课税溢利首

2,000,000

港元按

8.25%

计算香港利得税，而超过

2,000,000

港元的估计应课税溢利则按

16.5%

计算香港利得税。

本集团并无计提香港利得税、百慕达及

英属处女群岛所得税拨备，原因为截至

二零二五年及二零二四年三月三十一日

止年度于该等司法管辖区并无产生任何

应课税溢利。

---

2025
二零二五年 HK$’000
千港元
1,853
1,503
13,086
16,442
450
5,018
6,934
2,105
3,597
615

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/2025136

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

11. LOS FOR THE YEAR

二零二四年

HK$’000

千港元

Los for the year has ben arived

at after charging:

本年度亏损已扣除：

Directors’ remuneration (Note 12)

董事酬金（附注

）

2,249

Other staf costs:

其他员工成本：

– Retirement benefits scheme

contributions

－退休福利计划供款

2,428

– Salaries, alowance and benefits in kind

－薪金、津贴及实物利益

17,992

Total staf costs

总员工成本

22,669

Auditors’ remuneration

核数师酬金

– Audit services

－审计服务

Cost of inventories sold recognised

as expenses

确认为开支之已售存货成本

10,276

Depreciation of property,

plant and equipment (Note 15)

物业、厂房及设备折旧（附注

）

2,782

Depreciation of right-of-use asets (Note 16)

使用权资产折旧（附注

）

3,136

Expenses relating to short-term leases

有关短期租赁之开支

1,551

Writen of of inventories

撇销存货

11.

本年度亏损

---

袍 2025
二零二五年 HK$’000
千港元
–
–
–
120
120
115
–
355

薪金及 2025
二零二五年 HK$’000
千港元
1,220
–
260
–
–
–
–
1,480

退休福利 2025
二零二五年 HK$’000
千港元
18
–
–
–
–
–
–
18

总 2025
二零二五年 HK$’000
千港元
1,238
–
260
120
120
115
–
1,853

金威医疗集团有限公司

2024/2025

年报

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

12. DIRECTORS’, CHIEF EXECUTIVE’S AND

SENIOR MANAGEMENT’S EMOLUMENTS

(a) Directors’ and chief executive’s emoluments

The remuneration of each director for the years ended

31 March 2025 and 2024 are set out below:

Fes

Salaries and

other benefits

Retirement

benefits

scheme

contributionsTotal

袍金薪金及其他福利退休福利计划供款总计

二零二四年二零二四年二零二四年二零二四年

HK$’000HK$’000HK$’000HK$’000

千港元千港元千港元千港元

Executive directors

执行董事

Ng Chi Lung

吴志龙

–1,170181,188

Zheng Gang (note (a)

郑钢（附注

(a)

）

–5638571

Wu Qiyou (note (b)

吴其佑（附注

(b)

）

–154–154

Independent non-executive

directors

独立非执行董事

Wong Ka Wai, Jeane

黄嘉慧

120–120

Lau Tak Kei, Arthur

刘德基

120–120

Mr. Lin Yaomin (note (d)

林瑶珉（附注

(d)

）

–

Lam Huen Sum (note (c)

林绚琛（附注

(c)

）

96–96

3361,887262,249

Notes:

(a) Mr. Zheng Gang has resigned as an executive director

with efect from 22 August 2023.

(b) Mr. Wu Qiyou has ben apointed as an executive

director with efect from 22 August 2023.

(c) Dr. Lam Huen Sum has resigned as an independent non-

executive director with efect from 18 January 2024.

(d) Mr. Lin Yaomin has ben apointed as an independent

non-executive director with efect from 17 April 2024.

12.

董事、主要行政人员及高级管

理人员酬金

(a)

董事及主要行政人员酬金

各董事于截至二零二五年及二零

二四年三月三十一日止年度之薪

酬情况载列如下：

附注：

(a)

郑钢先生已辞任执行董事，自二

零二三年八月二十二日起生效。

(b)

吴其佑先生已获委任为执行董

事，自二零二三年八月二十二日

起生效。

(c)

林绚琛博士已辞任独立非执行董

事，自二零二四年一月十八日起

生效。

(d)

林瑶珉先生已获委任为独立非执

行董事，自二零二四年四月十七

日起生效。

---

2025
二零二五年 HK$’000
千港元
2,236
54
2,290

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/2025138

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

12. DIRECTORS’, CHIEF EXECUTIVE’S AND

SENIOR MANAGEMENT’S EMOLUMENTS

– continued

(a) Directors’ and chief executive’s emoluments

– continued

During the years ended 31 March 2025 and 2024, no

emoluments were paid by the Group to the directors

or chief executive oficer as an inducement to join or

upon joining the Group or as compensation for los of

ofice. None of the directors or chief executive oficer

has waived or has agred to waive any emoluments

during both years.

(b) Employes’ emoluments

The five highest paid individuals during the year ended

31 March 2025 included two (2024: two) directors.

Details of whose remuneration are set out in Note

12(a) above. Remuneration of the remaining thre

(2024: thre) non-directors, highest paid employes are

disclosed as folows:

二零二四年

HK$’000

千港元

Salaries and alowances

薪金及津贴

2,122

Retirement benefits scheme

contributions

退休福利计划供款

2,176

12.

董事、主要行政人员及高级管

理人员酬金－续

(a)

董事及主要行政人员酬金－续

于截至二零二五年及二零二四年

三月三十一日止年度，本集团并无

向董事或行政总裁支付酬金以吸

引其加盟本集团或作为加盟奖金

或离职补偿。于两个年度内，概无

董事或行政总裁已放弃或同意放

弃任何酬金。

(b)

雇员酬金

截至二零二五年三月三十一日止

年度，五名最高薪人士包括两名

（二零二四年：两名）董事。彼等之

酬金详情载于上文附注

12(a)

中。余

下三名（二零二四年：三名）非董事

之最高薪雇员之酬金披露如下：

---

2025
二零二五年
2
1

金威医疗集团有限公司

2024/2025

年报

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

12. DIRECTORS’, CHIEF EXECUTIVE’S AND

SENIOR MANAGEMENT’S EMOLUMENTS

– continued

(b) Employes’ emoluments – continued

The number of the highest paid employes whose

remuneration fel within the folowing bands is as

folows:

二零二四年

Nil to HK$1,000,000

零至

1,000,000

港元

HK$1,000,001 to HK$1,500,0001,000,001

港元至

1,500,000

港元

During the years ended 31 March 2025 and 2024,

no emoluments were paid by the Group to the senior

management or the five highest paid individuals as an

inducement to join or upon joining the Group or as

compensation for los of ofice.

None of the senior management or the five highest

paid individuals have waived or has agred to waive

any emoluments during the years ended 31 March

2025 and 2024.

There was no bonus paid or receivable by directors

or five highest paid employe after considering the

Group’s operational and financial performance during

the year ended 31 March 2025 (2024: Nil).

13. DIVIDENDS

The directors of the Company do not recomend the

payment of a final dividend for the year ended 31 March

2025 (2024: Nil).

12.

董事、主要行政人员及高级管

理人员酬金－续

(b)

雇员酬金－续

酬金属于下列范围之最高薪雇员

人数如下：

截至二零二五年及二零二四年三

月三十一日止年度，本集团并无向

高级管理人员或五名最高薪人士

支付酬金以吸引其加盟本集团或

作为加盟奖金或离职补偿。

概无高级管理人员或五名最高薪

人士于截至二零二五年及二零

二四年三月三十一日止年度已放

弃或同意放弃任何酬金。

于计及本集团截至二零二五年三

月三十一日止年度之经营及财务

表现后，董事或五名最高薪雇员概

无已付或应收花红（二零二四年：

无）。

13.

股息

本公司董事并不建议就截至二零二五年

三月三十一日止年度派发末期股息（二

零二四年：无）。

---

2025
二零二五年 HK$’000
千港元
(10,127)
563,650

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/2025140

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

14. LOS PER SHARE

The calculation of the basic and diluted los per share

atributable to the owners of the Company is based on the

folowing data:

(a) Basic

二零二四年

HK$’000

千港元

Los for the year atributable to

holders of ordinary shares of

the Company (HK$’000)

本公司普通股持有人应占本年度

亏损（千港元）

(17,110)

Weighted average number of

ordinary shares in isue (‘000)

已发行普通股之加权平均数

（千股）

563,650

(b) Diluted

The diluted los per share is the same as the basic los

per share as there was no dilutive potential ordinary

share in isue during years ended 31 March 2025 and

2024.

14.

每股亏损

本公司拥有人应占每股基本及摊薄亏损

乃根据以下数据计算：

(a)

基本

(b)

摊薄

由于截至二零二五年及二零二四

年三月三十一日止年度内概无已

发行摊薄潜在普通股，故每股摊薄

亏损与每股基本亏损相同。

---

金威医疗集团有限公司

2024/2025

年报

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

15. PROPERTY, PLANT AND EQUIPMENT

Leasehold

improvements

Machinery

and

Equipment

Furniture

and

fixtures

Motor

vehicles

Ofice

EquipmentTotal

租赁物业装修机器及设备家私及装置汽车办公室设备总计

HK$’000HK$’000HK$’000HK$’000HK$’000HK$’000

千港元千港元千港元千港元千港元千港元

Cost

成本

At 1 April 2023

于二零二三年四月一日

15,44712,6496,0875,5766,33646,095

Aditions

添置

37314,108–1014,491

Disposals/writen-of

出售／撇销

–(4,149)–(291)–(4,440)

Exchange realignment

汇兑调整

(688)(786)(308)(61)(237)(2,080)

At 31 March 2024

于二零二四年三月三十一日

15,13221,8225,7795,2246,10954,066

Aditions

添置

–41–41

Disposals/writen-of

出售／撇销

(12,115)(21,798)(5,763)–(6,007)(45,683)

Disposal of subsidiaries

出售附属公司

-(33)(33)

Exchange realignment

汇兑调整

(38)(65)(16)(9)(12)(140)

At 31 March 2025

于二零二五年三月三十一日

2,979–5,215578,251

Acumulated depreciation and

impairment los

累计折旧及减值亏损

At 1 April 2023

于二零二三年四月一日

15,4476,7935,4463,8704,81536,371

Provided for the year

本年度拨备

651,5511773046852,782

Disposals/writen-of

出售／撇销

–(2,083)–(282)–(2,365)

Impairment (Note 18)

减值（附注

）

472,46365331692,777

Exchange realignment

汇兑调整

(686)(376)(278)(44)(150)(1,534)

At 31 March 2024

于二零二四年三月三十一日

14,8738,3485,4103,8815,51938,031

Provided for the year

本年度拨备

1,2773,9431,179784576,934

Disposals/writen-of

出售／撇销

(13,135)(12,268)(6,577)–(5,884)(37,864)

Disposal of subsidiaries (Note 34)

出售附属公司（附注

）

–(31)(31)

Exchange realignment

汇兑调整

(36)(23)(12)(8)(13)(92)

At 31 March 2025

于二零二五年三月三十一日

2,979–3,951486,978

Carying values

账面值

At 31 March 2025

于二零二五年三月三十一日

–1,26491,273

At 31 March 2024

于二零二四年三月三十一日

25913,4743691,34359016,035

Note:

During the year ended 31 March 2024, impairment los of

HK$2,777,000 has ben recognised. Details of impairment

asesment are set out in note 18 to the consolidated financial

statements.

15.

物业、厂房及设备

附注：

于截至二零二四年三月三十一日止年度，减

值亏损

2,777,000

港元已获确认。减值评估详

情载于综合财务报表附注

。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/2025142

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

16. RIGHT-OF-USE ASETS

Leased

Properties

租赁物业

HK$’000

千港元

At 1 April 2023

于二零二三年四月一日

4,910

Aditions

添置

3,308

Depreciation provided for the year

年内折旧拨备

(3,136)

Impairment los recognised (Note 18)

已确认减值亏损（附注

）

(749)

Exchange realignment

汇兑调整

(195)

At 31 March 2024

于二零二四年三月三十一日

4,138

Aditions

添置

–

Depreciation provided for the year

年内折旧拨备

(2,105)

Early termination of leases

提前终止租赁

(2,028)

Exchange realignment

汇兑调整

(5)

At 31 March 2025

于二零二五年三月三十一日

–

16.

使用权资产

---

金威医疗集团有限公司

2024/2025

年报

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

16. RIGHT-OF-USE ASETS – continued

Note:

For both years, the Group leases an ofice and a property for

its operations. During the year ended 31 March 2025, lease

contracts are entered into for fixed terms of 1 year (2024:

1 to 3 years). Lease terms are negotiated on an individual

basis and contain diferent terms and conditions. In

determining the lease term and asesing the length of the

non-cancelable period, the Group aplies the definition of a

contract and determines the period for which the contract is

enforceable.

The Group regularly entered into short-term leases for staf

quarter. As at 31 March 2025 and 2024, the portfolio of

short-term leases is similar to the portfolio of short-term

leases to which the short-term lease expense disclosed

above.

During the year ended 31 March 2024, impairment los of

HK$749,000 has ben recognised. Details of impairment

asesment are set out in note 18 to the consolidated

financial statements.

No lease liabilities and related right-of-use asets were

recognised during the year ended 31 March 2025. As at 31

March 2024, lease liabilities of aproximately HK$5,130,000

were recognised with related right-of-use asets of

aproximately HK$4,138,000. The lease agrements do not

impose any covenants and leased asets may not be used as

security for borowing purposes.

Details of total cashflow for leases for the years ended 31

March 2025 and 2024 are set out in Note 33.

16.

使用权资产－续

附注：

于两个年度，本集团均租赁一间办公室

及一处物业作营运之用。于截至二零

二五年三月三十一日止年度，租赁合同

的固定租期为一年（二零二四年：一至

三年）。租赁条款乃个别磋商而定，所载

条款及条件各不相同。于厘定租期及评

估不可撤销期间的时长时，本集团应用

合同的定义并厘定可强制执行合同的期

间。

本集团定期就员工宿舍订立短期租约。

于二零二五年及二零二四年三月三十一

日，短期租赁组合与上文所披露短期租

赁开支的短期租赁组合相似。

于截至二零二四年三月三十一日止年

度，减值亏损

749,000

港元已获确认。减

值评估详情载于综合财务报表附注

。

于截至二零二五年三月三十一日止年度

并无确认租赁负债及相关使用权资产。

于二零二四年三月三十一日，租赁负债

约

5,130,000

港元及相关使用权资产约

4,138,000

港元已获确认。租赁协议并无

施加任何契诺，且租赁资产不得就借贷

用途用作抵押。

截至二零二五年及二零二四年三月

三十一日止年度的租赁现金流量总额详

情载于附注

。

---

2025
二零二五年 HK$’000
千港元
146,850
146,850
–

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/2025144

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

17. GODWIL

二零二四年

HK$’000

千港元

Cost

成本

At 1 April and 31 March

于四月一日及三月三十一日

146,850

Acumulated impairment loses

累计减值亏损

At 1 April and 31 March

于四月一日及三月三十一日

146,850

Carying amounts

账面值

At 31 March

于三月三十一日

–

Note:

Particulars regarding impairment testing on godwil are disclosed in

Note 18 to the consolidated financial statements.

18. IMPAIRMENT TESTING ON

NON-FINANCIAL ASETS INCLUDING

GODWIL

The Group tests for impairment of godwil anualy and

in the financial year in which the acquisition takes place, or

more frequently if there are indications that godwil might

be impaired.

For the purpose of impairment testing, the carying amount

of godwil has ben alocated to the CGU comprising the

operations of Beijing Huicheng Hospital Co., Ltd (“Beijing

Huicheng”) (formerly known as Beijing Zijing Hospital

Co., Limited), which is engaged in the provision of general

hospital services in the PRC.

The godwil asociated with Beijing Huicheng was fuly

impaired as at 31 March 2022.

As at 31 March 2025, property, plant and equipment

(including alocated corporate asets) that generate cash

flows were included in the CGU of Beijing Huicheng for

impairment asesment. During the year ended 31 March

2024, right-of-use asets were also included in the CGU for

this purpose.

17.

商誉

附注：

有关商誉减值测试之详情于综合财务报表附

注

中披露。

18.

非金融资产（包括商誉）减值测

试

本集团于每年及于进行收购之财政年度

均会测试商誉有否减值，当有迹象表明

商誉可能减值时，会更频密测试。

就减值测试而言，商誉的账面值已分配

至现金产生单位，该现金产生单位包括

于中国从事提供综合性医院服务的北京

惠城医院有限公司（「北京惠城」）（前称

北京紫荆医院有限公司）的业务。

于二零二年三月三十一日，与北京惠

城有关的商誉已悉数减值。

于二零二五年三月三十一日，产生现金

流量之物业、厂房及设备（包括已分配企

业资产）已计入北京惠城之现金产生单

位以进行减值评估。于截至二零二四年

三月三十一日止年度，使用权资产亦就

此目的计入现金产生单位。

---

金威医疗集团有限公司

2024/2025

年报

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

18. IMPAIRMENT TESTING ON

NON-FINANCIAL ASETS INCLUDING

GODWIL – continued

Beijing Huicheng – Provision of general hospital

services in the PRC

During the year ended 31 March 2024, the recoverable

amount of this CGU was determined by the Directors

with reference to a profesional valuation report isued

by an independent firm of profesionaly qualified valuers,

which was based on a value in use calculation using cash

flow projections based on financial budgets aproved

by management covering a five-year period, and a pre-

tax discount rate of 11.79% per anum. The cash flow

projections during the budgeted period were based on the

same expected gros margins of 48.5% throughout the

budget period. The cash flows beyond that five-year period

were extrapolated using an average growth rate of 7.6%

per anum, based on the CGU’s past performance and

management’s expectations for market development.

The Directors considered the increase in operating costs,

ken competition among hospital service providers, and the

suspension of operation of Beijing Huicheng from January

to April 2024 (please refer to the anouncements of the

Company dated 3 January 2024, 31 January 2024 and 22

April 2024). Based on the valuation report, the carying

amount of the CGU exceded its recoverable amount,

and impairment loses of aproximately HK$749,000 and

aproximately HK$2,777,000 were recognised on right-of-

use asets and property, plant and equipment, respectively,

during the year ended 31 March 2024.

18.

非金融资产（包括商誉）减值测

试－续

北京惠城－于中国提供综合性医院

服务

于截至二零二四年三月三十一日止年

度，此现金产生单位之可收回金额由董

事经参考由专业合资格估值师组成的独

立公司根据使用价值计算发布的专业估

值报告后厘定，而使用价值计算根据管

理层所批准之涵盖五年期财务预算所得

出之现金流量预测，以及除税前贴现率

每年

11.79%

计算。预算期内之现金流

量预测，乃基于整个预算期内相同之预

测毛利率

48.5%

计算。根据现金产生单

位之过往表现及管理层对市场发展之预

期，该五年期后之现金流量已采用

7.6%

之平均年增长率推断。

董事已考虑运营成本日益增加，医院服

务提供商之激烈竞争及北京惠城于二零

二四年一月至四月暂停营运（请参阅本

公司日期为二零二四年一月三日、二零

二四年一月三十一日及二零二四年四月

二十二日之公告）。根据估值报告，于截

至二零二四年三月三十一日止年度内，

该现金产生单位的账面值高于其可收回

金额，故已就使用权资产及物业、厂房

及设备分别确认减值亏损约

749,000

港

元及约

2,777,000

港元。

---

2025
二零二五年 HK$’000
千港元
–
–
–

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/2025146

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

18. IMPAIRMENT TESTING ON

NON-FINANCIAL ASETS INCLUDING

GODWIL – continued

Beijing Huicheng – Provision of general hospital

services in the PRC – continued

During the year ended 31 March 2025, the Directors

considered the prolonged suspension of operations of

Beijing Huicheng, including the suspension from January

to April 2024 (please refer to the anouncements of the

Company dated 3 January 2024, 31 January 2024 and 22

April 2024) and the further suspension since December 2024

(please refer to the anouncements of the Company dated

13 December 2024 and 10 February 2025), as the primary

factor for impairment asesment. Other factors, such as the

increase in operating costs and ken competition among

hospital service providers, were also taken into acount

as they may afect the CGU’s prospects should operations

resume in the future. In view of these factors, together with

the fact that the carying amounts of property, plant and

equipment (including alocated corporate asets) within the

CGU had already ben reduced to their recoverable amounts

through impairment loses recognised in the prior year, the

Directors concluded that no aditional impairment los was

required for the year ended 31 March 2025.

19. DEFERED TAX

二零二四年

HK$’000

千港元

Defered tax asets

递延税项资产

–

Defered tax liabilities

递延税项负债

–

–

18.

非金融资产（包括商誉）减值测

试－续

北京惠城－于中国提供综合性医院

服务－续

于截至二零二五年三月三十一日止年

度，董事认为北京惠城长期暂停营运（包

括于二零二四年一月至四月暂停营运）

（请参阅本公司日期为二零二四年一月

三日、二零二四年一月三十一日及二零

二四年四月二十二日之公告）及自二零

二四年十二月起进一步暂停营运（请参

阅本公司日期为二零二四年十二月十三

日及二零二五年二月十日之公告）为减

值评估的主要因素。运营成本增加及医

院服务提供商之激烈竞争等因素亦已纳

入考量，因此等因素或会影响该现金产

生单位的前景（倘日后恢复营运）。鉴于

上述因素，加上该现金产生单位内之物

业、厂房及设备（包括已分配企业资产）

的账面值已透过于过往年度确认的减值

亏损降至其可收回金额，董事得出结论

认为截至二零二五年三月三十一日止年

度无需再确认额外减值亏损。

19.

递延税项

---

2025
二零二五年 HK$’000
千港元
–

金威医疗集团有限公司

2024/2025

年报

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

19. DEFERED TAX – continued

The folowing are the defered tax asets/(liabilities)

recognised and movements thereon during the curent and

prior years:

Right-of-use

asets

Lease

liabilitiesTotal

使用权资产租赁负债总计

HK$’000HK$’000HK$’000

千港元千港元千港元

At 1 April 2023 (restated)

于二零二三年四月一日

（经重述）

(1,179)1,179–

(Charged)/credited to profit

or los

（扣除自）╱计入损益

320(320)–

Exchange realignment

汇兑调整

49(49)–

At 31 March 2024

于二零二四年三月三十一日

(810)810–

(Charged)/credited to profit

or los

（扣除自）╱计入损益

808(808)–

Exchange realignment

汇兑调整

(2)2–

At 31 March 2025

于二零二五年三月三十一日

–

20. INVENTORIES

二零二四年

HK$’000

千港元

Finished gods

制成品

1,063

19.

递延税项－续

以下为已确认递延税项资产╱（负债）及

其于本年度及过往年度之变动：

20.

存货

---

2025
二零二五年 HK$’000
千港元
3,751
1.744
5,495
(1,081)
4,414
–
4,414

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/2025148

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

21. OTHER RECEIVABLES, DEPOSITS AND

PREPAYMENTS

二零二四年

HK$’000

千港元

Prepayments (note (b)

预付款项（附注

(b)

）

2,695

Other receivables and deposits (note (c)

其他应收款项及按金（附注

(c)

）

1,334

4,029

Les: Alowance for expected credit loses

减：预期信贷亏损拨备

–

4,029

Les: Non-curent portion – rental deposits

(note (d)

减：非流动部分－租赁按金

（附注

(d)

）

(268)

3,761

Notes:

(a) Details of impairment asesment of other receivables for the

years ended 31 March 2025 and 2024 under expected credit

los model of HKFRS 9 are set out in Note 32(b).

(b) As at 31 March 2025, the prepayments mainly represents

the advance payments for online search engine advertising

of aproximately HK$1,782,000 (2024: aproximately

HK$1,686,000) and staf dormitory rentals of aproximately

HK$910,000 (2024: aproximately HK$610,000).

21.

其他应收款项、按金及预付款

项

附注：

(a)

根据香港财务报告准则第

号之预期信

贷亏损模式，截至二零二五年及二零

二四年三月三十一日止年度之其他应

收款项的减值评估详情载于附注

32(b)

。

(b)

于二零二五年三月三十一日，预付款

项主要指在线搜索引擎广告预付款

约

1,782,000

港元（二零二四年：约

1,686,000

港元）及员工宿舍租金约

910,000

港元（二零二四年：约

610,000

港元）。

---

2025
二零二五年 HK$’000
千港元
316

金威医疗集团有限公司

2024/2025

年报

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

21. OTHER RECEIVABLES, DEPOSITS AND

PREPAYMENTS – continued

Notes: – continued

(c) As at 31 March 2025, other receivables and deposits mainly

represent the deposits for online search engine advertising

services of aproximately HK$257,000 (2024: aproximately

HK$866,000), rental deposits for staf dormitory and

ofice of aproximately HK$111,000 (2024: aproximately

HK$424,000).

(d) As at 31 March 2024, the non-curent portion of deposits

represents the refundable rental deposit of aproximately

HK$268,000.

22. FINANCIAL ASETS AT FAIR VALUE

THROUGH PROFIT OR LOS

二零二四年

HK$’000

千港元

Financial asets at fair value

through profit or los:

按公平值计入损益之金融资产：

Listed securities held for trading:

持作买卖之上市证券：

– Equity securities listed in Hong Kong

—于香港上市之股本证券

21.

其他应收款项、按金及预付款

项－续

附注：－续

(c)

于二零二五年三月三十一日，其他应收

款项及按金主要指在线搜索引擎广告

服务按金约

257,000

港元（二零二四年：

约

866,000

港元）、员工宿舍及办公室租

赁按金约

111,000

港元（二零二四年：约

424,000

港元）。

(d)

于二零二四年三月三十一日，按金之非

流动部分指可退回租赁按金约

268,000

港元。

22.

按公平值计入损益之金融资产

---

2025
二零二五年 HK$’000
千港元
3,829
–
3,829

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/2025150

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

23. CASH AND BANK BALANCES

二零二四年

HK$’000

千港元

Cash and bank balances

现金及银行结余

3,644

Les: Restricted bank deposit

减：受限制银行存款

(1,503)

Cash and cash equivalent

现金及现金等值项目

2,141

Bank balances carying interest at market rate ranges from

0.01% to 0.25% (2024: from 0.01% to 0.25%) per anum.

As at 31 March 2025, cash and bank balances of the

Group included curencies denominated in Renminbi

(“RMB”) amounted to aproximately HK$3,448,000 (2024:

HK$3,222,000). RMB is not frely convertible into foreign

curencies in the PRC. Under the PRC’s Foreign Exchange

Control Regulations and Administration of Setlement, Sale

and Payment of Foreign Exchange Regulations, the Group is

permited to exchange RMB for foreign curencies through

banks authorisation to conduct foreign exchange busines.

As at 31 March 2024, the Group’s bank balances of

RMB1,388,000 (equivalent to HK$1,503,000) was restricted

due to the civil complaint filed with the People’s Court

of Qianhai Shenzhen City by China Merchants Hainan

Development Investment Co, Ltd. (Note 37).

Bank balances are deposits with creditworthy banks with no

recent history of default.

23.

现金及银行结余

银行结余按市场年利率介乎

0.01%

至

0.25%

（二零二四年：介乎

0.01%

至

0.25%

）计息。

于二零二五年三月三十一日，本集团之

现金及银行结余包括以人民币（「人民

币」）计值为数约

3,448,000

港元（二零

二四年：

3,222,000

港元）之款项。人民币

于中国不可自由兑换为外币。根据中国

外汇管制条例及结汇、售汇及付汇管理

规定，本集团获准透过获授权进行外汇

业务之银行将人民币兑换为外币。

于二零二四年三月三十一日，因招商局

海南开发投资有限公司向深圳前海合作

区人民法院发起民事诉状，本集团人民

币

1,388,000

元（相当于

1,503,000

港元）

的银行结余被冻结（附注

）。

银行结余为于近期并无拖欠还款记录且

信誉良好银行之存款。

---

2025
二零二五年 HK$’000
千港元
286
5,767
6,053

2025
二零二五年 HK$’000
千港元
–
–
–
286
286

金威医疗集团有限公司

2024/2025

年报

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

24. TRADE AND OTHER PAYABLES

二零二四年

HK$’000

千港元

Trade payables

贸易应付款项

1,270

Acruals and other payables (Note)

应计费用及其他应付款项（附注）

14,240

15,510

Note:

As at 31 March 2025, the acruals and other payables mainly

represents the acrued salaries of aproximately HK$1,263,000.

As at 31 March 2024, the acruals and other payables mainly

represents the provision for legal claims of aproximately

RMB8,151,000 (equivalent to aproximately HK$8,827,000) (Note

37), provision of liquidated damages and costs of aproximately

RMB1,400,000 (equivalent to aproximately HK$1,512,000) and

acrued salaries of aproximately HK$1,853,000.

The folowing is an aged analysis of trade payables presented

based on invoice date at the end of the reporting period:

二零二四年

HK$’000

千港元

0 to 90 days0

至

日

–

91 to 180 days91

至

日

181 to 365 days181

至

日

–

Over 365 days

超过

日

1,270

The average credit period on purchases of certain gods is in

range from 30 to 90 days (2024: 30 to 90 days).

24.

贸易及其他应付款项

附注：

于二零二五年三月三十一日，应计费用及其

他应付款项主要指应计薪资约

1,263,000

港

元。

于二零二四年三月三十一日，应计费用及其

他应付款项主要指法律索偿拨备约人民币

8,151,000

元（相当于约

8,827,000

港元）（附

注

）、违约赔偿金及费用拨备约人民币

1,400,000

元（相当于约

1,512,000

港元）及应

计薪资约

1,853,000

港元。

下文为于报告期末按发票日期呈列之贸

易应付款项之账龄分析：

购买若干货品之平均信贷期介乎

至

日（二零二四年：

至

日）。

---

2025
二零二五年 HK$’000
千港元
–
–
–
–
–
–

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/2025152

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

25. LEASE LIABILITIES

二零二四年

HK$’000

千港元

Lease liabilities payable:

应付租赁负债：

Within one year

一年内

3,006

Within a period of more than one year but

not exceding two years

一年后但不超过两年期间

1,088

Within a period of more than two years but

not later than five years

两年后但不超过五年期间

1,036

5,130

Les: Amounts due for setlement within

12 months shown under curent

liabilities

减：应于

个月内结付之款项，

于流动负债项下列示

(3,006)

Amounts due for setlement after

12 months shown under non-curent

liabilities

应于

个月后结付之款项，

于非流动负债项下列示

2,124

As at 31 March 2024, the weighted average incremental

borowing rate aplied to lease liabilities is 7.5% per anum.

25.

租赁负债

于二零二四年三月三十一日，应用于租

赁负债之加权平均增量借贷率为每年

7.5%

。

---

2025
二零二五年 HK$’000
千港元
10,100
429
10,529
10,529

金威医疗集团有限公司

2024/2025

年报

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

26. BOROWINGS

二零二四年

HK$’000

千港元

Loans from a director – unsecured (note (a)

来自一名董事之贷款－无抵押

（附注

(a)

）

4,500

Other loans – unsecured (note (b)

其他贷款－无抵押（附注

(b)

）

2,599

7,099

Carying amount repayable:

应偿还账面值：

Within one year or on demand

一年内或按要求

7,099

Notes:

(a) As at 31 March 2025, loans from a director were unsecured,

bearing fixed interest rate at 6% per anum and repayable

within twelve months.

(b) As at 31 March 2025, the Group’s unsecured other loans

borowings were clasified as curent liabilities, and were

unsecured, interest-fre and repayable on demand.

26.

借款

附注：

(a)

于二零二五年三月三十一日，来自一名

董事之贷款为无抵押，按固定年利率

6%

计息及于十二个月内偿还。

(b)

于二零二五年三月三十一日，本集团之

无抵押其他贷款借款获分类为流动负

债，为无抵押，免息及按要求偿还。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/2025154

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

27. SHARE CAPITAL

Number of sharesAmount

股份数目金额

HK$’000

千港元

Authorised:

法定：

Ordinary shares of HK$0.01 each (before

share consolidation) and HK$0.05 each

(after share consolidation)

每股面值

0.01

港元（于股份合并前）

及每股面值

0.05

港元（于股份合并

后）之普通股

At 1 April 2023

于二零二三年四月一日

110,000,000,0001,100,000

Share consolidation (Note (i)

股份合并（附注

(i)

）

(88,000,000,000)–

At 31 March 2024, 1 April 2024 and

31 March 2025

于二零二四年三月三十一日、

二零二四年四月一日及

二零二五年三月三十一日

22,000,000,0001,100,000

Non-voting convertible preference

shares of HK$0.01 each

(before share consolidation)

and HK$0.05 each

(after share consolidation) (Note (i)

每股面值

0.01

港元（于股份合并前）及

每股面值

0.05

港元

（于股份合并后）之无投票权可换股

优先股（附注

(i)

）

At 1 April 2023

于二零二三年四月一日

40,000,000,000400,000

Share consolidation (Note (i)

股份合并（附注

(i)

）

(32,000,000,000)–

At 31 March 2024, 1 April 2024 and

31 March 2025

于二零二四年三月三十一日、

二零二四年四月一日及

二零二五年三月三十一日

8,000,000,000400,000

27.

股本

---

金威医疗集团有限公司

2024/2025

年报

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

Number of sharesAmount

股份数目金额

HK$’000

千港元

Isued and fuly paid:

已发行及悉数缴足：

Ordinary shares of HK$0.01 each

(before share consolidation)

and HK$0.05 each

(after share consolidation)

每股面值

0.01

港元（于股份合并前）及

每股面值

0.05

港元

（于股份合并后）之普通股

At 1 April 2023

于二零二三年四月一日

2,818,249,94428,183

Share consolidation (Note (i)

股份合并（附注

(i)

）

(2,254,599,956)–

At 31 March 2024, 1 April 2024 and

31 March 2025

于二零二四年三月三十一日、

二零二四年四月一日及

二零二五年三月三十一日

563,649,98828,183

Non-voting convertible preference

shares of HK$0.01 each

(before share consolidation)

and HK$0.05 each

(after share consolidation) (Note (i)

每股面值

0.01

港元（于股份合并前）及

每股面值

0.05

港元

（于股份合并后）之无投票权可换股

优先股（附注

(i)

）

At 1 April 2023

于二零二三年四月一日

98,500,000985

Share consolidation (Note (i)

股份合并（附注

(i)

）

(78,800,000)–

At 31 March 2024, 1 April 2024 and

31 March 2025

于二零二四年三月三十一日、

二零二四年四月一日及

二零二五年三月三十一日

19,700,000985

27.

股本－续

27. SHARE CAPITAL – continued

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/2025156

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

27. SHARE CAPITAL – continued

Notes:

(i) The convertible preference shares are non-voting shares and

non-redemable. The holders of the convertible preference

shares are entitled to receive the same dividends as the

holders of ordinary shares. In adition, the holders of the

convertible preference shares have the right to convert any

convertible preference share into the Company’s ordinary

shares at any time at the conversion price at the rate of 1 to 1

each. The conversion price wil be subject to adjustments only

upon ocurence of certain dilutive events.

(i) On 9 August 2023, the directors of the Company

proposed to implement a share consolidation (the “Share

Consolidation”) on the basis that (i) every five (5) isued and

unisued ordinary shares (the “Existing Share(s)”) in the

then existing share capital of the Company of HK$0.01 each

into one (1) consolidated ordinary share (the “Consolidated

Share(s)”) of HK$0.05 each; and (i) every five (5) isued

and unisued non-voting convertible preference share(s)

(the “Existing Preference Share(s)”) in the then existing

share capital of the Company of HK$0.01 each into one (1)

consolidated convertible preference share (the “Consolidated

Preference Share(s)”) of HK$0.05 each.

Folowing the pasing of the ordinary resolution aproving the

Share Consolidation by the shareholders of the Company and

the fulfilment of al the conditions precedent of the Share

Consolidation, the Share Consolidation has become efective

on 13 September 2023. Further details regarding the Share

Consolidation were set out in the Company’s circular dated

23 August 2023 and the Company’s anouncements dated 9

August 2023, 11 September 2023 and 12 September 2023.

There was no exercise of any conversion rights ataching to

the Existing Preference Shares or Consolidated Preference

Shares (as the case may be) during the year ended 31 March

2025 (2024: Nil).

27.

股本－续

附注：

(i)

可换股优先股为无投票权股份及不可

赎回。可换股优先股持有人有权获发与

普通股持有人相同之股息。此外，可换

股优先股持有人有权随时按

1:1

之比率

按换股价将可换股优先股转换成本公

司普通股。换股价仅于发生若干摊薄事

项时方可予以调整。

(i)

于二零二三年八月九日，本公司董事建

议按照

(i)

将本公司当时现有股本中每五

(5)

股每股面值

0.01

港元之已发行及未

发行普通股（「现有股份」）合并为一

(1)

股每股面值

0.05

港元之合并普通股（「合

并股份」）；及

(i)

将本公司当时现有股

本中每五

(5)

股每股面值

0.01

港元之已

发行及未发行无投票权可换股优先股

（「现有优先股」）合并为一

(1)

股每股面

值

0.05

港元之合并可换股优先股（「合并

优先股」）的基准实施股份合并（「股份

合并」）。

于本公司股东通过批准股份合并之普

通决议案及达成股份合并之所有先决

条件后，股份合并已于二零二三年九月

十三日生效。有关股份合并之进一步详

情载于本公司日期为二零二三年八月

二十三日之通函以及本公司日期为二

零二三年八月九日、二零二三年九月

十一日及二零二三年九月十二日之公

告。

截至二零二五年三月三十一日止年度，

现有优先股或合并优先股（视情况而定）

所附带的任何换股权均未行使（二零

二四年：无）。

---

金威医疗集团有限公司

2024/2025

年报

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

28. RESERVES

(a) The contributed surplus of the Company represents

the diference betwen the agregate net asets of the

subsidiaries acquired by the Company under the group

reorganisation in 2001 and the nominal amount of the

Company’s shares isued for the acquisition.

(b) For the years ended 31 March 2025 and 2024, the

Company had no distributable reserves (including

share premium, capital reserve and acumulated los).

Under the Companies Law (Revised) Chapter 22 of

the Cayman Islands, the share premium acount of

the Company is available for paying distributions or

dividends to shareholders subject to the provisions

of its Memorandum and Articles of Asociation and

provided that imediately folowing the distribution

or dividend the Company is able to pay its debt as

they fal due in the ordinary course of busines. In

acordance with the Company’s Articles of Asociation,

dividends shal be distributed out of the retained profits

or other reserves, including the share premium acount

and capital reserve of the Company.

28.

储备

(a)

本公司之缴入盈余指本公司根据

于二零一年之集团重组所收购

之附属公司之总资产净值与本公

司就收购发行之股份之面值两者

间之差额。

(b)

截至二零二五年及二零二四年三

月三十一日止年度，本公司概无可

供分派储备（包括股份溢价、资本

储备及累计亏损）。根据开曼群岛

公司法（经修订）第

章，在本公司

之组织章程大纲及细则规限下，如

紧随分派或派息后本公司有能力

偿还其于日常业务过程中到期之

债务，则本公司之股份溢价账可以

分派或以股息方式派付予股东。根

据本公司之组织章程细则，股息须

自本公司保留溢利或其他储备（包

括股份溢价账及资本储备）拨付。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/2025158

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

29. SHARE OPTION SCHEME

The Company adopted a share option scheme on 20 April

2002 (the “2002 Share Option Scheme”), which was

terminated by the shareholders at the anual general

meting of the Company held on 10 August 2011. Pursuant

to the 2002 Share Option Scheme, the Company may grant

options at HK$1 per ofer to any director, employe, any

suplier of gods or services, any customer, any person or

entity that provides research, development or other technical

suport or any shareholder of the Group or any investe or

any holder of any securities isued by any member of the

Group or any investe, for the primary purpose of providing

incentives to them, to subscribe for shares in the Company.

The total number of shares in respect of which options may

be granted under the 2002 Share Option Scheme shal not

exced 10% of the isued share capital of the Company

from time to time. No participant shal be granted an option,

if exercise in ful, would result in the total number of shares

already isued under al the options granted to him or her

that are for the time being subsisting and unexercised in

any 12-month period would exced 1% of the total number

of shares in isue. The exercise price of the share wil be

determined at the higher of the average of closing prices of

the shares on the Stock Exchange on the five trading days

imediately preceding the date of grant of the options; the

closing price of the shares on the Stock Exchange on the

date of grant; and the nominal value of the shares. The share

options are exercisable for a period not later than 10 years

from the date of grant.

Folowing the expiry of the 2002 Share Option Scheme, no

further share option may be or has ben granted thereunder.

As at 31 March 2025, no share option was outstanding

under the 2002 Share Option Scheme (2024: Nil).

29.

购股权计划

本公司于二零二年四月二十日采纳

一项购股权计划（「二零二年购股权

计划」），其由股东于本公司于二零一

年八月十日举行之股东周年大会上终

止。根据二零二年购股权计划，本公

司可以每项授出购股权建议收取

港元

之代价向本集团任何董事、雇员、任何

货品或服务供应商、任何客户以及提供

研究、开发或其他技术支援之任何人士

或实体，或本集团或任何受投资实体之

任何股东或本集团任何成员公司或受投

资实体所发行任何证券之任何持有人授

出可认购本公司股份之购股权，以奖励

上述人士。根据二零二年购股权计划

可予授出之购股权涉及之股份总数不得

超过本公司不时已发行股本

10%

。倘于

悉数行使后，将导致于任何十二个月期

间根据授予一名参与者之全部于当时已

存在且尚未行使之购股权而已发行之股

份总数，超逾已发行股份总数

1%

，则不

得向该参与者授出购股权。股份之行使

价将以股份于紧接授出购股权日期前五

个交易日在联交所之平均收市价；股份

于授出日期在联交所之收市价；及股份

面值三者中之较高者厘定。购股权可于

不迟于自授出日期起计

年之期间内行

使。

二零二年购股权计划届满后，不可且

并无据其进一步授出购股权。

于二零二五年三月三十一日，二零二

年购股权计划项下并无尚未行使购股权

（二零二四年：无）。

---

金威医疗集团有限公司

2024/2025

年报

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

29. SHARE OPTION SCHEME – continued

The Company also adopted a share option scheme (the

“2011 Share Option Scheme”) on 10 August 2011, which

has expired on the tenth aniversary of the date of adoption.

Pursuant to the 2011 Share Option Scheme, the Company

may grant options not les than the highest of (1) the closing

price of the shares as stated in the daily quotations shet of

the Stock Exchange on the date of grant, which must be a

busines day; (2) the average closing price of the shares as

stated in the daily quotations shets of the Stock Exchange

for the five busines days imediately preceding the date

of the grant; and (3) the nominal value of the share on the

date of grant to any employe of the Company or any of

its subsidiaries including any executive and non-executive

directors of the Company or any of its subsidiaries, and any

supliers, consultants, agents and advisers or any person

who, in the sole discretion of the Board, has contributed or

may contribute to the Group. The total numbers of shares

may be isued upon exercise of al outstanding options

granted and yet to be exercised under the 2011 Share

Option Scheme and any other share option schemes of the

Company must not exced 30% of the relevant clas of

shares in isue from time to time. No options may be granted

under the 2011 Share Option Scheme or any other share

option schemes of the Company if this wil result in this limit

being exceded. Any grant of options to a conected person

(including but not limited to a director, chief executive or

substantial shareholder) or its asociates must be aproved

by the independent non-executive directors (excluding any

independent nonexecutive director who is the grante of

the options). No participant shal be granted an option, if

exercise in ful, would result in the total number of share

isued and to be isued upon exercise of the options

granted to him or her that for the time being subsisting and

unexercised in any 12-month period would exced 1% of

the total number of shares in isue. The share options are

exercisable for a period not later than 10 years from the date

of grant but subject to the early termination of the 2011

Share Option Scheme.

Folowing the expiry of the 2011 Share Option Scheme, no

further share option may be or has ben granted thereunder.

As at 31 March 2025, no share option was outstanding

under the 2011 Share Option Scheme (2024: Nil).

29.

购股权计划－续

本公司亦于二零一年八月十日采纳

一项购股权计划（「二零一年购股权

计划」），其已于采纳日期第十周年之日

届满。根据二零一年购股权计划，本

公司可向本公司或其任何附属公司之

任何雇员，包括本公司或其任何附属公

司之任何执行及非执行董事，及任何供

应商、顾问、代理及咨询人或董事会全

权酌情认为对本集团曾经或可能作出贡

献之任何人士授出购股权，惟行使价不

得低于下列各项最高者：

(1)

联交所每日

报价表所报股份于授出日期（须为营业

日）之收市价；

(2)

联交所每日报价表所

报股份于紧接授出日期前五个营业日之

平均收市价；及

(3)

股份于授出日期之面

值。因行使根据二零一年购股权计划

及本公司任何其他购股权计划授出而尚

未行使的所有购股权而可发行的股份总

数，不得超过不时已发行相关类别股份

的

30%

。若有关行使将导致此上限被超

逾，则不可根据二零一年购股权计划

或本公司任何其他购股权计划授出购股

权。向关连人士（包括但不限于董事、主

要行政人员或主要股东）或其联系人士

授出任何购股权，均须获得独立非执行

董事（不包括身为购股权承授人的任何

独立非执行董事）批准。倘悉数行使后，

将导致于任何十二个月期间因行使其获

授的购股权（当时续存及未获行使者）而

已发行及将予发行的股份总数超过已发

行股份总数的

1%

，任何参与者概不会

获授购股权。购股权可于不迟于自授出

日期起计

年之期间内予以行使，惟须

受提早终止二零一年购股权计划所规

限。

二零一年购股权计划届满后，不可且

并无据其进一步授出购股权。

于二零二五年三月三十一日，二零一

年购股权计划项下并无尚未行使购股权

（二零二四年：无）。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/2025160

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

30. RETIREMENT BENEFITS SCHEME

The Group operates a Mandatory Provident Fund Scheme

(the “Scheme”) for al qualifying employes in Hong Kong.

The asets of the Scheme are held separately from those of

the Group in funds under the control of truste. The Group

contributes 5% of relevant payrol costs to the Scheme,

which contribution is matched by employes.

The employes of the Company’s PRC subsidiaries are

members of the state-managed retirement benefits scheme

operated by the PRC government. The Company’s PRC

subsidiaries are required to contribute a certain percentage

of their payrol to the retirement benefits scheme to fund

the benefits. The only obligation of the Group with respect

to the retirement benefits scheme is to make the required

contributions under the scheme.

During the years ended 31 March 2025 and 2024, there was

no forfeiture of retirement benefits schemes contributions

(by employers on behalf of employes who leave the scheme

prior to vesting fuly in such contributions) in the Group. As

at 31 March 2025 and 2024, no forfeited contribution under

the retirement benefits schemes of the Group is available to

reduce the contribution payable in future years.

30.

退休福利计划

本集团为香港全体合资格雇员设立强制

性公积金计划（「计划」）。计划之资产与

本集团之资产分开持有，存入由信托人

控制之基金。本集团按相关薪酬成本

5%

向计划供款，雇员亦会作出相应供款。

本公司中国附属公司之雇员为中国政府

运作之国家管理退休福利计划成员。本

公司之中国附属公司须按薪酬开支之若

干百分比向退休福利计划供款以拨付退

休福利。本集团就退休福利计划之唯一

责任为根据计划作出所需供款。

截至二零二五年及二零二四年三月

三十一日止年度，本集团并无没收任何

退休福利计划供款（即雇员在有关供款

悉数归其所有前退出该计划，由雇主代

雇员处理的供款）。于二零二五年及二零

二四年三月三十一日，本集团之退休福

利计划项下并无任何被没收供款可用于

扣减未来年度之应缴供款。

---

2025
二零二五年 HK$’000
千港元
10,529
(3,829)
6,700
(6,755)
NA
不适用

金威医疗集团有限公司

2024/2025

年报

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

31. CAPITAL RISK MANAGEMENT

The Group manages its capital to ensure that entities in

the Group wil be able to continue as a going concern

while maximising the return to stakeholders through the

optimisation of the debt and equity balance. The Group’s

overal strategy remains unchanged from prior year.

The capital structure of the Group consists of debts (which

include borowings and lease liabilities), cash and bank

balances and equity atributable to equity holders of the

Company, comprising isued share capital and reserves.

Gearing ratio

The gearing ratio at 31 March 2025 and 2024 was as

folows:

二零二四年

HK$’000

千港元

Debt (Note (a)

债务（附注

(a)

）

12,229

Cash and bank balances

现金及银行结余

(3,644)

Net debt

净债务

8,585

Equity (Note (b)

股本（附注

(b)

）

1,407

Net debt to equity ratio

净债务对资本比率

610.16%

Notes:

(a) Debt comprises lease liabilities and borowings as detailed

in Notes 25 and 26 to the consolidated financial statements

respectively.

(b) Equity includes al capital and reserves of the Group.

As part of review, the management considers the cost

of capital and risk asociated with each clas of capital.

Based on recomendation of the manager, the Group wil

balance its overal capital structure through the payment of

dividends, the isue of new shares and new debts.

31.

资本风险管理

本集团管理其资本以确保本集团之实

体将能持续经营，并通过优化债务及权

益结余为股东带来最大回报。于过往年

度，本集团之整体策略维持不变。

本集团之资本结构包括债务（包括借款

及租赁负债）、现金及银行结余以及本公

司权益持有人应占股本（包括已发行股

本及储备）。

资本负债比率

于二零二五年及二零二四年三月三十一

日之资本负债比率如下：

附注：

(a)

债务包括分别于综合财务报表附注

及

详述之租赁负债及借款。

(b)

股本包括本集团之全部资本及储备。

作为审阅之一部分，管理层认为，资本

成本及风险与各类资本相关。根据管理

人的推荐建议，本集团将透过派付股

息、发行新股及新债平衡其整体资本架

构。

---

2025
二零二五年 HK$’000
千港元
316
1,744
3,829
5,767
–

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/2025162

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

32. FINANCIAL INSTRUMENTS

Categories of financial instruments

二零二四年

HK$’000

千港元

Financial asets

金融资产

Financial asets at FVTPL

按公平值计入损益之金融资产

Financial asets at amortised cost:

按摊销成本之金融资产：

– Other receivables and deposits

－其他应收款项及按金

1,334

– Cash and bank balances

－现金及银行结余

3,644

Financial liabilities

金融负债

Financial liabilities at amortised cost:

按摊销成本之金融负债：

– Trade and other payables

－贸易及其他应付款项

5,170

– Lease liabilities

－租赁负债

5,130

Financial risk management objectives and policies

The Group’s activities expose it to a variety of financial

risks: market risk (including curency risk and interest rate

risk), credit risk and liquidity risk. The Group’s overal risk

management programe focuses on the unpredictability

of financial markets and seks to minimise potential

adverse efects on the Group’s financial performance. The

management manages and monitors these exposures to

ensure apropriate measures are implemented on a timely

and efective maner.

32.

金融工具

金融工具分类

财务风险管理目标及政策

本集团之业务面对多种财务风险：市场

风险（包括货币风险及利率风险）、信贷

风险及流动资金风险。本集团之整体风

险管理方案著重于未能预测的金融市

场，务求将对本集团财务表现之潜在不

利影响减至最低。管理层管理及监察该

等风险，确保以及时有效之方式实施有

关措施。

---

金威医疗集团有限公司

2024/2025

年报

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

32. FINANCIAL INSTRUMENTS – continued

Financial risk management objectives and policies

– continued

(a) Market risk

The Group’s activities expose it primarily to the

financial risks of changes in foreign exchange rates,

price risk and interest rates.

Market risk exposures are measured using sensitivity

analysis.

There has ben no change to the Group’s exposure to

market risks or the maner in which it manages and

measures the risk.

Foreign curency risk management

The Group has minimal exposures to foreign curency

risk as most of its busines transactions, asets and

liabilities are principaly denominated in the functional

curencies of the respective subsidiaries. The Group

curently does not have a foreign curency hedging

policy in respect of foreign curency transactions,

asets and liabilities. The Group wil monitor its foreign

curency exposure closely and wil consider hedging

significant foreign curency exposure should the ned

arise.

32.

金融工具－续

财务风险管理目标及政策－续

(a)

市场风险

本集团之业务主要令本集团承受

汇率、价格风险及利率变动之财务

风险。

所承受之市场风险以敏感度分析

计量。

本集团所承受之市场风险或管理

及计量风险之方法并无变动。

外币风险管理

本集团之外币风险甚微，原因为本

集团之大部份业务交易、资产及负

债主要以有关附属公司之功能货

币计值。本集团目前并无有关外币

交易、资产及负债之外币对冲政

策。本集团将严密监控其外币风

险，并将于有必要时考虑对冲重大

外币风险。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/2025164

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

32. FINANCIAL INSTRUMENTS – continued

Financial risk management objectives and policies

– continued

(a) Market risk – continued

Price risk

The Group is exposed to equity price risk through its

investments in equity securities and debt instruments

measured at FVTPL. For equity securities and debt

instruments measured at FVTPL quoted in The Stock

Exchange of Hong Kong Limited.

Sensitivity analyses

The sensitivity analyses have ben determined based on

the exposure to equity price risk at the reporting date.

For sensitivity analysis of equity securities and debt

instruments with fair value measurement categorised

within Level 1.

If the prices of the respective equity instruments and

debt instruments had ben 10% (2024: 10%) higher/

lower, the post-tax profit for the year ended 31 March

2025 would increase/decrease by HK$32,000 (2024:

increase/decrease by HK$24,000) as a result of the

changes in fair value of investments at FVTPL.

Interest rate risk

No significant cash flow interest rate risk during

the year ended 31 March 2025 and 2024 as the

borowings were bearing fixed interest rate.

32.

金融工具－续

财务风险管理目标及政策－续

(a)

市场风险－续

价格风险

本集团因其按公平值透过损益列

账之方式计量之股本证券及债务

工具投资而承受股本价格风险。股

本证券及债务工具以香港联合交

易所有限公司之报价而按公平值

透过损益列账之方式计量。

敏感度分析

敏感度分析已根据于报告日期所

承受的股本价格风险厘定。按公平

值计量之股本证券及债务工具敏

感度分析分类于第一级内。

倘相关股本工具及债务工具的价

格已上升╱下跌

10%

（二零二四

年：

10%

），则由于按公平值透

过损益列账之投资公平值变动，

截至二零二五年三月三十一日止

年度的除税后溢利将增加╱减少

32,000

港元（二零二四年：增加╱

减少

24,000

港元）。

利率风险

由于借款按固定利率计息，故于截

至二零二五年及二零二四年三月

三十一日止年度概无重大现金流

量利率风险。

---

金威医疗集团有限公司

2024/2025

年报

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

32. FINANCIAL INSTRUMENTS – continued

Financial risk management objectives and policies

– continued

(b) Credit risk and impairment asesment

The credit risk of the Group mainly arises from bank

balances, deposits and other receivables. The carying

amounts of these balances represent the Group’s

maximum exposure to credit risk in relation to financial

asets.

In respect of cash deposited at banks, the credit risk

is considered to be low as the counterparties are

reputable banks. The existing counterparties do not

have defaults in the past. Therefore, expected credit

los rate of cash at bank is asesed to be close to zero

and no provision was made as of 31 March 2025 and

2024.

In respect of the deposits and other receivables, the

credit quality has ben individual asesed by general

aproach with reference to historical information

about the counterparties. The Group recognised the

alowance for expected credit loses by asesing

the credit risk characteristics of deposit and other

receivables, discount rate and the likelihod of recovery

and considering the prevailing economic conditions.

32.

金融工具－续

财务风险管理目标及政策－续

(b)

信贷风险及减值评估

本集团之信贷风险主要来自银行

结余、按金及其他应收款项。该等

结余的账面值即为本集团就金融

资产承受的最大信贷风险。

就存放于银行的现金而言，由于对

手方为信誉良好的银行，故信贷风

险被视为较低。现有对手方于过往

并无违约。因此，银行现金的预期

信贷亏损率被评估近乎为零，以及

截至二零二五年及二零二四年三

月三十一日并无计提拨备。

就按金及其他应收款项而言，信贷

质素经参考对手方历史资料后透

过一般方法作出单独评估。本集团

透过评估按金及其他应收款项之

信贷风险特征、贴现率及收回可能

性并考虑当前经济状况确认预期

信贷亏损之拨备。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/2025166

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

32. FINANCIAL INSTRUMENTS – continued

Financial risk management objectives and policies

– continued

(b) Credit risk and impairment asesment

– continued

The Group’s internal credit risk grading asesment

comprises the folowing categories:

Internal credit

RatingDescription

Other receivables and

deposits

内部信贷评级描述其他应收款项及按金

Low riskThe counterparty has a low risk of default and

does not have any past due amounts

12-months ECL

低风险对手方的违约风险较低，且并无任何过往逾期款项

个月预期信贷亏损

DoubtfulThere have ben significant increases in credit risk

since initial recognition through information

developed internaly or external resources

Lifetime ECL – non-credit

impaired

违约自首次确认以来，通过内部获取的资讯或

外部资源，信贷风险显著增加

全期预期信贷亏损

–

无信贷减值

LosThere is evidence indicating the aset is credit-

impaired

Lifetime ECL – credit impaired

损失有证据显示资产已出现信贷减值全期预期信贷亏损

–

信贷减值

Writen-ofThere is evidence indicating that the debtor is in

severe financial dificulty and the Group has no

realistic prospect of recovery

Amount is writen-of

撇销有证据显示债务人处于严重财务困难且本集团并

无实际收回前景

撇销金额

32.

金融工具－续

财务风险管理目标及政策－续

(b)

信贷风险及减值评估－续

本集团内部信贷风险分级评估包

括以下类别：

---

2025
Average loss rate	二零二五年 Other receivables and deposits	Allowance ECL
	其他应收款项	预期信贷
平均亏损率 %	及按金 HK$’000	亏损拨备 HK$’000
	千港元	千港元
61.98%	1,744	1,081

金威医疗集团有限公司

2024/2025

年报

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

32. FINANCIAL INSTRUMENTS – continued

Financial risk management objectives and policies

– continued

(b) Credit risk and impairment asesment

– continued

As part of the Group’s credit risk management,

the Group aplies internal credit rating for other

receivables and deposits. The folowing table provides

information about the exposure to credit risk for other

receivables and deposits which are asesed on a

general aproach.

Gros carying amount

二零二四年

Average

los rate

Other

receivables and

deposits

Alowance

ECL

平均亏损率

其他应收款项

及按金

预期信贷

亏损拨备

%HK$’000HK$’000

Internal credit rating

内部信贷评级千港元千港元

Low risk (12-month ECL)

低风险（

个月预期信贷亏损）

–1,334–

During the year ended 31 March 2025, the alowance

for the expected credit los related to the other

receivables and deposits made by the Group was

aproximately HK$1,081,000 (2024: reversal of

alowance for the expected credit los of aproximately

HK$372,000).

32.

金融工具－续

财务风险管理目标及政策－续

(b)

信贷风险及减值评估－续

作为本集团信贷风险管理的一部

分，本集团对其他应收款项及按金

采用内部信贷评级。下表提供有关

按一般方法评估的其他应收款项

及按金的信贷风险的敞口之资料。

总账面值

截至二零二五年三月三十一日止

年度，本集团有关其他应收款项

及按金之预期信贷亏损拨备约为

1,081,000

港元（二零二四年：拨回

之预期信贷亏损拨备约

372,000

港

元）。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/2025168

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

32. FINANCIAL INSTRUMENTS – continued

Financial risk management objectives and policies

– continued

(b) Credit risk and impairment asesment

– continued

The closing los alowances for other financial asets

at amortised cost as at 31 March 2025 and 2024

reconcile to the opening los alowances as folows:

Other

receivables

and deposits

(12m ECL)

其他应收

款项及按金

（

个月预期

信贷亏损）

HK$’000

千港元

At 1 April 2023

于二零二三年四月一日

Reversal of los alowance recognised

in profit or los during the year, net

年内于损益确认之

亏损拨备拨回净额

(372)

Exchange realignment

汇兑调整

At 31 March 2024 and 1 April 2025

于二零二四年三月三十一日及

二零二五年四月一日

–

Provision of los alowance recognised

in profit or los during the year, net

年内于损益确认之亏损拨备计提净额

1,089

Exchange realignment

汇兑调整

(8)

At 31 March 2025

于二零二五年三月三十一日

1,081

32.

金融工具－续

财务风险管理目标及政策－续

(b)

信贷风险及减值评估－续

于二零二五年及二零二四年三月

三十一日之按摊销成本计量之其

他金融资产之期末亏损拨备与期

初亏损拨备之对账如下：

---

金威医疗集团有限公司

2024/2025

年报

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

32. FINANCIAL INSTRUMENTS – continued

Financial risk management objectives and policies

– continued

(c) Liquidity risk management

Ultimate responsibility for liquidity risk management

rests with the board of directors, which has built an

apropriate liquidity risk management framework

for the management of the Group’s short, medium

and long-term funding and liquidity management

requirements. The Group manages liquidity risk by

maintaining adequate reserves, banking facilities and

reserve borowing facilities, by continuously monitoring

forecast and actual cash flows and matching the

maturity profiles of financial asets and liabilities.

The folowing tables detail the Group’s remaining

contractual maturity for its financial liabilities which

are included in the maturity analysis provided internaly

to the key management personel for the purpose of

managing liquidity risk. For non-derivative financial

liabilities, the tables reflect the undiscounted cash

flows of financial liabilities based on the earliest date

on which the Group can be required to pay. The tables

include both interest and principal cash flows.

32.

金融工具－续

财务风险管理目标及政策－续

(c)

流动资金风险管理

董事会肩负流动资金风险管理之

最终责任，而董事会已建立一个合

适之流动资金风险管理框架，用以

管理本集团之短期、中期及长期资

金及流动资金管理需求。本集团透

过保持充足之储备、银行信贷及储

备借贷融资，以及持续对预测及实

际现金流量进行监察，并配合金融

资产及负债之到期情况，借以管理

流动资金风险。

下表详细载列本集团之金融负债

之剩余合约期限，已计入提供予内

部主要管理人员之期限分析，以管

理流动资金风险。就非衍生金融负

债而言，下表反映基于本集团被要

求付款之最早日期之金融负债之

未贴现金流量。下表均包括利息

及主要现金流量。

---

Weighted average effective interest rate	Within 1 year	Within 1 to 2 years	Within 2 to 5 years	Total undiscounted cash flows	Carrying amount
加权平均				未贴现
实际利率 %	一年内 HK$’000	一至两年内 HK$’000	两至五年内 HK$’000	现金流量总值 HK$’000	账面值 HK$’000
	千港元	千港元	千港元	千港元	千港元
–	5,767	–	–	5,767	5,767

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/2025170

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

32. FINANCIAL INSTRUMENTS – continued

Financial risk management objectives and policies

– continued

(c) Liquidity risk management – continued

At 31 March 2025

Non-derivative financial liabilities

非衍生金融负债

Trade and other payables

贸易及其他应付款项

At 31 March 2024

Weighted

average

efective

interest

rate

Within

1 year

Within

1 to 2

years

Within

2 to

5 years

Total

undiscounted

cash flows

Carying

amount

加权平均

实际利率一年内一至两年内两至五年内

未贴现

现金流量总值账面值

%HK$’000HK$’000HK$’000HK$’000HK$’000

千港元千港元千港元千港元千港元

Non-derivative financial liabilities

非衍生金融负债

Trade and other payables

贸易及其他应付款项

–5,170–5,1705,170

Lease liabilities

租赁负债

7.53,2561,1971,0885,5415,130

8,4261,1971,08810,71110,300

32.

金融工具－续

财务风险管理目标及政策－续

(c)

流动资金风险管理－续

于二零二五年三月三十一日

于二零二四年三月三十一日

---

于以下日 31 March 2025
二零二五年
三月三十一日 HK$’000
千港元
316

金威医疗集团有限公司

2024/2025

年报

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

32. FINANCIAL INSTRUMENTS – continued

Fair value measurements

The folowing note provides information about how the

Group determine fair values of various financial asets and

financial liabilities.

Fair value of the Group’s financial asets and

financial liabilities that are measured at fair value

on recuring basis

The folowing table gives information about how the fair

value of these financial asets are determined (in particular,

the valuation techniques and input used).

Fair value as at

Fair value

hierarchy

Valuation techniques and

key inputs

于以下日期之公平值公平值层级估值方法及主要输入数据

31 March

二零二四年

三月三十一日

HK$’000

千港元

Financial asets

金融资产

Financial asets at fair value through

profit or los

237Level 1Quoted bid prices in

an active market

按公平值计入损益之金融资产第

级于活跃市场之报价

During the years ended 31 March 2025 and 2024, there

were no transfers of fair value measurements betwen Level

1 and Level 2, and there were no transfers into or out of

Level 3 for both financial asets and financial liabilities.

The carying amount of al other asets and liabilities were

aproximate to their fair value.

32.

金融工具－续

公平值计量

以下附注提供有关本集团如何厘定各项

金融资产及金融负债公平值之资料。

按持续基准以公平值计量之本集团

金融资产及金融负债之公平值

下表提供有关如何厘定该等金融资产之

公平值之资料（具体而言，估值方法及所

用之输入数据）。

于截至二零二五年及二零二四年三月

三十一日止年度，金融资产及金融负债

第

级及第

级之间并无公平值计量转

移，且并无自第

级转入或转出。

全部其他资产及负债之账面值与其公平

值相若。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/2025172

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

33. RECONCILIATION OF LIABILITIES ARISING

FROM FINANCING ACTIVITIES

The table below details changes in the Group’s liabilities

from financing activities, including both cash and non-cash

movement. Liabilities arising from financing activities are

liabilities for which cash flows were, or future cash flows

wil be, clasified in the Group’s consolidated cash flow

statement as cash flows from financing activities.

Borowings

Lease

liabilitiesTotal

借款租赁负债总计

HK$’000HK$’000HK$’000

千港元千港元千港元

At 1 April 2023

于二零二三年四月一日

–4,4944,494

Financing cash flows:

融资现金流量：

– Repayment of lease liabilities

—偿还租赁负债

–(2,739)(2,739)

– Proceds from borowings

—借款所得款项

10,419–10,419

– Repayment of borowings

—偿还借款

(3,288)–(3,288)

– Interest paid

—已付利息

(34)–(34)

Non-cash movement:

非现金变动：

– Interest expenses

—利息开支

– Exchange realignment

—汇兑调整

(32)(207)(239)

– Adition of lease liabilities

—租赁负债增加

–3,3083,308

At 31 March 2024

于二零二四年三月三十一日

7,0995,13012,229

Financing cash flows:

融资现金流量：

– Repayment of lease liabilities

—偿还租赁负债

–(2,382)(2,382)

– Proceds from borowings

—借款所得款项

5,600–5,600

– Repayment of borowings

—偿还借款

(2,159)–(2,159)

Non-cash movement:

非现金变动：

– Interest expenses

—利息开支

–190190

– Exchange realignment

—汇兑调整

(11)(6)(17)

– Gain on early termination

of lease

—提前终止租赁之收益

–(2,932)(2,932)

At 31 March 2025

于二零二五年三月三十一日

10,529–10,529

33.

来自融资活动之负债对账

下表为本集团来自融资活动之负债变动

详情，包括现金及非现金变动。来自融

资活动之负债乃为现金流量或未来现金

流量于本集团综合现金流量表分类为来

自融资活动现金流量之负债。

---

金威医疗集团有限公司

2024/2025

年报

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

34. DISPOSAL OF SUBSIDIARIES

On 23 September 2024, the Group disposed of its 100%

equity interest in Sino Busines Investment Development

Limited (“Sino Busines”) and its subsidiaries (colectively,

the “Disposal Group”) to an independent third party at

a cash consideration of aproximately RMB60,000. The

Disposal Group was previously engaged in the provision of

general hospital services in the PRC, but had ben dormant

since July 2022. Upon completion of the disposal, the Group

lost control over the Disposal Group and, from that date,

ceased to consolidate its financial results and position in the

Group’s consolidated financial statements.

The agregate net liabilities of the Disposal Group as at the

date of disposal were as folow:

HK$’000

千港元

Property, plant and equipment

物业、厂房及设备

Cash and cash equivalents

现金及现金等值项目

1,594

Trade and other payables

贸易及其他应付款项

(11,740)

Release of translation reserve

解除换算储备

(500)

Net inter-company balances

公司间结余净额

Total identifiable net liabilities disposed of

已出售可识别总负债净值

(10,398)

Cash consideration

现金代价

Gain on disposal

出售收益

10,458

Net cash outflow on disposal:

出售现金流出净额：

Cash consideration received

已收现金代价

Bank balances and cash disposed of

已出售银行结余及现金

(1,594)

(1,534)

34.

出售附属公司

于二零二四年九月二十三日，本集团

以现金代价约人民币

60,000

元向一

名独立第三方出售其于

Sino Busines

Investment Development Limited

（「

Sino

Busines

」）及其附属公司（统称「出售

集团」）的

100%

股权。出售集团先前在

中国从事提供综合性医院服务，但已于

二零二年七月起处于停业状态。于出

售完成后，本集团失去对出售集团的控

制权，因此自该日起，其财务业绩及状

况不再综合入账至本集团的综合财务报

表。

出售集团于出售日期的总负债净值如

下：

---

2025
二零二五年 HK$’000
千港元
1,146
18
1,164

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/2025174

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

35. MATERIAL RELATED PARTY

TRANSACTIONS

Other than as disclosed elsewhere in these consolidated

financial statements, the Group has folowing transaction

with a related party:

Compensation of key management personel

Except as detailed in note 12 to the consolidated financial

statements paid to the Company’s directors, other member

of key management during the year was as folows:

二零二四年

HK$’000

千港元

Salaries and alowances

薪金及津贴

1,082

Retirement benefits scheme contributions

退休福利计划供款

1,100

The emoluments of the directors are decided by the

remuneration comite of the Company having regard

to individual’s performance, the Group’s performance and

profitability, remuneration benchmark in the industry and

prevailing market condition.

35.

重大关连人士交易

除该等综合财务报表的其他部分所披露

者外，本集团与关连人士有以下交易：

主要管理人员薪酬

除综合财务报表附注

所详述支付予本

公司董事之薪酬外，其他主要管理成员

年内薪酬如下：

董事之酬金由本公司薪酬委员会按照个

人表现、本集团之业绩及盈利状况，亦

以业界薪酬指标及当时市况而厘定。

---

金威医疗集团有限公司

2024/2025

年报

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

36. PARTICULARS OF PRINCIPAL SUBSIDIARIES

OF THE COMPANY

Details of the Company’s principal subsidiaries at 31 March

2025 and 2024 are as folows:

Name of subsidiaries

Place of

incorporation/

establishment

and operation

Isued and

fuly paid

ordinary share/

/registered capital

Proportion of nominal

value of isued ordinary

share capital indirectly

held by the Company

Principal

activities

附属公司名称

注册成立╱

成立及营业地点

已发行及缴足

普通股╱注册资本

由本公司间接持有之

已发行普通股本

面值比例主要业务

二零二五年二零二四年

%

Beijing Huicheng Hospital Co., Ltd

#

(formerly known as Beijing Zijing Hospital Co., Ltd

#

)*

The PRCRegistered

RMB20,000,000

99.7499.74Provision of general hospital services

北京惠城医院有限公司

#

（前称北京紫荆医院有限公司

#

)

*

中国注册资本

人民币

20,000,000

元

提供综合性医院服务

Edinburgh International Hospital Management

(Shenzhen) Co., Ltd.

#*@

The PRCRegistered

RMB6,000,000

–75Investment holdings

爱丁堡国际医院管理（深圳）有限公司

#*@

中国注册资本

人民币

6,000,000

元

投资控股

Edinburgh International Diabetes Hospital (Hainan) Co., Ltd

#*@

The PRCRegistered

RMB5,000,000

–75Provision of general hospital services

爱丁堡国际糖尿病医院（海南）有限公司

#*@

中国注册资本

人民币

5,000,000

元

提供综合性医院服务

#

The English transliteration of the Chinese names in this report,

where indicated, is included for information only, and should

not be regarded as the oficial English names of such Chinese

names.

* Company established in the PRC with limited liability.

@

Subsidiaries disposed of on 23 September 2024 as part of the

Disposal Group (Note 34).

The above table lists the subsidiaries of the Company which,

in the opinion of the directors of the Company, principaly

afect the results or net asets of the Group. To give details

of other subsidiaries would, in the opinion of the directors,

result in particulars of excesive length.

36.

本公司之主要附属公司详情

本公司于二零二五年及二零二四年三月

三十一日之主要附属公司详情如下：

#

本报告所示中文名称之英文翻译仅供

参考，不得视为有关中文名称之正式英

文名称。

*

于中国成立的有限责任公司。

@

作为出售集团的一部分，附属公司已

于二零二四年九月二十三日出售（附注

）。

本公司董事认为上表所列本公司附属公

司对本集团业绩或净资产有重大影响。

董事认为提供其他附属公司之资料将使

篇幅过于冗长。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/2025176

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

36. PARTICULARS OF PRINCIPAL SUBSIDIARIES

OF THE COMPANY – continued

(b) Details of non-wholy owned subsidiaries

that have material non-controling interests

The table below shows details of non-wholy owned

subsidiaries of the Group that have material non-

controling interests:

Name of subsidiaries

Place of

incorporation/

establishment

and principal

place of busines

Proportion of ownership

interests and voting rights

held by non-controling interests

Los atributable to

non-controling interests

Acumulated

non-controling interests

附属公司名称

注册成立╱成立

地点及主要营业地点

非控股权益所持之

拥有权益及投票权之比例非控股权益应占亏损累计非控股权益

二零二五年二零二四年二零二五年二零二四年二零二五年二零二四年

HK$’000HK$’000HK$’000HK$’000

千港元千港元千港元千港元

Edinburgh International

Hospital Management

(Shenzhen) Co., Ltd. and

its subsidiary*

The PRC–%25%(6)(268)–(2,863)

爱丁堡国际医院管理（深圳）

有限公司及其附属公司

*

中国

* Subsidiaries disposed of on 23 September 2024 as part

of the Disposal Group (Note 34).

Sumarised financial information in respect of the

Group’s subsidiaries that have material non-controling

interests during the year ended 31 March 2024 is set

out below. The sumarised financial information below

represents amounts before intragroup eliminations.

36.

本公司之主要附属公司详情

－续

(b)

拥有重大非控股权益之非全资

附属公司之详情

下表载列拥有重大非控股权益之

本集团之非全资附属公司之详情：

*

作为出售集团的一部分，附属公

司已于二零二四年九月二十三日

出售（附注

）。

截至二零二四年三月三十一日止

年度，有关拥有重大非控股权益之

本集团附属公司之财务资料概要

载列如下。下列财务资料概要乃集

团内抵减前之金额。

---

金威医疗集团有限公司

2024/2025

年报

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

36. PARTICULARS OF PRINCIPAL SUBSIDIARIES

OF THE COMPANY – continued

(b) Details of non-wholy owned subsidiaries

that have material non-controling interests

– continued

Edinburgh International Hospital Management

(Shenzhen) Co., Ltd and its subsidiary

二零二四年

HK$’000

千港元

Non-curent asets

非流动资产

Curent asets

流动资产

3,103

Curent liabilities

流动负债

(13,012)

Equity atributable to owners of

the Company

本公司拥有人应占权益

(7,044)

Non-controling interests

非控股权益

(2,863)

Revenue

收益

–

Expenses

开支

(1,070)

Los for the year

本年度亏损

(1,070)

Los atributable to owners of the Company

本公司拥有人应占亏损

(802)

Los atributable to non-controling interests

非控股权益应占亏损

(268)

Los for the year

本年度亏损

(1,070)

36.

本公司之主要附属公司详情

－续

(b)

拥有重大非控股权益之非全资

附属公司之详情－续

爱丁堡国际医院管理（深圳）有限公

司及其附属公司

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/2025178

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

二零二四年

HK$’000

千港元

Other comprehensive income

atributable to owners of the Company

本公司拥有人应占其他全面

收益

Other comprehensive income atributable

to non-controling interests

非控股权益应占其他

全面收益

Other comprehensive income for the year

本年度其他全面收益

Total comprehensive expense atributable to owners

of the Company

本公司拥有人应占全面

开支总额

(373)

Total comprehensive expense atributable to

non-controling interests

非控股权益应占全面

开支总额

(125)

Total comprehensive expense for the year

本年度全面开支总额

(498)

Net cash used in operating activities

经营活动所用现金净额

(2,645)

Net cash generated from investing activities

投资活动所得现金净额

Net decrease in cash and cash equivalents

现金及现金等值项目之

减少净额

(2,640)

36.

本公司之主要附属公司详情

－续

(b)

拥有重大非控股权益之非全资

附属公司之详情－续

爱丁堡国际医院管理（深圳）有限公

司及其附属公司－续

36. PARTICULARS OF PRINCIPAL SUBSIDIARIES

OF THE COMPANY – continued

(b) Details of non-wholy owned subsidiaries

that have material non-controling interests

– continued

Edinburgh International Hospital Management

(Shenzhen) Co., Ltd and its subsidiary – continued

---

金威医疗集团有限公司

2024/2025

年报

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

37. LITIGATION

During the year ended 31 March 2024, the Group’s former

subsidiaries, Edinburgh International Hospital Management

(Shenzhen) Co. Ltd. (“Edinburgh Hospital Management”)

and Edinburgh International Diabetes Hospital (Hainan) Co.

Ltd. (“Edinburgh International Diabetes”), were involved

in litigation procedings in the PRC.

A civil complaint (the “Civil Complaint I”) was filed by

China Merchants Hainan Development Investment Co. Ltd.

(“China Merchants”) with the People’s Court of Qianhai

Shenzhen against Edinburgh Hospital Management, arising

from a coperation agrement entered into on 31 July

2020 relating to the provision of funding and management

services for the establishment of an international diabetes

centre in Hainan. Pursuant to the civil judgment isued

on 6 September 2022 and subsequently upheld by the

Intermediate People’s Court of Shenzhen on 31 March 2023

(“Civil Judgment I”), the court ordered, among other

things, the termination of the coperation agrement, the

refund of aproximately RMB4.9 milion of unutilised funds

by Edinburgh Hospital Management, and the payment of

liquidated damages and legal costs of aproximately RMB1.4

milion.

In a separate proceding, on 13 June 2023, a further civil

complaint (the “Civil Complaint I”) was filed by China

Merchants with the People’s Court of Qionghai City against

Edinburgh International Diabetes for the refund of the

remaining investment amount of aproximately RMB3.2

milion. This claim related to the funds advanced under

the same coperation arangement that was the subject of

Civil Complaint I. On 11 September 2023, the court isued

its judgment (“Civil Judgment I”), ordering Edinburgh

International Diabetes and Edinburgh Hospital Management

to jointly return RMB3.2 milion, and for Edinburgh

International Diabetes to pay legal costs of aproximately

RMB37,000.

37.

诉讼

于截至二零二四年三月三十一日止年

度，本集团前附属公司爱丁堡国际医院

管理（深圳）有限公司（「爱丁堡医院管

理」）及爱丁堡国际糖尿病医院（海南）有

限公司（「爱丁堡国际糖尿病」）在中国涉

及诉讼程序。

招商局海南开发投资有限公司（「招商

局」）就爱丁堡医院管理向深圳前海合

作区人民法院提起民事诉状（「民事诉

状

I

」），起因为双方于二零二零年七月

三十一日就设立海南国际糖尿病中心

提供资金及管理服务订立的合作协议。

根据二零二年九月六日发出并其后经

深圳市中级人民法院于二零二三年三月

三十一日维持原判的民事判决书（「民事

判决书

I

」），法院颁令（其中包括）终止合

作协议、爱丁堡医院管理退还约人民币

4,900,000

元未动用资金，以及支付约人

民币

1,400,000

元的违约赔偿金及法律费

用。

在另一诉讼程序中，招商局于二零二三

年六月十三日向琼海市人民法院就爱丁

堡国际糖尿病提出进一步民事诉状（「民

事诉状

I

」），要求退还余下的投资款项

约人民币

3,200,000

元。该索偿与民事诉

状

I

所涉及的同一合作安排下垫付的资金

有关。于二零二三年九月十一日，法院

作出判决（「民事判决书

I

」），颁令爱丁堡

国际糖尿病及爱丁堡医院管理共同退还

人民币

3,200,000

元，以及爱丁堡国际糖

尿病支付法律费用约人民币

37,000

元。

---

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/2025180

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

37. LITIGATION – continued

During the year ended 31 March 2025, the Group completed

the disposal of its entire interests in the Disposal Group (as

defined in Note 34), which included Edinburgh Hospital

Management and Edinburgh International Diabetes, the

entities directly involved in the aforementioned litigations. As

a result, both entities ceased to be subsidiaries of the Group,

and the Group no longer has any ongoing involvement in

conection with Civil Complaint I or Civil Complaint I.

For further details of Civil Complaint I and the related court

rulings, please refer to the Company’s anouncements dated

10 March 2022 and 7 September 2022.

For further details in relation to the disposal of the Disposal

Group, please refer to the Company’s anouncements dated

20 September 2024 and 23 September 2024 and Note 34 to

the consolidated financial statements.

38. EVENTS AFTER THE END OF THE

REPORTING PERIOD

Saved as disclosed elsewhere in these consolidated financial

statements, the Group had the folowing significant event

after the end of the reporting period:

Pursuant to the Company’s anouncement dated 14 March

2025, the Company proposed to raise funds by way of

rights isue on the basis of 1 rights share for every 1 existing

share held by the qualifying shareholders at the subscription

price of HK$0.05 per rights share (the “Rights Isue”). The

Rights Isue was conditional upon, among other things,

the aproval by the shareholders of the Company at the

extraordinary general meting and the granting of the listing

of, and permision to deal in, the rights shares by The Stock

Exchange of Hong Kong Limited. The Rights Isue wil be

completed in June 2025.

37.

诉讼－续

截至二零二五年三月三十一日止年度，

本集团完成出售其于出售集团（定义见

附注

）的全部权益，当中包括爱丁堡医

院管理及爱丁堡国际糖尿病，即上述诉

讼直接涉及的实体。因此，该两个实体

不再为本集团的附属公司，且本集团不

再继续涉及民事诉状

I

或民事诉状

I

。

有关民事诉状

I

及相关法院裁决之更多详

情，请参阅本公司日期为二零二年三

月十日及二零二年九月七日之公告。

有关出售出售集团之更多详情，请参阅

本公司日期为二零二四年九月二十日及

二零二四年九月二十三日之公告以及综

合财务报表附注

。

38.

报告期末后事项

除该等综合财务报表其他部份所披露者

外，本集团于报告期末后发生下列重大

事项：

根据本公司日期为二零二五年三月十四

日之公告，本公司建议按合资格股东每

持有一股现有股份获发一股供股份的

基准，以认购价每股供股份

0.05

港元

进行供股集资（「供股」）。供股须待（其中

包括）本公司股东于股东特别大会上批

准及香港联合交易所有限公司批准供股

股份上市及买卖后，方可作实。供股将

于二零二五年六月完成。

---

2025
二零二五年 HK$’000
千港元
20,892
8
20,900
773
14,949
102
15,824
2,868
346,796
10,100
359,764
(343,940)

金威医疗集团有限公司

2024/2025

年报

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

39. STATEMENT OF FINANCIAL POSITION AND

RESERVES OF THE COMPANY

二零二四年

HK$’000

千港元

Non-curent asets

非流动资产

Interests in subsidiaries

于附属公司之权益

20,892

Property, plant and equipment

物业、厂房及设备

20,905

Curent asets

流动资产

Other receivables and deposits

其他应收款项及按金

Amounts due from subsidiaries

应收附属公司款项

1,959

Cash and bank balances

现金及银行结余

2,364

Curent liabilities

流动负债

Acruals and other payables

应计费用及其他应付款项

1,358

Amounts due to subsidiaries

应付附属公司款项

318,049

Borowings

借款

4,500

323,907

Net curent liabilities

流动负债净额

(321,543)

39.

本公司之财务状况及储备表

---

2025
二零二五年 HK$’000
千港元
(323,040)
(323,040)
29,168
(352,208)
(323,040)

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/2025182

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

二零二四年

HK$’000

千港元

Total asets les curent liabilities

资产总值减流动负债

(300,638)

Net liabilities

负债净额

(300,638)

Capital and reserves

资本及储备

Share capital

股本

29,168

Reserves

储备

(329,806)

Deficiency in asets

资产亏绌

(300,638)

The financial statements were aproved and authorised for

isue by the Board of Directors on 26 June 2025 and are

signed on its behalf by:

Ng Chi LungWu Qiyou

吴志龙吴其佑

DirectorDirector

董事董事

财务报表于二零二五年六月二十六日由

董事会批准及授权刊发，并由下列董事

代表签署：

39. STATEMENT OF FINANCIAL POSITION AND

RESERVES OF THE COMPANY – continued

39.

本公司之财务状况及储备表

－续

---

金威医疗集团有限公司

2024/2025

年报

Notes to the Consolidated Financial Statements

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

39. STATEMENT OF FINANCIAL POSITION AND

RESERVES OF THE COMPANY – continued

ShareCapitalContributedAcumulated

premiumreservesurpluslosesTotal

股份溢价资本储备缴入盈余累计亏损总计

HK$’000HK$’000HK$’000HK$’000HK$’000

千港元千港元千港元千港元千港元

At 1 April 2023

于二零二三年四月一日

440,289295,6101,452(1,060,137)(322,786)

Los for the year

本年度亏损

–(7,020)(7,020)

At 31 March 2024

于二零二四年三月三十一日

440,289295,6101,452(1,067,157)(329,806)

Los for the year

本年度亏损

–(22,402)(22,402)

At 31 March 2025

于二零二五年三月三十一日

440,289295,6101,452(1,089,559)(352,208)

40. COMPARATIVE FIGURES

Certain comparative figures have ben reclasified to

conform with the curent year’s presentation.

41. AUTHORISATION FOR ISUE OF

CONSOLIDATED FINANCIAL STATEMENT

The consolidated financial statements were aproved and

authorised for isue by the Board of Directors on 26 June

2025.

39.

本公司之财务状况及储备表

－续

40.

比较数字

若干比较数字已重新分类以符合本年度

之呈报方式。

41.

授权刊发综合财务报表

综合财务报表于二零二五年六月二十六

日获董事会批准及授权刊发。

---

2025
二零二五年 HK$’000
千港元
16,120
(7,368)
11
(7,357)
(10,127)
2,770
(7,357)

2025
二零二五年 HK$’000
千港元
9,832
(16,587)
(6,755)
(6,509)
(246)
(6,755)

GOD FELOW HEALTHCARE HOLDINGS LIMITED

ANUAL REPORT 2024/2025184

Financial Sumary

财务摘要

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

RESULTS

For the year ended 31 March

截至三月三十一日止年度

二零二四年二零二三年二零二年二零二一年

HK$’000HK$’000HK$’000HK$’000

千港元千港元千港元千港元

Revenue

收益

38,96255,35354,23853,886

Los before taxation

除税前亏损

(16,344)(5,651)(7,546)(39,403)

Taxation

税项

(1,043)(26)(1,319)–

Los for the year

本年度亏损

(17,387)(5,677)(8,865)(39,403)

(Los)/profit for the year

atributable to:

应占本年度（亏损）╱

溢利：

– Owners of the Company

－本公司拥有人

(17,110)(5,881)(12,689)(30,183)

– Non-controling interests

－非控股权益

(277)2043,824(9,220)

(17,387)(5,677)(8,865)(39,403)

As at 31 March

于三月三十一日

二零二四年二零二三年二零二年二零二一年

HK$’000HK$’000HK$’000HK$’000

千港元千港元千港元千港元

ASETS AND LIABILITIES

资产及负债

Total asets

总资产

29,14641,69660,448191,376

Total liabilities

总负债

(27,739)(22,321)(34,081)(158,476)

Net asets

资产净值

1,40719,37526,36732,900

Equity atributable to owners

of the Company

本公司拥有人应占权益

4,35722,19029,59140,229

Non-controling interests

非控股权益

(2,950)(2,815)(3,224)(7,329)

1,40719,37526,36732,900

业绩

---

A

N

N

U

A

L

R

E

P

O

R

T

/

年

报

852 2722 4388

w.gf-healthcare.com/

Unit 3309, 33rd Flor, West Tower, Shun Tak Centre,

168-200 Conaught Road Central, Hong Kong

香港上环干诺道中

168-200

号

信德中心西翼

楼

室